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SUMMARY
Cytokines are intercellular messengers which orchestrate host defence, 
repair and haemopoiesis. The potential that cytokines have in the 
pharmacological manipulation of the immune and haemopoeitic systems 
has lead them to be at the forefront of biomedical research. In human 
medicine, cytokines now feature in many clinical trials ranging from those 
involving infectious diseases to those involving the treatment o f cancer.
The potential benefits to therapeutics that cytokines offer is now being 
realised in veterinary medicine. The cat suffers from a number of 
neoplastic, infectious, immune mediated, and inflammatory diseases and, 
in addition, can provide a model for human diseases such as HIV. This 
thesis describes the cloning, sequencing and expression of feline 
recombinant interferon-y with the ultimate aim of exploring the potential 
of this cytokine in the treatment and prevention of diseases in cats.
Initially feline specific cDNA, encoding interferon-y, was amplified using 
the polymerase chain reaction (PCR). Messenger RNA was harvested 
from feline lymphocytes which had been incubated with a non-specific 
mitogen. This mRNA was then used to create a library of first strand 
cDNA molecules, from which the interferon specific cDNA was amplified 
using synthetic primers and the process of PCR. Subsequently, the 
products of PCR were sub-cloned into plasmid vector and sequenced. The 
feline interferon cDNA coding region was found to be 568bp, coding for a
peptide of 166 amino acids. In addition, the sequence showed a high 
degree of homology to the human interferon-y molecule.
Expression of the interferon gene was achieved using the baculovirus 
system. This system produces a glycosylated product and can be scaled up 
to producing large quantities of recombinant protein. Since the ultimate 
aim was to use the interferon in-vivo, then both of these factors were 
important in the choice of expression system. Recombinant baculovirus, 
expressing interferon protein, was generated by homologous 
recombination of a transfer vector containing the interferon cDNA and 
linearized wild-type baculovirus. Expression and biological activity of the 
protein was determined by two biological assays. The first was a viral 
interference assay based upon the ability of interferon to protect cells 
against viral infection, and the second assay was based on the ability of 
interferon to up-regulate MHC Class II antigens on cells. Both assays 
confirmed that the baculovirus system was producing a biologically active 
protein. Immunological detection of the interferon protein was carried out 
using antisera raised against synthetic peptides. These peptides were 
selected by analysis of regions of the interferon protein sequence which 
were predicted to be immunogenic sites. Western blot analysis of the 
interferon protein, using polyclonal antisera, demonstrated the mature 
recombinant protein to be around 20kDa. Partial purification of the 
interferon protein was carried out using a combination of salt precipitation 
and ion exchange/FPLC chromatography.
The potential benefits and drawbacks that recombinant feline interferon-y 
offers for the treatment of feline diseases is discussed in the final chapter. 
The advent of recombinant DNA technology, coupled with the ever 
increasing amount of experimental data demonstrating the biological
function o f these cytokines, will undoubtedly lead to a rational approach to 
introducing these molecules into clinical trials. This thesis, in part, 
demonstrates an approach for taking a gene from the cloning stage towards 
clinical application.
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1.0 INTRODUCTION
1.1 GENERAL OVERVIEW
Cytokines are regulatory glycoproteins that can be produced by virtually 
every nucleated cell type in the body; they have pleiotropic regulatory 
effects on the haemopoeitic and many other cell types that participate in 
host defence and repair processes (Oppenheim, 1994). Cytokines therefore 
include lymphocyte-derived factors known as lymphokines, monocyte- 
derived factors known as monokines, haemopoeitic colony stimulating 
factors and connective tissue growth factors. It is difficult to define 
cytokines because of their pleiotropic actions but table 1.1 shows some of 
their characteristic features.
The field of cytokine research today has evolved from four originally 
independent sources. The first is the area of lymphokine research, carried 
out by immunologists; secondly, the area of interferon research, carried out 
initially by virologists; thirdly, the area of haemopoeitic research, studying 
the effects o f the colony stimulating factors and fourthly, the area of 
growth factor research. Inasmuch as the cytokine field has emerged from 
different sources there is now, after much research, a unifying concept of 
the cytokine. However, the field of cytokine nomenclature is still 
confusing, with older names still being used and an ever increasing list of 
interleukins.
It has been difficult to assign unique biological activities to most cytokines 
because most cells express multiple receptor types on their surfaces and 
can thus respond to many different cytokines. Further, cytokines can have 
multiple biological functions which overlap, and so there exists
3
Cytokines are simple polypeptides or glycoproteins with a molecular 
weight usually below 30 kDa. Only one known cytokine, IL-12, is a 
heterodimer.
Constitutive production of cytokines is usually low or absent. Production 
is controlled by inducing stimuli at the level of transcription or translation.
Cytokines act in a paracrine or autocrine fashion and their action is usually 
transient.
Most cytokine actions can be attributed to altered patterns of gene 
expression in the target cell.
Table 1.1 The characteristic features o f cytokines
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considerable redundancy in their actions (reviewed by Oppenheim and 
Saklatvala 1994). These overlapping functions may provide alternative 
pathways or greater co-operation between cytokines in cellular signalling. 
Such interactions are further amplified by the capacity of certain cytokines 
to induce other cytokines, resulting in cascades and networks of interacting 
cell signals. While cytokines are intimately involved in orchestrating the 
non-specific and specific immune responses, they also influence the 
activities of connective tissue, neural, endothelial, epithelial and 
haemopoeitic cells involved in tissue repair and homeostasis. In addition, 
there is increasing evidence that cytokines may be involved in normal 
development (Oppenheim and Saklatvala, 1994).
Interferon was first described by Isaacs and Lindenmann (1957) as a factor 
produced by a variety of virus infected cells capable of inducing cellular 
resistance to homologous or heterologous viruses but its role in immune 
regulation was not suspected at this time. Several years later Wheelock 
(1965) described a functionally related virus-inhibitory protein produced 
by mitogen (PHA) activated T cells. Although in the virus inhibition assay 
the factor was indistinguishable from typical interferon, Wheelock noted 
that the PHA induced leukocyte-derived factor was inactivated at pH2. In 
1973, Youngner and Salvin showed that interferon derived from 
lymphocyte cultures by mitogenic stimulation was antigenically distinct 
from "classical" interferon and proposed the use of the term type II 
interferon for the former. In 1980 the term type II interferon and immune 
interferon were replaced by the term interferon-gamma. At the same time, 
the names interferon-a and interferon-(3 were introduced for the two 
antigenically distinct varieties of type I interferons. It is now well 
established that interferon gamma is structurally distinct from the two
5
other interferon species known as alpha and beta interferons (Gray and 
Geodell 1982).
1.0.1 THE INTERFERON FAMILY
The Interferons are a family of glycoproteins related by their ability to 
protect cells from viral infection (Pestka and Langer et al 1987). The 
interferons can be divided into two very distinct families of proteins. The 
Interferon-a/p superfamily (also known as the type I interferons) include a 
group of structurally related genes and proteins, further subdivided into 
subfamilies IFN-a, IFN-p, IFN-co, and IFN-t. The second family consists 
of a single gene encoding the interferon-y protein (type II interferon). 
Interferon-a/p and IFN-y were initially distinguished from each other by 
their different stability's at pH 2 and distinct antigenic specificities. When 
the sequences of the genes and proteins of the major interferons were 
elucidated in the early 1980’s it became clear that all members of the IFN- 
a /p  family were structurally related to each other, but IFN-y was 
completely distinct. In addition, it has been established that two types of 
Interferon receptor exist, one for IFN-a/p and one for IFN-y (Vilcek and 
Oliveira 1994).
1.0.3 INTERFERON ALPHA AND BETA
The properties of interferon alpha and beta have been reviewed by Pestka 
and Langer et al (1987) and by De Maeyer and De Maeyer-Guignard 
(1994). Interferon-a is produced by peripheral blood mononuclear cells 
and is also known as leukocyte interferon or type I interferon. Twenty six 
IFN-a genes (including several pseudogenes) have been identified in man. 
These genes have common structures, i.e. they lack introns and appear to
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derive from a common ancestral precursor. The reasons for the complexity 
of the IFN-a gene system remain unclear, but recent studies suggest 
different IFN-a species effect distinct arrays of biological responses in 
different cells (Farrar and Shreiber 1993).
Interferon-P is also known as type I interferon or fibroblast interferon 
because of its cell of origin. In man there is only one distinct type of IFN- 
p which is encoded by a single gene which is located next to the IFN-a 
locus in both man (chromosome 9) and the mouse. Based on the general 
organisation of their genes and proteins, IFN-a and IFN-p are thought to 
have evolved from a common ancestral precursor. However, IFN-p only 
shares limited antigenic relatedness to the IFN-a family, and the proteins 
display only 15-30% amino acid homology. Nevertheless, both forms of 
type I interferon bind the same receptor on the surface of target cells. Both 
forms of type I interferon are inducible by virus.
The human interferon beta gene codes for a protein of 166 amino acids 
with about 29% homology to human interferon-aD or IFN-a 1. The 
bovine, equine and porcine interferon p gene families contain many genes, 
whereas the human and most other mammalian species contain only one. 
The lion and rabbit genomes contain two interferon P genes (Pestka and 
Langer et al, 1987).
Interferons other than a , P and y have been reported such as Interferon-co 
and t  which are also termed type I interferons (reviewed by De Maeyer 
and De Maeyer Guignard 1994). In humans, Interferon-co shares 60% 
homology to the interferon-a gene. Interferon-T has only been described 
in sheep and cattle and is also termed trophoblast interferon. These 
interferons are the major secretory products o f the trophoblast of ruminant
7
ungulates during pregnancy, in the period immediately preceding 
attachment and implantation of the fertilised ovum. Interferon-i shares 
most of the biological functions of the other interferons but is poorly 
responsive to viral induction.
A summary of the functions of interferon-a and p is shown in tables 1.2 
and 1.3.
1.0.4 EVOLUTIONARY RELATIONSHIPS 
OF INTERFERON GENES
The homology between human interferon-a and p genes suggest that they 
originated from a common ancestral gene around 300 million years ago, 
about the time of the divergence of mammals, reptiles and birds from fish 
and amphibia. This result suggests that amphibia and fish contain only an 
interferon-a or P gene homologous to the mammalian counterparts, but not 
both, and is in agreement with weak hybridisation of human interferon 
beta, but not interferon alpha to amphibia and fish DNA. There appears to 
be no clear homology between the interferon alpha and beta genes with the 
interferon-gamma gene.
All three classes of Interferon genes appear to be evolving at a rate 
comparable to the immunoglobulin genes (Pestka and Langer et al 1987).
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Antiviral effect Broad spectrum antiviral activity
Effect on cell growth and Inhibition of replication of normal and tumour 
division cells. IFN-a and p prolong G l, reduce the
rate of entry into S phase, and lengthen S and 
G2, resulting in a slower replication rate. 
Cells show different sensitivities to these 
actions
Modulation o f  the expression One of the mechanisms responsible for the 
o f  MHC class I  and II immunomodulatory actions of IFN-a and P
but modulation of MHC II is more 
specifically a function of IFN-y.
Stimulation o f  macrophage More a function of IFN-y 
activity
Stimulation o f  NK cell Contributes to the antitumour activity of IFN- 
activity a  and p
Up or down-regulation o f  DTH can be up or down regulated by IFN-a 
delayed type hypersensitivity or P, depending on the timing of action
Antitumour al activity The mechanism of antitumour activity is only
partially understood. Involves stimulation of 
immune effector cells and possibly direct 
antiproliferative activity
Table 1.2 A synopsis of the principal biological activities of IFN-a and P
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PROPERTIES OF THE INTERFERONS
PROPERTY IFN-a IFN-P IFN-y
Nomenclature
Major inducers
M.W.(kDa)
amino-acids
subunit
pH stability
No. of genes
Chromosomal lcn.
murine
human
Type I / 
leukocyte
Virus
20
165-166
Single
Polypeptide
Stable
26
4
9
presence of introns none
Cellular source T cells 
B cells 
Macrophages
Type I / 
Fibroblast
Virus / LPS 
ds-poly RNA
20-25
166
Single
Polypeptide
Stable
1
4
9
none
Fibroblasts 
Epithelial cells
Type II / 
Immune
Antigens / 
Mitogens
17-34
143
Noncovalent
Homodimer
Labile
1
10
12
T cells 
NK cells
Table 1.3 The characteristic features of the different interferon species.
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1.1 INTERFERON GAMMA
1.1.1 OVERVIEW
30 years of research into the actions of gamma-interferon has demonstrated 
the minor role that it plays as a direct anti-viral agent and shows that it has 
a more important role in the co-ordination of immune responses (reviewed 
by Farrar and Shreiber 1993)
Interferon-y is unrelated to type I interferons both at the gene and protein 
levels Gray et al (1982). Moreover, IFN-y is induced by a unique set of 
stimuli and is produced only by T lymphocytes and NK cells. Importantly, 
viral infection of these cells does not directly induce IFN production. Pace 
et al (1985) demonstrated that IFN-y has a 10-100 fold lower specific anti­
viral activity than the type I interferons but is 100-10,000 times more 
active as an immunomodulator than are the other classes o f interferons. 
Thus the conclusion can be made that IFN-y is primarily an 
immunomodulator with some anti-viral activity, while the type I 
interferons are primarily antiviral cytokines.
The human (Gray et al, 1982), murine (Gray and Goedell, 1983), bovine 
(Cerretti et al, 1986), canine (Zucker et al, 1992), ovine (Radford et al, 
1991)
, equine (Curren et al, 1994), rabbit (Samudzi et al, 1991) and rat (Dijkema 
et al, 1986) interferon cDNA's have been cloned. Although there is a 
reasonable degree of homology between the DNA sequences of these 
genes, the different interferon-y molecules are generally species specific.
l i
1.1.2 MOLECULAR CHARACTERISTICS OF HUMAN AND 
MURINE INTERFERON-y
Both humans and mice only contain one interferon-y gene which is 
considerably more complex than the type I interferon genes. The human 
and murine genes are 6kb in size and contain four exons and three introns 
(Gray and Goedell 1982). Using in situ hybridisation techniques the gene 
has been localised to chromosome 12 in man and chromosome 10 in the 
mouse, Trent et al (1982), and Naylor et al (1984).
The molecular characteristics of human and murine interferon gamma 
species have been reviewed by Farrar and Schreiber (1993). Activation of 
the human gene leads to generation of a 1.2 KB mRNA that encodes a 166 
amino acid polypeptide. Two polypeptides self-associate to form a 
homodimer with an apparent molecular weight of 34 kDa. Only the dimer 
can display biological activity, possibly because it is the only form of the 
molecule which can effect interferon-y receptor dimerization. The mature 
human interferon-y molecule has no cysteine residues and thus the 
homodimer is held together by non-covalent forces. The molecule is 
sensitive to extremes of heat and pH. The dimeric nature of the human 
interferon molecule is depicted in figure 1.1
The individual human and murine polypeptide chains contain two N-linked 
glycosylation sites (residues 25 and 97 in human interferon-y and residues 
16 and 69 in the murine form). These are independently and differentially 
glycosylated giving rise to subunits of differing molecular weights. 
Natural human and murine interferon-y homodimeric molecules display 
molecular weights which range from 30-50KDa. Whereas glycosylation is
12
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Figure 1.1 Schematic representation of the human IFN-y molecule. IFN-y is 
synthesised as a 166 amino acid polypeptide that contains a 23 amino acid 
signal sequence (shaded box). Two polypeptides self associate to form a 
noncovalent homodimer(frorn Farrar and Shreiber, 1993)
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not important for full biological activity of the interferon molecule it 
appears to influence the biological half-life in the circulation.
Current data indicates that both the amino and carboxy terminal regions 
play critical roles in maintaining the active conformation o f the protein. 
Recently, the X-ray crystallographic structure of human interferon-y was 
resolved to 3.5A. (Ealick et al 1991). This study confirmed the dimeric 
nature of the mature protein. The individual subunits have a flattened 
prolate elliptical shape. However, the overall structure of the dimer is 
compact and globular. The molecule appears to be primarily helical (62%) 
and lacks beta sheet structure. Each subunit consists of 6 alpha helices 
held together by short non-helical regions. The dimer is formed by a 
unique intertwining of the helices across the subunit face which provides 
an opportunity for multiple interactions along each subunit. This type of 
subunit interaction is highly unusual and has only been seen in a few other 
proteins. The model predicts that the subunits associate in an antiparallel 
fashion, thereby leading to a juxtaposition of the amino and carboxy 
termini of the opposing polypeptide chains. Whereas the amino termini 
co-ordinates have been firmly established, the carboxy termini do not 
adopt a rigid conformation in solution, as determined using either X-ray 
crystallography or nuclear magnetic resonance approaches. Nevertheless, 
the model suggests that each interferon-gamma dimer may be able to bind 
two interferon-gamma receptors. The structure of the human interferon-y 
is shown in figure 1.2.
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Figure 1.2 Stereo views of the human recombinant interferon-y dimer (from 
Ealick et al 1991). (A) is a view approximately parallel to the dimer twofold 
axis and (B) is a view approximately perpendicular to the dimer two fold 
axis.
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1.1.3 PRODUCTION OF INTERFERON-y
The mechanisms involved in the production of human and murine 
interferon-y have been reviewed by Farrar and Schreiber (1993), De 
Maeyer and De Maeyer Guignard (1994) and Vilcek and Le (1994). What 
follows is a synopsis of the current understanding.
The T lymphocyte represents the major cellular source o f IFN-y. All 
CD8+ T cell populations and certain subsets of CD4+ T cells can produce 
the protein. Interferon-y biosynthesis has been demonstrated in the TH\ 
helper T cell subset and also in TH q cells which are thought to be a less 
well differentiated/activated CD4+ cell. The external stimuli which cause 
production of the protein are similar to those of other T cell derived 
cytokines. The major physiological stimulus is antigen presented in the 
context of MHC I or MHC II. In addition T cell-dependent production of 
IFN-y is enhanced by products of activated T cells and macrophages such 
as IL-2, hydrogen peroxide, and leukotrienes LTB4, LTC4, and LTD4. 
The cellular sources of interferon-y are represented diagramatically in 
figure 1.3.
The induction of interferon-y appears to be regulated at both the level of 
gene transcription and mRNA stabilisation. T cell lymphokine gene 
expression has been reviewed by Fraser et al (1993). Interferon-y is 
produced by T cells after stimulation of the T cell receptor (TCR). The 
TCR has no intrinsic tyrosine kinase function but cross-linking of the TCR 
complex leads to activation o f cytoplasmic protein tyrosine kinases (PTKs) 
which interact with the TCR. Two src-family PTKs, fyn  and lek, have 
been implicated in this signalling mechanism. Subsequently, there is
16
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Figure 1.3 Sources and production of interferon-y (from Farrar and Shreiber, 1993)
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tyrosine phosphorylation of cellular proteins. Phospholipase C-yl (PLC) is 
one of the proteins whose tyrosine phosphorylation is induced following 
TCR stimulation and activation of PLC leads to the generation o f inisotol 
triphosphate and diacylglycerol. The former leads to an increase in free 
calcium ions (Ca2+), whereas the latter activates protein kinase C (PKC).
The generation of free calcium ions is considered to be an important event 
in mediating gene transcription and is inhibited by the immunomodulatory 
drug Cyclosporin A (CSA). The mechanism by which these early 
signalling events are transduced to the nucleus is unclear but the outcome 
is to activate transcription factors which regulate gene transcription. The 
nature of the transcription factors regulating interferon-y gene transcription 
is largely unknown.
T cell activation involves the induction of lymphokine mRNA which 
belongs to a class of short-lived mRNA characterised by the presence of 
repeated (AUUUA)n sequences in their 3' non-coding region. The human 
interferon-y mRNA bears these features of instability shared by most 
interleukin mRNA. It has been suggested that these AU motifs may be 
recognition sequences for inducible ribonuclease activity (Troutt and 
Kelso 1992). Interferon-y mRNA stabilisation by activation of protein 
kinase C or increased cAMP in a cytolytic T cell clone has been recently 
demonstrated by Kaldy and Schmitt-Verhulst (1995). While an increase in 
calcium ions generates increased gene transcription, increased PKC 
activity does not. However, PKC and cAMP induced PKA activity have 
now been shown to stabilise interferon-y mRNA by an unknown 
mechanism. cAMP levels can be increased by physiological doses of
18
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Figure 1.4 Shematic representation of the process of T cell activation and 
IFN-y production
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prostaglandin E2 (PGE2) or Histamine, both of which are potent 
inflammatory mediators.
While TCR-generated signals can contribute to the activation of cytokine 
gene expression, this alone is generally insufficient to induce gene 
transcription. Evidence suggests that accessory receptors are involved in 
full activation of the T cell (reviewed by Fraser et al 1993). One o f the 
most studied Mco-stimulatoryM molecule is CD28, a 44kDa glycoprotein 
member of the Ig superfamily which is expressed by both CD4+ and CD8+ 
T cells. The ligand for CD28 is another member of the IG superfamily 
called B7, found on activated B cells and antigen presenting cells (APCs). 
CD28 signal transduction in the context of TCR-generated signals 
increases the mRNA level and secretion of a number of T cell derived 
cytokines such as IL-2, as well as Interferon-y. The mechanisms of T cell 
activation are represented in figures 1.4 and 1.5.
Interferon-y can also be produced by NK cells. Mitogens can induce 
interferon-y production from human and murine NK cells expanded in- 
vitro with IL-2. in addition, production of IFN-y can be rapidly induced 
from naive NK cells by the action of microbial products in conjunction 
with TNF-a.
Two recently described cytokines are noteworthy in terms of their 
respective abilities to regulate interferon-y production in both a positive 
and negative fashion. IL-12, (formerly known as Natural Killer cell 
stimulatory factor (NKSF) produced from B cells and macrophages, has a 
positive effect on interferon-y gene transcription and IL-10 , produced by 
TH2 cells, B cells and macrophages has a negative effect on interferon-y 
production (reviewed by Farrar and Schreiber 1993).
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Figure 1.5 Signalling events in Tcell activation and interferon-y production
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The exact mechanism of IL-12 induction is unclear but probably involves 
bacteria, bacterial products or parasitic infection. The mechanisms by 
which IL-12 stimulates production of interferon-y is, as yet, undetermined. 
However, it is thought that IL-12 induces Interferon-y production in T cells 
and NK cells in a manner that is at least partially distinct from the 
conventional pathway of T cell activation. IL-12 induction is not inhibited 
by Cyclosporin-A (CSA) which is known to antagonise Ca2+ induced gene 
transcription following activation of the TCR. It appears from studies on T 
cells that IL-12 induces interferon-y production at the level of gene 
transcription and also, in conjunction with IL-2, stabilises the mRNA 
transcribed (Chan, S.H. et al 1992). The role of IL-12 in induction of 
interferon-y has been reviewed by Trinchieri (1993). IL-12 is particularly 
effective in inducing interferon-y production, either directly or with strong 
synergistic effect with several other inducers of interferon-y production, 
including IL-2, mitogens, and ligands for TCR-CD3 and CD28 on T cells 
as well as IL-2 and CD 16 ligands on NK cells. Anti-IL-12 antibodies 
inhibit interferon-y production in response to various stimuli, both in vivo 
and in vitro, indicating that IL-12 is required for optimal production of 
Interferon-y. IL-12 is thought to act both directly and indirectly, via the 
induction of interferon-y, on T cells to generate THi type responses. 
Interferon-y has a positive feedback effect by enhancing the production of 
IL-12 by monocytes and macrophages. This may, in part, be due to the 
ability of Interferon-y to block endogenous IL-10 production by 
macrophages. The existence of positive and negative feedback loops 
suggests that once either a THi or TH2 type response is determined early 
during the immune response, it remains stable, unless major changes take 
place in the balance of cytokine production during the response.
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Figure 1.6 Schematic representation of the regulation of IFN-y production by 
IL-10 and IL-12
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The mechanisms by which IL-10 downregulates production of IFN-y is 
currently being elucidated. The target for IL-10 appears to be the antigen 
presenting cell (APC) as well as the T cell. The current hypothesis is that 
IL-10 may inhibit the expression of accessory molecules required for full 
activation of the T cell for interferon-y production. The regulation of 
interferon-y production by IL-10 and IL-12 is shown diagramatically in 
figure 1.6.
It is worthy of note that Interferon-y is rarely seen in the circulation of 
individuals undergoing immunological stimulation possibly due to the 
rapid removal of IFN-y from the circulation by IFN-y receptors which are 
ubiquitously expressed on all cells.
1.1.4 THE INTERFERON GAMMA RECEPTOR
Studies concerning the interferon-y receptor has been reviewed by Pestka 
and Langer (1987) and, more recently, by Farrar and Schreiber (1993) and 
Vilcek and Oliveira (1994).
Interferon-gamma exerts its pleiotropic actions on cells through the 
interaction with a specific receptor which is ubiquitously expressed on all 
cells apart from the erythrocyte. Even platelets have a high level of 
receptor expression (around 300 receptors per cell) and it has been 
postulated that these cells may serve to transport interferon-y through the 
circulation. The highest levels of receptor expression are actually seen in 
those tissues which are not normally associated with the immune system. 
In particular skin, nerve and syncitial trophoblast cells of the placenta 
express high levels of interferon-y receptor. The receptor binds ligand 
with high affinity (K a=10^-10^M _1) and js expressed on most cells at
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modest levels of around 200-25000 sites per cell. Human and murine 
interferon-y receptors display strict species specificity in their ability to 
interact with human and murine interferon-y.
The receptor is synthesised in the endoplasmic reticulum and is 
glycosylated as it moves from the endoplasmic reticulum into the golgi 
apparatus. Only fully glycosylated receptors are expressed at the cell 
surface. Fully mature receptors that are expressed at the plasma membrane 
have molecular masses that vary between 80 and 95 KD. These 
differences arise because of cell specific differences in glycosylation. 
Following ligand binding the intracellular domain of the receptor is 
phosphorylated on serine and threonine residues. The rate and extent of 
the phosphorylation correlates with the magnitude of the biological 
response. The phosphorylated receptor/ligand complex is internalised, 
enters an acidified endosomal compartment, and dissociates. Free 
interferon-y is ultimately degraded in the lysosome. In many cells the 
receptor then enters a large intracellular pool of receptors that is usually 2- 
4 times larger than the cell surface pool. The ability of receptor recycling 
in macrophages remains controversial with some groups suggesting that 
this occurs while others suggest that internal receptors are degraded.
The complete characterisation of the human and murine interferon-y 
receptor was made possible by the cloning of the respective cDNAs, Aguet 
et al (1988) and Gray et al (1989). The genes for human and murine 
receptors have been localised to chromosome 6 and 10 respectively. Both 
genes are around 30Kb in size and each consist of seven 7 exons. Upon 
activation the gene gives rise to a single 2.3kb mRNA transcript. The 
human and murine proteins are organised in a similar manner. The mature 
human and murine proteins consist of 472 and 451 amino acids,
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Figure 1.7 Diagram showing the structure of the human Interferon-y receptor 
(from Farrar and Shreiber, 1993)
respectively, and have predicted molecular masses of 52.5 and 48.5 KDa. 
Both proteins are symmetrically orientated around single 23 amino acid 
transmembrane domains. Each possesses a 228 amino acid extracellular 
domain that contains 10 cysteine residues and 5 potential N-linked 
glycosylation sites which all appear to be occupied. The extracellular 
domain is sufficient to account for high affinity binding and receptor 
glycosylation is not critical for binding activity. The structure of the 
human interferon-y receptor is shown in figure 1.7.
Based upon primary sequence comparisons, the interferon-y receptor bears 
little identity to any other known proteins. More specifically, it is neither a 
member of the type one cytokine receptor family (haemopoeitic- 
characterised by the WSXWS motif) or the immunoglobulin superfamily. 
More refined sequence analysis suggests that the interferon-y receptor 
belongs to a newly emerging class of receptor termed the type II receptor 
family whose members include the receptor for interferon alpha. The 
members of this family share a similarly organised 210 amino acid binding 
domain which contains conserved cysteine pairs at both amino and 
carboxy termini. The type two family seems to be only distantly related to 
the type I family.
The intracellular domains of the human and murine interferon-y receptors 
are 221 and 200 residues, respectively. Both are rich in serine and 
threonine residues which together constitute 25% of the residues of this 
domain. In addition of the 6 tyrosine residues in the human receptor, 5 are 
conserved with the murine receptor, which is noteworthy considering the 
overall low sequence identity between the human and murine intracellular 
domains.
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Expression of the human and murine cDNA across species boundaries 
confirmed that the receptor bound ligand in an appropriate species specific 
manner and that receptors expressed across species lines were unable to 
induce a functional response in transfected cells (Hemmi et al, 1989). This 
result suggested that additional species specific components were required 
for full activation of the interferon-y receptor and supported conclusions 
reached from seminal experiments conducted by Jung et al (1987). This 
group used murine:human somatic cell hybrids to investigate the minimal 
requirements to form a functionally active human interferon-y receptor in 
murine cells. Fusion of murine and human fibroblasts was known to 
generate stable cell hybrids that contained a full complement of murine 
chromosomes but only a random assortment of human chromosomes. All 
hybrids that contained human chromosome 6, bound human interferon-y. 
However, responsiveness to the human ligand was observed only in cells 
that contained both human chromosome 6 and chromosome 21. This 
obligate requirement for two or more distinct species specific gene 
products led to the hypothesis that functionally active human receptors 
were composed of at least two distinct polypeptides: the receptor 
responsible for ligand binding and a species specific accessory protein(s) 
for full functionality.
Recently the identification and sequence of an accessory factor required 
for activation of the human and murine interferon-y receptor has been 
reported, Soh and Donnely et al (1994), Hemmi and Bohni et al (1994). It 
is now well recognised that human chromosomes 6 and 21 and mouse 
chromosomes 10 and 16 are required for sensitivity to interferon-gamma 
as measured by the induction of class I major histocompatibility complex 
antigens. This indicates that the binding of interferon-gamma to the 
receptor is necessary but not sufficient for the induction o f these antigens.
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The newly cloned second component of the interferon-y receptor has been 
termed accessory factor-1 (AF-1) by one group (Soh and Donnelly et al 
(1994)), and Interferon-y (3-chain by the other (Hemmi and Bohni et al 
(1994). Analysis of the sequence of this newly cloned component revealed 
that it shares some structural homology with the known components of the 
Interferon-a and Interferon-y receptors, indicating that it is a new member 
of the Interferon-receptor family. Whether additional ’accessory factors' 
exist that are needed for a fully functional IFN-y receptor is not yet clear. 
Soh et al (1994) found that AF-1 did not confer full antiviral protection 
against encephalomyocarditis virus in cells that express the binding 
portion (a-chain) of the human interferon-y receptor, suggesting that yet 
another factor(s) encoded by human chromosome 21 is required. In 
contrast Hemmi et al (1994) found that the newly cloned (3-chain of the 
murine interferon-y receptor was sufficient to restore what appears to be 
full responsiveness to murine interferon-y in cells that express the a-chain 
of the murine interferon-y receptor.
1.1.5 INTERFERON-MEDIATED SIGNAL TRANSDUCTION
The interferons can induce an anti-viral state and modulate cell growth, 
differentiation and the immune response. Interferon a/(3 (type I) and IFN-y 
(type II) induce distinct but overlapping sets o f genes through independent 
cell surface receptors (Muller et al, 1993). The interactions of interferons 
with their specific cell-surface receptors is followed by the rapid activation 
o f DNA binding factors which stimulate the transcription of a set o f genes 
containing interferon response sequences (IRS’s) homologous to the 
prototypic sequence GGGAAANNGAAACT (De Maeyer and De Maeyer 
Guignard 1994).
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Until recently events in the signalling tranduction pathway after interferon 
binding to receptor have been poorly defined. Some reports had indicated 
that signalling involved protein kinases, receptor phosphorylation and/or 
ion fluxes. Other reports had suggested that internalisation of the receptor 
ligand complex was required for signal transduction (reviewed by Farrar 
and Schreiber, 1993). This, however, would be insufficient to mediate 
signalling events. This is based upon two observations. Firstly, whereas 
human interferon-y receptors expressed in normal murine cells effect 
ligand internalisation and degradation with the same kinetics as 
functionally active receptors, no biological response is observed. Second, 
mutant human receptors lacking the carboxy terminal 39 amino acids when 
expressed in murine cells containing human chromosome 21, are also 
functionally inactive despite their ability to mediate ligand internalisation.
Recent work from several labs has lead to the elucidation of the backbone 
of the signal transduction pathways following interferon binding (Muller et 
al 1993; Watling et al 1993; Hunter, 1993). It has been demonstrated that 
interferons induce tyrosine phosphorylation and activation of transcription 
factor sub-units in the cytoplasm, which then translocate into the nucleus 
to initiate gene transcription. The initial insight into this pathway came 
from the observation that sub-units of an interferon-alpha transcription 
factor-Interferon Stimulated Gene Factor 3 (ISGF3), are localised in the 
cytoplasm. Following interferon alpha binding to the receptor, three of 
these cytoplasmic proteins p i 13, p84, p91 (Designated Signal Transducer 
and Activators of Transcription,or STAT, proteins) become 
phosphorylated on tyrosine, migrate to the nucleus and assemble into a 
complex together with p48, a sequence specific DNA-binding protein, to 
bind to the interferon-stimulable response elements and initiate gene 
transcription. The p91 and p84 subunits are derived from alternate
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splicing of the same gene and differ only in a 38 amino acid extension at 
the carboxy terminal of p91. PI 13 is derived from a distinct gene but is 
related over its whole length to p91. p48 contains an amino terminal 
DNA-binding domain related in sequence to those of the transcription 
factors IRF-1, IRF-2 and cMyb, and a carboxy terminal domain required 
for the binding of the other ISGF3 subunits.
The next steps in elucidating signal transduction pathways came from the 
analysis of mutants of an HT1080 human fibrosarcoma cell clone, which 
expresses the bacterial gpt gene under the control of an interferon-a and 
interferon-y inducible promoter, selected for non-responsiveness to 
interferon-a, Muller et al (1993). Mutant complementation group U3 cells 
lack a functional p91 gene and therefore express neither p91 or p84. 
Interferon-a responsiveness is restored to U3 cells by the expression of 
p91 or p84 complementary DNAs. Mutant group U2 cells lack a 
functional p48 gene and responsiveness is restored by expression o f p48. 
Mutant group U1 cells, which contain functional p i 13, p91/p84 and p48 
genes and bind interferon-a proved to be a mutant in the TYK2 protein 
tyrosine kinase (ptk) gene. Up to that time there was no known function 
for tyk2 and its related non receptor tyrosine kinases JAK1 and JAK2. 
However, this finding suggested that interferon-a binding to its receptor, 
which lacks intrinsic PTK activity, might lead to activation of TYK2, 
which in turn may lead to the phosphorylation of p91, p84 and p i 13.
The complementation of interferon resistant mutant cell lines has provided 
direct evidence for the involvement of the JAK family of non-receptor 
PTKs in the interferon signalling pathways. This family has three known 
members, JAK1, JAK2, and TYK2. Each is around 130kDa in mass and is 
characterised by the presence of a classical C-terminal protein tyrosine
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kinase domain, an adjacent kinase or kinase related domain and five 
further domains of substantial amino acid similarity with other members of 
the JAK family extending towards the amino terminus, Muller et al (1993).
The demonstration that TYK2 is required for interferon-a signalling then 
raised the question of how the interferon-a receptor would activate this 
tyrosine kinase and how the receptor functions. Interferon-y has an 
unrelated receptor and induces expression of a different but overlapping 
set o f genes through a distinct response element known as the Gamma 
Activation Sequence (GAS). The GAS is given by the sequence 
TTTCATATTACTCT. Interferon-y stimulates tyrosine phosphorylation of 
cytoplasmic p91, but not pi 13 or p84. Phosphorylated p91 bind directly to 
the GAS element after translocation to the nucleus.
Interferon-y induced phosphorylation of p91 also occurs at tyr701 and this 
modification is required for GAS binding. The failure o f U3 cells to 
respond to interferon-y suggests the essential role for p91. The selective 
phosphorylation of p91 after interferon-y binding suggests that a PTK 
other than TYK2 is responsible.
Kerr and co-workers were able to demonstrate the possible nature of the 
PTK involved. They showed that the U4A mutant cell line, which 
responds to neither interferon-a or y, expresses a truncated form of JAK1 
mRNA and no JAK1 protein, can be complemented for both interferon-a 
and y responses by expression of JAK1 cDNA.
In a second study the same group selected a new HT1080 cell line termed 
gl A, which was unable to respond to interferon-gamma but could respond 
to interferon-alpha and had functional p91, p84, p i 13 and p48 genes.
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Figure 1.9 A model for IFN-a and IFN-y activation of gene transcription. 
After IFN-y binding to receptor, the receptor dimersises and binds JAK1 and 
JAK2. Both receptor and JAK1 and 2 become phosphorylated and catalyse 
the phosphorylation of STATL This then becomes an active gene 
regulatory factor.
34
Interferon-y stimulates both JAK1 and JAK2 tyrosine phosphorylation in 
parental cells but neither JAK1 or JAK2 is phosphorylated in g lA  cells. 
Expression of JAK2 cDNA in g lA  cells restores interferon-y 
responsiveness, and interferon-y induced phosphorylation of JAK1 and 
JAK2. A full length JAK2 protein is detected in g lA  cells which suggests 
that there is an inactivating point mutation in JAK2 in g lA  cells (although 
the mutation could be in another protein which is required for the 
activation of JAK2).
Activation of the JAK family of PTKs can be summarised as follows. 
Interferon-y elicits tyrosine phosphorylation of JAK1 and JAK2, but not 
TYK. The mechanism by which interferon binding with receptor causes 
this tyrosine phosphorylation of the PTKs is still uncertain. Johnson and 
Szente (1994) have suggested the following scenario. When interferon 
gamma binds with its specific receptor there is internalisation of the 
protein which is then degraded. Soon after internalisation the carboxyl 
terminal region of the fragmentary or intact interferon-y molecule could 
bind to the receptor at a site that was initially inaccessible in the 
cytoplasm. Such binding could displace JAK2 from the same site and 
thereby free it to act upon other proteins. However, as stated above, ligand 
receptor internalisation is insufficient alone for signal transduction and a 
second co-factor is required. Activation of the janus kinases leads to 
phosphorylation of the receptor and the STAT protein P91 (GAF or 
Interferon-y activation factor). STAT91 dimerises and migrates to the 
nucleus where it binds to the GAS element, initiating gene transcription. 
Figures 1.8 and 1.9 show the general sheme of the JAK-STAT mechanism 
of signal transduction.
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Interferon-a induces phosphorylation of JAK1 and TYK2. Both U1 and 
U4A cells fail to respond to interferon-a and lack functional TYK2 and 
JAK1 respectively, which implies that both of these PTKs are required for 
the interferon alpha response. The failure of U4A and g lA  cells to 
respond to interferon-y indicates that both JAK1 and JAK2 are required for 
the interferon-y response. The other conclusion that can be drawn from the 
analysis of the mutants is that the JAK PTKs cannot be placed in any linear 
order because if either is missing then the second is not phosphorylated. 
The exact mechanism of phosphorylation of these kinases following 
receptor binding has yet to be established.
There are still gaps in the understanding of signal transduction pathways 
mediated by the interferons. One of these is how different interferon alpha 
species induce transcription of different sets of genes. Another obvious 
gap is the mechanism by which receptor binding leads to phosphorylation 
of the PTKs.
1.2 INTERFERON-y BIOLOGY
1.2.1 INTRODUCTION
Reported biological functions of interferon-y have been reviewed by Farrar 
and Schreiber (1993), De Maeyer and De Maeyer Guignard (1994), Pestka 
and Langer (1987) and De Maeyer and De Maeyer Guignard (1992).
Despite the many documented functions of inteferons it is not easy to 
determine how essential interferons are in host defence and immune 
responses. The reason for this uncertainty is the extensive redundancy in 
cytokine actions. Some of the antiviral and immunomodulatory actions of
36
IFN-a/p of IFN-y can be mimicked by other cytokines, notably by TNF or 
IL-1. To what extent these and other cytokines can substitute for the 
actions of the interferons is uncertain. Help for this problem is coming 
from the use of 'gene knockout' mice, that is mice which lack a functional 
interferon-y gene or interferon-y receptor gene. To generate mice lacking a 
specific functional gene, embryonic stem cells taken from the 
preimplantation mouse embryo are cultured and injected with a targeting 
vector in which DNA, homologous the the interferon-y or interferon-y 
receptor gene, is incorporated. Homologous recombination leads to 
removal of the essential portion of the gene. Embryonic stem cells 
carrying the mutation are selected and re-introduced into an early embryo.
Mice with a targeted deletion of the interferon-y gene and mice with a 
targeted deletion in the interferon-y receptor gene have recently been 
generated. Both types of mice develop normally and show no overt 
phenotypic abnormalities. In addition the immune system does not show 
any developmental abnormalities and receptor deficient mice are able to 
mount a normal cytotoxic T cell response against infection with 
lymphocytic choriomeningitis virus and develop undiminished antibody 
levels when immunised with various antigens. Despite this it may be that 
the deficiency is affecting the development of immune responses in a more 
subtle way. In addition, a complete deletion in the structural gene for 
interferon-y or its receptor may be promoting the development of 
compensatory pathways that are not normally present when the interferon- 
y system is intact. Thus it may be that studies using gene knockout mice 
may underestimate the importance of interferon-y in the immune response.
Despite the ability of the receptor deficient mice to mount specific immune 
responses, these animals showed severe defects in the defence against
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several infectious agents. Inoculation of a sublethal dose of Listeria 
monocytogenes into receptor deficient mice caused death in the majority of 
mice by the fifth day after infection. Increased mortality was accompanied 
by a more abundant multiplication of the organism in the organs of the 
mice. In addition, these mice were also more susceptible to infection with 
vaccinia virus than wild-type mice. This increased sensitivity was 
accompanied by a higher titre of virus in the organs of affected mice. 
Hence, it appears that interferon-y may be restricting viral replication in 
the early stages of infection.
Infection of receptor deficient mice with the BCG strain of Mycobacterium 
bovis also demonstrated increased susceptibility compared to wild-type 
mice. In wild type mice there is development of granulomatous 
inflammatory lesions in their livers, spleens and lungs which reach a peak 
at 2-3 weeks following inoculation with M.bovis. Subsequently, the
cellular immune response leads to the gradual elimination of 
mycobacteriam from the organs and complete recovery from infection. In 
contrast, in receptor deficient mice the elimination of the organism was 
impaired and all infected mice died within 7-9 weeks of infection. 
Extensive inflammatory lesions and large numbers of mycobacteriam were 
found in the livers, lungs and spleens. This increased susceptibility to 
infection with M.bovis has also been demonstrated in mice with a mutant 
interferon-y structural gene.
The exact mechanism whereby interferon-y promotes host resistance 
organisms requires further investigation. Interferon-y is known to be the 
principal agent responsible for macrophage activation. The receptor 
deficient mice showed decreased formation of granulomatous lesions 
following infection with M.bovis. The presence of activated macrophages
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in granulomas is thought to be essential for the elimination of 
mycobacteriam, Listeria and other infectious agents. Endogenous TNF-a 
is also thought to be important in granuloma formation during 
mycobacteriam infection, probably acting in concert with interferon-y. In 
the infected, receptor deficient mice, production of endogenous TNF-a 
was also impaired. Another factor which may contribute to increased 
susceptibility to infectious agents is the important role that interferon-y 
plays in the regulation of MHC class II expression. In the infected, 
receptor deficient mice MHC II expression was significantly lower than 
infected wild-type mice.
1.2.2 MHC CLASS ANTIGEN INDUCTION
Interferon-y is an extremely pleiotropic cytokine that has a major 
physiological role in regulating immune and inflammatory processes. 
Clearly one of the major roles of IFN-y is in the enhancement o f MHC I 
expression and the induction of MHC II expression. IFN-y acts at the level 
of MHC gene transcription and is important in promoting antigen 
presentation during the inductive phase of the immune response. Thus a 
prime target for interferon-y action is the macrophage.
Work from several laboratories has shown that interferon gamma is one of 
the major cytokines responsible for activating or regulating the 
differentiation and function of mononuclear phagocytes. Interferon-y has 
been shown to effect the differentiation of immature myeloid precursors 
into mature monocytes. It promotes antigen presenting function, not only 
through the induction of MHC II but also by increasing levels of 
intracellular enzymes which may be required for antigen processing. In 
addition, IFN-y augments expression of macrophage cell surface proteins
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such as ICAM 1 that enhance the functional consequences of the 
interaction between macrophages and T cells during antigen presentation.
MHC class II molecules present antigens to T lymphocytes and the tight 
regulation of their expression is of critical importance to the control of the 
immune response. However, the mechanism of interferon-y induced MHC 
class II expression remains obscure. Induction of MHC class II genes is 
characterised by a long lag period and total dependence on de novo 
synthesis of protein. These genes thus exhibit a secondary response to 
interferon-y which has led to the postulation of an intermediary activator 
which is itself induced by interferon-y. It has not been possible to define 
interferon response elements in MHC II genes. In addition none of the 
now well documented interferon-y inducible elements have been found to 
bind to class II promoter sequences. Furthermore, it has been suggested 
that the constitutive and inducible modes of class II expression are 
controlled by distinct regulatory mechanisms, Steimle et al (1994).
The MHC class II transactivator CIITA was recently cloned by genetic 
complementation of an MHC class II mutant B lymphocyte line (Steimle et 
al 1994). CIITA is expressed in a cell specific manner which correlates 
with MHC class II expression. CIITA expression has been studied in 
MHC class II negative cells. In these cells it was found that interferon 
gamma could induce CIITA expression and this precedes expression of 
MHC class II genes. It is now established that CIITA is required for both 
constitutive and inducible expression of MHC II molecules and that it is 
itself inducible by gamma interferon. It has also been found that 
expression of CIITA cDNA in the absence of interferon gamma is alone 
sufficient to switch on MHC class II expression. Thus the model for 
induced expression o f MHC class II by interferon gamma is as follows.
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Figure 1.10 A model for MHC Class II antigen induction by IFN-y 
(from Steimle et al, 1994)
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Interferon gamma induced intracellular signals activate expression of the 
CIITA gene. There is no direct evidence that there is binding of the CIITA 
to the MHC class II promoter and therefore CIITA may act as a gene and 
tissue specific co-activator. The model for MHC class II induction is 
represented in figure 1.10
The main target cell for interferon-y is the macrophage. In experiments 
carried out in mice, the administration of recombinant murine interferon- 
gamma resulted in increased expression of MHC antigens on macrophages 
and on other cell types. In addition, interferon-gamma enhances MHC 
class II expression on T cells, B cells and tumour cells. Stimulation or 
expression of MHC class II antigens on certain tumours has been observed 
with both interferon-a and y. Cells of established lines derived from 
human tumours such as melanoma, breast carcinoma can be induced to 
express class II antigens by interferon-y. However, this is not a general 
property of all tumour cells and some are resistant to the effects of 
interferon-y.
1.2.3 NON-SPECIFIC HOST DEFENCES
There is little doubt that IFN-y is the major physiological macrophage 
activating factor and therefore is the primary cytokine responsible for 
inducing non-specific cell mediated mechanisms of host defence. Work 
from several laboratories has established interferon gamma's ability to 
activate non-specific cytocidal activity in macrophages towards a variety 
of intracellular and extracellular parasites and neoplastic cells. IFN-y 
induces the expression of undefined structures on macrophages that 
recognise target cells, promote the elaboration of macrophage-derived 
cytocidal compounds such as reactive nitrogen and oxygen intermediates
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Figure 1.12 The role of Interferon-y in host defences
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and TNF-a, and also reduces the susceptibility of macrophages to 
microbial infection. The importance of IFN-y in the clearance of microbial 
pathogens has been demonstrated using animal models. Mice pre-treated 
with neutralising antibody to IFN-y lose their capacity to resolve infection 
from microbial pathogens such as Listeria monocytogenes, Toxoplasma 
gondii, and Leishmania major. In addition the experiments carried out in 
gene 'knockout' mice, described above, have confirmed this.The induction 
of nitric oxide (NO) production is thought to be one of the principal 
mechanisms of macrophage cytotoxicity for tumour cells, bacteria, 
protazoa, helminths and fungi. NO is an unstable free radical gas that, in 
addition to its role in host defences, functions as an intercellular messenger 
in vasodilation and neurotransmission, At least three related genes encode 
NO synthases in different tissues. Endothelial and neural NO synthases 
are constitutive enzymes that are activated by Ca2+/calmodulin. In 
contrast, macrophages and many other cells contain a transcriptionally 
inducible NO synthase (iNOS) that remains undetectable until these cells 
are activated. In murine macrophages the most potent activators o f gene 
transcription appear to be interferon-y and bacterial lipopolysaccharide 
(LPS). The promoter region of the murine iNOS gene was recently shown 
to be responsive to interferon-y and LPS.
More recently, Interferon regulatory factor I (IRF-1) has been identified as 
a transcription factor critically important for the induced expression of the 
iNOS gene and NO synthesis in murine macrophages. IRF-1 and the 
related IRF-2 protein are transcription factors involved in the regulation of 
IFN-a/b genes and some IFN-inducible genes. IRF-1 functions as a 
transcription activator, whereas IRF-2 inhibits transcription. IRF-1 is 
strongly induced by the action of interferon-y, (Vilcek et al, 1994).
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1.2.4 IMMUNE EFFECTOR FUNCTIONS
In addition to enhancing non-specific cell mediated cytocidal activities, 
IFN also enhances the ability of macrophages to participate in other 
immune response effector functions. It enhances the expression of high 
affinity Fc receptors on macrophages and monocytes (FcyRI) and thereby 
enhances the capacity of these cells to take part in antibody dependent 
cellular cytotoxicity (ADCC). Interferon-y also enhances the biosynthesis 
of a variety of complement proteins by macrophages and fibroblasts and 
regulates the expression of complement receptors on the mononuclear 
phagocyte plasma membrane thereby promoting humoral immunity 
through the enhancement of complement activity.
IFN-y also exerts its effects on other cells of the immune system. It 
regulates immunoglobulin isotype switching on B cells and antagonises 
the ability of IL-4 to induce MHC II expression on murine B cells. These 
responses result from the direct effect of interferon-y on the B cell. B cell 
responses are also affected indirectly by the ability of interferon-y, in 
synergy with IL-12, to regulate the development of specific subsets of 
CD4+ T cells. Interferon-y has a profound antiproliferative effect on TH2 
cells but not THj. Thus interferon-y plays a major role in determining the 
type of immune effector function that eventually develops during specific 
immune responses. The opposing effects of IL-10 and IFN-y thereby serve 
to cross regulate the development of specific immune responses. IL-10 
inhibits IFN-y production by T cells and NK cells and thus diverts the 
response to the humoral pole. In contrast, IFN-y inhibits the expansion of 
TH2 like cells which eliminates the source of IL-10 and diverts the 
response to that of cell mediated immunity. The involvement of
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Figure 1.13 Schematic representation of the involvement of interferon-y in 
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interferon-y in the generation of THj and TH2 cells is represented 
diagrammatically in figure 1.13.
1.2.5 INTERFERON AND TNF-a
Interferon-y is intimately related to the regulation of TNF-a production. It 
is well established now that LPS induced macrophages produce increased 
amounts of TNF-a when pre-treated with interferon-y. It was initially 
thought that interferon-y treatment alone could induce TNF-a production 
but this was not substantiated in other laboratories and the initial findings 
may have been due to the increased sensitivity of cells to minute traces of 
LPS in the cell medium. Studies indicate that the enhancement of TNF 
production may be due to either increased gene transcription or increased 
stability of TNF mRNA. in addition, interferon-y enhances TNF receptor 
expression on certain cell types. The role that interferon plays in TNF 
regulation demonstrates a further role in non-specific defence mechanisms 
by the enhancement of the inflammatory response (Farrar and Shreiber
1993).
During the inflammatory response, cells leave the circulation at the site of 
the response , but to do this, they must extravasate through the vascular 
endothelium. This process is intimately related to the up-regulation of cell 
surface adhesion molecules on the surface of endothelial cells. Interferon- 
y has been found to up-regulate ICAM-1 and MHC class I molecules on 
these cells, while TNF-a has been found to up-regulate ICAM-1, ELAM-1 
and MHC-class I (reviewed by Farrar and Schreiber 1993). Further, the 
two cytokines appear to act synergistically to amplify these effects. Thus, 
the co-operative ability of Interferon-y and TNF-a to modulate cell 
migration serves to expand and amplify the overall inflammatory process.
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1.2.6 INTERFERON AND NK CELLS
Natural killer cells probably function as an early defence line against 
viruses because of their ability to kill virus-infected cells as well as a 
variety of tumour cells. In both cases, the killing of the cells occurs in a 
non-MHC restricted fashion. NK cells are positively regulated by all three 
classes of interferons and can also be indirectly stimulated by inducers of 
interferon production such as viruses or mitogens. The mechanisms by 
which interferon enhances NK cell function have been reviewed by Reiter
(1993) and Reiter and Rappaport (1993). In general, it is possible to define 
at least four mechanisms by which interferon may enhance or activate NK 
function. Firstly, IFN could induce NK cell proliferation; secondly, it 
could convert the NK precursor cell into an active NK cell; thirdly, it could 
enhance binding of NK cells to target cells, and fourthly, it could enhance 
the lytic efficiency of NK-target cell conjugates.
In contrast, interferon can also have a negative effect on both NK cell and 
lymphokine activated killer cell (LAK) mediated cytotoxicity. The 
negative modulatory effect of interferon on these cells has been reviewed 
by Reiter (1993). Pretreatment of target cells with interferon causes them 
to become refractory to the effects of NK cells and LAK cells but the cells 
still remain susceptible to killing by cytotoxic T cells. This suggests that 
interferon does not induce a general resistance to T cells but induces 
specific resistance to NK cells. Interferons have been found to have this 
protective effect on many cell types but the degree of protection may vary 
between cell phenotypes. Interestingly, tumour cells are found to be less 
protected than normal cells. Thus, interferon, by stimulating cytotoxic 
cells and by simultaneously protecting normal cells from lysis, might
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thereby make the NK system and inducible selective defence system 
against tumour and virus-infected cells. However, because protection by 
interferon may extend to some transformed cells, there will be occasions 
when these cells will escape killing by NK and LAK cells
1.2.7 RESOLUTION FROM VIRAL INFECTION
There are essentially two ways in which the interferons are involved in the 
antiviral response and resolution of viral infections. The first, is the ability 
of interferon species to protect cells against viral infection by the 
activation of enzyme pathways which inhibit viral protein synthesis 
(described below). This is important in the early stages of infection and is 
a non-specific defence mechanism to limit viral replication and 
dissemination. As discussed earlier, interferon-a and p are far more potent 
antiviral agents as regards this process of viral limitation. Viruses differ in 
their capacity to induce interferon. Myxoviruses, paramyxoviruses and 
toga viruses are the best inducers; picoma viruses and poxviruses induce 
moderate amounts; herpesviruses are poor inducers, and adenoviruses are 
non-inductive. In general, viruses which dramatically inhibit cellular 
mRNA synthesis are poor inducers.
The ability of viruses to induce interferon and their susceptibility to the 
action of interferon are not necessarily related (Onions and Jarrett, 1994). 
For example, in dog cell cultures vaccinia virus does not induce interferon 
but its growth is inhibited when exogenous interferon is added to the 
culture. In contrast, in these cells influenza B induces interferon but is 
insensitive to its action.
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Different strains of the same virus type may induce different quantities of 
interferon, and their virulance may be related to the amount of interferon 
induced. For example, certain strains of rubella virus which induce high 
levels of interferon are less teratogenic than strains which induce small 
amounts.
What follows is a description of the induction of the antiviral state by the 
interferon species. Several of the interferon-stimulated genes code for 
proteins responsible for the antiviral state, such as the dsRNA-dependent 
Pl/eIF-2a kinase, the (2'-5') oligo adenylate synthetase, and the Mx 
proteins. These antiviral mechanisms have been reviewed by De Maeyer
(1994).
The (2'-5') oligo adenylate synthetase, or (2'-5')An synthetase is 
constitutively expressed in many cells but its concentration can be 
increased by several orders of magnitude by the addition of interferon. 
Interferon-a and P are far more potent at enzyme induction than 
interferon-y. IFN treatment alone does not significantly increase the 
intracellular concentration of the synthatase enzyme or increase the extent 
of the protein kinase phosphorylation. However, infection of IFN-treated 
cells with either EMC virus, reovirus, influenza virus, vaccinia virus, or 
simian 40 virus causes a significant increase in the intracellular 
concentration of the synthetase enzyme and/or the extent of eIF-2a 
phosphorylation. When activated by ds RNA, (2'-5')An synthetase 
polymerizes ATP into a series of 2'-5’-linked oligomers (ppp(A2'p)n) of 
which the trimer is the most abundant. These oligomers, collectively 
called 2-5A, then activate a latent endoribonuclease, designated RNase L, 
which is responsible for the antiviral activity. The third enzyme of this 
system, which is present in interferon untreated and treated cells, is a 2'-5’
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phosphodiesterase that catalyses the degradation of 2-5A. The dsRNA 
required to activate the system are most likely to be intermediates or by­
products of viral RNA replication. The system serves then to degrade viral 
RNA.
Activation of the protein kinase Pl/eIF2 (a serine threonine kinase) is the 
second pathway of IFN-induced translational control that is dependent on 
the presence of dsRNA. Pl/eIF2 is activated by interferon treatment and 
the presence of dsRNA. Following activation, it first autophosphorylates 
and then phosphorylates the a subunit of eIF2, the eukaryotic protein 
synthesis initiation factor. As a result, the recycling of the a subunit is 
inhibited and the initiation of translation cannot begin. This system then 
serves to prevent viral mRNA translation.
The Mx proteins are a family of interferon a/p  inducible GTPases that 
display antiviral activity against specific viruses such as influenza virus.
The antiviral responses induced by interferon are depicted 
diagrammatically in figure 1.14. The individual importance of each 
system in the antiviral response has yet to be resolved.
The second mechanism by which interferon is involved in antiviral 
immunity is by its immunomodulatory actions, and this is really the 
domain of interferon-y. As described, interferon-y stimulates natural killer 
cells, cytotoxic T cells, and upregulates both MHC class I and II antigens. 
These effects produce a local stimulus for cell killing by these effector 
cells and, in addition, because interferon-y is produced by NK cells and 
CTLs, there is a local positive feedback loop which amplifies the immune 
response.
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It has been suggested by one group (Ramsay et al 1993), that the major 
function of the effector cells (NK cells and CTLs) is to focus antiviral 
cytokines at the site of virus replication. This group used recombinant 
vaccinia viruses (rVV), constructed to encode murine cytokine genes, to 
examine the antiviral effects of these molecules. It was found, in the 
murine model, that in the absence of classical, anti-viral effector cells, 
animals were able to control infection with rVV infection when the rVV 
expressed interferon-y. This group also suggest that TNF-a and IFN-y 
synergise as antiviral agents. This is evidence that, while interferon-y is 
important in directing the immune response against viruses, it may also be 
directly anti-viral.
As a final point on antiviral mechanisms, it is noteworthy that some 
viruses have evolved mechanisms which evade the immune response. For 
example, The human herpes virus EBV has "captured" the human IL-10 
gene by recombination (Rhode et al, 1993). Expression of this in the host 
may direct the immune response away from the cell mediated pole and 
thus evade the antiviral CTL responses. In addition, a recent report 
(Alcami and Smith, 1995) has suggested that a variety of orthopoxviruses 
have captured the interferon-y receptor gene which is able to bind and 
neutralise IFN-y in a non-species specific manner. This interferes with the 
anti-viral action of this cytokine.
SUMMARY
The above review of the biological functions of interferon-y underlines the 
pleiotropism of this cytokine and its intimate relationship with non­
specific and specific effector arms of the body's defence mechanisms. One 
can appreciate now that the primary function of interferon-y is that of a
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pivotal immunoregulatory cytokine rather that an anti-viral agent. The 
various roles that interferon plays in the host defence mechanisms 
therefore include a role in innate immunity (macrophages/neutrophils), 
lymphocyte migration, antigen recognition by T cells and effector T cell 
development. This is depicted in figure 1.15.
1.3 CLINICAL APPLICATION
1.3.1 OVERVIEW
Interferon-gamma is a pleiotropic cytokine which has numerous effects on 
the immune system and host defence. The pivotal role that interferon 
plays
in host defence and immunity has made it an attractive candidate in the 
treatment of infectious, immune related and neoplastic disorders. In 
addition, because of interferon-gamma's role in antigen presentation, the 
potential of immune interferon as a vaccine adjuvant is also being 
explored. The following paragraphs will briefly highlight some of the 
clinical applications being found for human recombinant interferon- 
gamma.
1.3.2 THE PHARMACOLOGY OF RECOMBINANT 
HUMAN INTERFERON-y
The pharmacology of recombinant interferon-y has been reviewed by 
Kruskal and Ezekowitz (1994). Recombinant human interferon-y is an 
E.coli derived protein which is available by parenteral route only. The 
drug can be given by the intravenous and intramuscular routes but the 
usual route is subcutaneous, which provides the most sustained release.
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Pharmacokinetic data, derived from healthy volunteers, demonstrate rapid 
clearance after intravenous administration. Mean half-times for a dose of 
100ug/m2 by the i.v, i.m and s.c routes are, respectively, 0.6, 2.9, and 5.9 
hours. In a large placebo-controlled clinical trial of interferon-y ( 5 0 u g / m 2  
or 1.5ug/kg for patients less than 0.5 m2) for chronic granulomatous 
disease, the drug was generally well tolerated. Adverse reactions reported 
significantly more frequently from treated patients included fever, 
headaches, chills, and erythema at the site of injection. The magnitude of 
these reactions was usually mild and they were effectively treated 
symptomatically (i.e. paracetemol). The drug gave fewer reactions when 
given at bedtime, and patients less than 10 years of age had fewer adverse 
reactions than older patients. Only four of the 128 patients on the 
interferon trial had to discontinue treatment because of toxicity. Patients 
treated with much higher doses (e.g> 1 0 0 u g / m 2 )  rarely had more severe 
reactions, e.g. cardiovascular (hypotension, syncope, tachycardia, heart 
block, congestive heart failure, and myocardial infarction), pulmonary 
(bronchospasm, interstitial pneumonia), CNS (confusion, seizures, 
parkisonism, transient ischaemic attacks), haemostatic (deep vein 
thrombosis, pulmonary embolism), metabolic (hyperglycaemia and 
hyponatraemia), GI (bleeding, hepatic insufficiency, pancreatitis), and 
reversible renal insufficiency.
1.3.3 INTERFERON ADJUVANT PROPERTIES
The adjuvant properties of interferon have been reviewed by Heath and 
Playfair, (1992) and Heath and Playfair, (1993). Interferon-y is a product 
o f activated T cells, serving to activate macrophages to produce its array of 
pro-inflammatory cytokines, while also upregulating the MHC Class II 
molecule expression on these antigen presenting cells. These properties
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make interferon-y an ideal candidate for use as a vaccine adjuvant. Heath 
and Playfair (1991) have studied the effects o f enhanced MHC expression 
and cytokine effects on lymphocyte trafficking, to adjuvanticity. It was 
found that both interferon-y and the adjuvant saponin had effects on 
lymphocyte traffic, causing homing of labelled lymphocytes to an injection 
site in the skin. There was, however, an inverse relationship between the 
enhancement of lymphocyte traffic and adjuvant effects in different strains 
of mice. Balb/c mice, which showed a very poor adjuvant effect, showed 
strong lymphocyte homing to an interferon-y injection site and the homing 
lymphocytes were predominantly CD8+ T cells. The relationship between 
CD8+ homing and lack of adjuvanticity in these mice is still unclear. In 
contrast there was a positive relationship between enhancement of MHC 
Class II expression in vivo and adjuvanticity in different mouse strains. 
There is therefore evidence that interferon-y acts as an adjuvant by 
enhancing antigen presentation by up regulation of MHC class II antigens 
on antigen presenting cells. This is supported by the fact that interferon-y 
must be administered at the same site as the antigen to produce an adjuvant 
effect and that passively transferred peritoneal cells from mice injected 
previously with interferon-y and antigen prime the recipient mice more 
effectively than cells from donors that have received antigen alone, or 
mixtures of cells from antigen-injected and interferon-y injected mice. In 
terms of measurable immune responses in the animal, interferon-y is 
known to enhance T-cell help for antibody, secondary antibody responses, 
delayed type hypersensitivity and antibody affinity.
Playfair and DeSouza (1987) first demonstrated the adjuvant effect of 
interferon-y when it was used with a Plasmodium yoelli murine malaria 
vaccine. The administration of 5000 units of interferon-y intraperitoneally 
at the same time and site on two occasions, two weeks apart, conferred
57
over 90% immunity to mice challenged with a lethal dose of parasitized 
red blood cells. Moreover, they showed that antibody, delayed type 
hypersensitivity (DTH), and T-helper cell responses were all increased 
with the use of recombinant interferon-y as an adjuvant. The increased 
survival was a result of the adjuvant effect of the interferon-y rather than a 
direct result of the interferon on the parasitized cells, since no survival 
benefit was seen with interferon alone.
The administration of recombinant interferon-y at the time of primary 
immunisation with glycoprotein G of vesicular stomatitis virus (Anderson 
1988) enhanced the secondary antibody response to a booster dose of the 
viral protein. In each of these studies, interferon-y was most effective 
wrhen administered at the same time as the vaccine antigen. To ensure 
interferon-y delivery with the antigen, Heath and Playfair (1990) 
conjugated biotinylated interferon with avidin antigen and compared the 
DTH and antibody response to avidin in mice immunised with the 
conjugate or avidin and interferon-y alone. They noted a 50% increase in 
the DTH response and no significant increase in the antibody response in 
animal immunised with the conjugate. An explanation proposed to explain 
the increased adjuvanticity of the conjugate is that it allows specific 
activation of those antigen presenting cells that phagocytose the antigen, 
thus resulting in a more focused increase in the immune response.
In studies particularly relevant to the immunocompromised host, Heath, et 
al, (1989), Demonstrated that interferon-y could increase the response rate 
to a malaria vaccine in different strains of immunocompromised mice. 
They inoculated several strains of immunodeficient mice with two, 
biweekly doses of P. yoelli vaccine mixed with interferon-y as an adjuvant. 
Biozzi low responder mice, which normally produce low levels of
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antibody, were 100% protected against lethal challenge by the addition of 
interferon-y to the vaccine; mice administered only the vaccine were 
totally unprotected. Mice depleted of CD4+ cells by the use of anti-CD4 
monoclonal antibody, showed 50-66% increased survival when interferon- 
y was added to the vaccine.
Interferon-gamma has also been shown to be effective in other systems. 
Schijns, (1994), has demonstrated increased immunogenicity of an 
inactivated rabies vaccine in mice by administration of exogenous 
interferon-gamma.
While there is now a fairly large body of data on the use of cytokines as 
adjuvants in animals, data from human studies is more scarce. Two human 
clinical trials have been conducted with IL-2 and interferon-y, both in 
haemodialysis patients as subjects and hepatitis B as the vaccine, as 
infection with this virus is a problem in dialysis patients.
Quiroga et al (1990) used a large group of haemodialysis patients, of 
which 41 received vaccine alone, and 40 vaccine plus 2 x 10^ units of 
in terferon-y/m ^ (a higher dose than needed in mice, which was 
approximately 2x10^ units/m ^). Similar proportions o f patients 
seroconverted in both groups (81% and 89%, respectively), but the 
interferon-y group responded earlier, and mean titres were higher, although 
not significantly so. In a small trial with healthy male students, interferon- 
y added to hepatitis B vaccine, given intradermally, accelerated the 
development of protective levels of antibody.
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1.3.4 INTERFERON AND CHRONIC 
GRANULOMATOUS DISEASE
Chronic granulomatous disease (CGD) is an immunodeficiency 
characterised by recurrent pyogenic infections beginning early in life. 
Phagocytes from CGD patients fail to produce superoxide and other 
reactive oxygen intermediates important in bacterial killing. This results 
from a failure of a membrane associated NADPH oxidase which contains a 
unique, phagocyte-specific cytochrome b. CGD is known to be genetically 
heterogenous, with a common X-linked form, and a less common variant 
X-linked and autosomal recessive form. Classical X-linked CGD results 
from deletions or mutations in the gp91 phox gene, which encodes the 
phagocyte-specific cytochrome b.
The initial rationale for the use of interferon-y in CGD came from in-vitro 
experiments demonstrating that it could increase the magnitude of the 
respiratory burst, and increase expression of gp91 phox in phagocytes from 
normal patients. A large controlled trial of interferon-y in X-linked CGD 
revealed a clear clinical benefit in reducing the number of serious 
infections with minimal toxicity, (reviewed by Kruskal and Ezeckowitz, 
1994).
1.3.5 INTERFERON AND INFECTIOUS DISEASES
During the past decade , much work has been carried out to establish the 
role of interferon-y in macrophage activation which is essential in the fight 
against intracellular pathogens. It has also been shown that interferon-y 
also has an effect on granulocytes, including migration and adherence, 
phagoctosis and oxidative killing. Although most of the effects of
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interferon-y on the inflammatory response are beneficial to the host, 
interferon-y has also been shown to be a pivotal mediator of LPS-induced 
Schwartzman reaction and lethality (reviewed by Kullberg and van f  Wout,
1994).
As a consequence of the importance of interferon-y in killing of 
intracellular parasites, attention has been focused on the treatment of such 
conditions as Toxpoplasma gondii and Leishmaniasis. These, and other 
similar disorders are becoming increasingly important with the emergence 
of the AIDS epidemic. Leishmania has served as a model to study the 
regulation of killing mechanisms of macrophages. The profile of 
cytokines released in mice infected with L. major determines whether 
protective immunity or exacerbation occurs. Leishmania resistant strains 
of mice produce interferon-y, but not IL-4, whereas susceptible strains 
produced IL-4 and IL-10 but not interferon-y mRNA. The knowledge of 
the immunopathology of leishmania infection now opens the door to 
alternative therapy, as reviewed by Ho et al (1994). The treatment of 
leishmaniasis has not changed for over 70 years, pentavalent antimony 
being the drug of choice. However, the response rate is only 70-80%, and 
the toxicity is significant. A number of studies with interferon-y in 
patients with visceral leishmaniasis has now been performed, and even 
those patients who had not responded to pentavalent antimony the clinical 
outcome has been encouraging.
Interferons were originally described as selective antiviral agents. As 
discussed above, it is now well established that while interferon-a and p 
are primarily antiviral cytokines, interferon-y is primarily an 
immunomodulator with some antiviral activity. As a consequence 
interferons a  and P have been more widely investigated as direct antiviral
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agents and have been used in the treatment of acute and chronic virus 
infections with some success. Less success has been observed with 
interferon-y when used as a direct antiviral cytokine. Where interferon-y 
may be important in the treatment of viral diseases is in terms of immune 
enhancement, i.e. in the redirection of the immune response such that more 
efficient viral clearance occurs. Administration of bovine interferon-y 
prior to experimental infection of cattle with bovine herpes virus I (BHV-
1) reduces virus induced suppression of cell mediated cytotoxicity 
(Bielfeldt Ohmann and Babiuk, 1984).
In summary, Interferon-y may become a useful therapeutic agent in the 
treatment of intracellular parasitism, especially in instances where the host 
may be immunocompromised. While the effectiveness of interferon-y as 
an antiviral agent may be limited it may be beneficial in terms of immune 
enhancement of the host to aid viral clearance
1.3.6 INTERFERON IN AUTOIMMUNE DISEASE
There is conflicting evidence of the role that interferon-gamma plays in 
autoimmune disease, both in its possible protective role and also in its role 
in immunopathegenesis. Evidence that supports the idea that interferon- 
gamma produces immunopathology in autoimmune disease comes from 
experiments in transgenic mice which express interferon gamma under the 
control of a rat insulin promoter (Sarvetnick, 1988). These mice develop 
severe insulinitis and become hypoglycaemic thereby developing a 
syndrome similar to insulin dependent diabetes mellitus, which is 
commonly thought to be an autoimmune disease.
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In contrast interferon-gamma appears to play a protective role in some 
murine models of experimental autoimmune encephalomyelitis (EAE) 
(Billiau, 1988), where administration of interferon-gamma seemed to 
enhance survival. However, when recombinant interferon-gamma is given 
to patients suffering from multiple sclerosis (the natural human disease 
which resembles murine EAE), there appears to be an exacerbation of 
clinical signs (Panitch, 1987). Together, these results suggest that 
interferon-gamma may play different roles in the development of 
autoimmune disease and may act through a variety of different 
mechanisms. Further experimental work needs to be carried out to 
determine the molecular mechanisms responsible for the apparent 
contradictory roles of interferon-gamma in autoimmune disease.
1.3.7 INTERFERON-GAMMA IN NEOPLASTIC DISEASE
The abnormal population of cells constituting a malignancy demonstrates 
temporal unrestricted growth preference over its normal counterparts, 
inhibition of differentiation, and the tendency to invade tissues and 
metastasise. The development of certain tumours is related to mutations in 
oncogenes that regulate cell growth and differentiation and/or to mutations 
or loss of tumour suppressor genes.
Interferons may be important in the treatment of cancer for two reasons. 
Firstly, they modulate the immune response and could therefore potentially 
augment the anti tumour response, and secondly, they can affect cell 
growth and differentiation. In terms of tumour treatment, interferon-a has 
warranted the greatest interest. A large-scale assessment of interferon-a as 
treatment for spontaneous malignancies began in the United States of 
America in 1979. By far, the most significant impact has been seen in
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human patients with Hairy Cell leukaemia. Mechanisms o f action of 
interferon-a probably differ depending on the tumour type. In hairy cell 
leukaemia, interferon-a's action may involve effects on differentiation, 
apoptosis and cell-cycle arrest, but in such tumours as gastro-intestinal 
malignancies the action appears to involve the potentiation of 
chemotherapeutic drugs such as 5-florouracil (Zwierzina, 1993).
The use of interferon-y in malignancies has been disappointing, But has 
been used in such tumours as renal cell carcinoma (Farace et al, 1993), 
malignant melanoma (Charak et al, 1992) and ovarian and cervical cancer 
(Colombo et al, 1992 and Iwasaka et al, 1990, respectively) with varying 
results. The rationale behind treatment using interferon-y is to augment the 
immune response, i.e. to enhance effector cell function and possibly to 
upregulate MHC expression on tumour cells. More success in the 
treatment of malignant disease with interferon-y may come with the advent 
of gene therapy for cancer.
1.3.8 INTERFERON-GAMMA IN ALLERGIC DISEASE
Although the original definition of allergy by Von Pirquet in 1906 
encompasses a whole spectrum of immune responses, the term allergy is 
now equivalent to type I hypersensitivity (reviewed by Banchereau and 
Miossec, 1994). The term atopy is currently used to describe the abnormal 
reaction and diseases which are associated with the production of IgE 
following low exposure to allergens. These IgE molecules can bind via 
their Fc portions to high affinity Fc receptors on basophils and mast cells. 
Exposure to allergen allows cross linking of Fc receptors on these cells and 
the production of inflammatory mediators which are responsible for the 
clinical signs associated with allergy. IL-4 is known to cause isotype
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switching in B-cells to produce IgE, and IL-5 is a potent activator of 
eosinophils. Both IL-4 and IL-5 are cytokines produced by TH2 cells, and, 
in addition, T cells isolated from inflammatory infiltrates from allergy 
patients have been found to be predominantly of the TH2 type. Thus, 
imbalances in the TH 1/TH2 system, biased toward the TH2 type, may be 
involved in the manifestation of allergy.
An important feature of the TH1/TH2 system is the ability of one subset to 
regulate the other, i.e. th l cytokines (IL-2, IFN-y) downregulate the TH2 
response and TH2 cytokines (IL-4, IL-5, IL-10) downregulate the THj 
response. Thus, the TH2 response may be reversed by boosting the THj 
response and interferons, therefore, represent good candidates for such 
therapeutic application.
1.4 AIMS OF THE PROJECT
As described above, numerous clinical trials are in progress to assess the 
use of recombinant interferons in disease treatment and prevention. The 
aim of this project was to clone, sequence and express cDNA encoding 
feline interferon-gamma with the ultimate goal of examining the potential 
of this cytokine in diseases of felidae. This project forms part of a larger 
cytokine project being developed in the department of Veterinary 
Pathology at Glasgow University. The aims of this larger project are to 
clone and express a panel o f feline cytokine genes in order to develop new 
strategies in disease control, prevention and in developing our 
understanding of the pathogenesis of various diseases.
The detailed aims of this project were as follows:
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1) To amplify, using the polymerase chain reaction, cDNA encoding feline 
interferon-gamma from mRNA derived from mitogen stimulated, feline 
lymphocyte cultures.
2) To sub-clone the PCR product into plasmid vector and to sequence the 
recombinant insert.
3) To express the feline interferon-gamma cDNA as a glycosylated protein 
in a Baculovirus system.
4) To establish a biological assay for feline interferon-gamma based upon 
cytopathic effect reduction and MHC class II antigen induction.
5) To purify the resultant protein by FPLC and to assay for biological 
activity.
The proceeding chapters will describe the experimental approach to . 
achieve these objectives and the results obtained.
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2.0.1 MATERIALS
The following section lists only those materials used routinely. Less 
frequently used materials are detailed in the appropriate methods section.
2.0.1 CHEMICALS
All chemicals were of ultrapure or equivalent purity and were obtained 
from Gibco BRL, Pharmacia LKB, or The Sigma Chemical company, 
except:
Ampicillin (Penbritin™) Beecham Ltd.
Ethanol James Burroughs Ltd.
2.0.2 RADIOCHEMICALS
[Alpha 32pj dCTP for labelling of DNA probes and [3^S] dATP alpha S 
for DNA sequencing were obtained from Amersham International pic.
2.0.3. COMPLETE KITS
Quick prep™ mRNA purification kit: Pharmacia 
First strand cDNA synthesis kit : Pharmacia 
TA cloning kit : Invitrogen
PCR kit : Cetus
Sequenase version 2.0 sequencing k i t : Pharmacia
2.0.4. EQUIPMENT
Tissue culture flasks and other plasticware: Nucleon (Delta)
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Collodian dialysis tubes : Sartorius 
Autoradiography film: Amersham life science 
Sequencing Apparatus: Pharmacia
2.0.5. EXPERIMENTAL ANIMALS
SPF cats: Specific pathogen free cats were obtained from a breeding unit 
and housed at Glasgow University. They were aged approximately 18 
months at the time of lymphnode harvest. The study was carried out in 
accordance with home office regulations.
Rabbits’. 4 SPF rabbits were used to raise antisera to synthetic peptides. 
The animals were maintained on a commercial diet in the University of 
Glasgow animal house and all procedures were carried out in accordance 
with Home Office Regulations.
2.0.6 BACTERIAL STRAINS
Escherichia coli (E.coli) DH5a™strain (Gibco BRL). This is a 
recombination negative strain which is provided competent. The strain can 
be used for blue-white screening as the <|)80A/<3cZAM15 marker provides 
a-complementation of the (3-galactosidase gene within vectors. The DH5a 
strain was used to amplify pCRscript SK(+) plasmids containing PCR 
products.
E.coli strain INVvlF ' (Invitrogen) is a recombination negative strain 
(recAl) which enables stable replication of high copy number plasmids. 
The genotypes endAl and h sd R ll  improve the quality of minipreps. 
INVaF' confers blue-white screening of recombinant plasmids by alpha
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complementation of P-galactosidase with the (|)80A/acZAM15 genotype. 
This bacterial strain was used to amplify the Baculovirus transfer vector 
during the expression work. These bacterial strains are provided in the TA 
cloning vector kit (Invitrogen) and are competent.
2.0.7 CLONING VECTORS
pCR-scriptluSK(+) phagemid (Stratagene) is a 2961-bp phagemid 
designed by incorporating a S r f  site into the pBluescript SK(+) phagemid. 
This cloning vector includes an ampicillin-resistance gene, a lac promotor 
for gene expression, T3 and T7 RNA polymerase binding sites, an fl 
intergenic region for single stranded DNA rescue and the SK multiple 
cloning site, which is modified to include the SrfI restriction-endonuclease 
target sequence. The SK designation indicates the polylinker is oriented 
such that the lac-Z transcription proceeds from Sac 1 to Kpn 1.
pAcCL29-l Baculovirus Transfer vector: The transfer vector used in the 
experiments described in this thesis was a polyhedrin promotor based 
expression vector termed pAcCL29-l, Livingstone and Jones (1989). The 
pAcCL29 series of transfer vectors were originally derived from the 
transfer vector pAcYMl. The major difference is that each vector has the 
M l3 intergenic region necessary for single stranded DNA production, after 
superinfection of transformed bacteria with the M l3 helper phage (e.g. 
M l3 K07). This is particularly advantageous if modifications need to be 
made to the inserted foreign gene to study structure and function. The 
pAcCL29 vectors are also slightly smaller than pAcYMl and should, 
therefore, be able to accept more foreign DNA before becoming
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unstable. pAcCL29 has a single BamHl cloning site whereas pAcCL29-l 
has a multi-cloning site consisting Sst 1, Kpn 1, BamH \,X b a  1, Sal 1, Pst 
1. The Sal 1 site is not unique (King and Possee 1992).
2.0.8 RESTRICTION ENDONUCLEASES
All were from Gibco BRL or from Northumbria Biologicals Ltd. All were 
supplied and used with appropriate reaction buffers.
2.0.9 OTHER ENZYMES
MuLV Reverse Transcriptase-Pharmacia (provided in cDNA synthesis kit) 
Taq polymerase- Cetus (provided in their PCR kit)
Sequenase sequencing enzyme- Amersham (in the sequenase V.2.0 kit)
T4 DNA ligase- Stratagene (in their ligation kit)
2.0.10 OLIGONUCLEOTIDE PRIMERS
Primers for both PCR amplification and DNA sequencing were supplied 
by Alto Biosciences, University of Birmingham. They were supplied 
purified and lyophilised. After reconstitution with ultrapure, autoclaved 
water the concentration was determined by spectrophotometry.
2.0.11 BUFFERS, SOLUTIONS & GROWTH MEDIA
Where indicated, autoclaving was carried out at 121°C for 20 minutes. 
Antibiotics:
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Ampicillin: sodium ampicillin at lOOmg/ml in distilled water sterilised by 
filtration and stored in 1ml aliquots at -20°C. Used at a final concentration 
of 50ug/ml.
Penicillin/Streptomycin: purchased as a tissue culture grade solution from 
Gibco-BRL. Supplied at lOOOIU/ml and stored at -20°C.
Buffers and solutions:
BHK21 medium’, purchased as a lOx sterile liquid from Gibco BRL. 
Concanavalin-A: (Sigma) stored dry at 4°c.
DEPC/DEPC Treated water. Diethyl pyrocarbonate (Sigma), DEPC water 
was prepared by the addition of two drops of DEPC to 500ml of water. 
The water was allowed to stand for 3 hours and then autoclaved. All 
procedures involving DEPC were carried out in a safety cabinet.
DMSO: dimethylsulphoxide (Fisons).
DNA Gel Loading Buffer. 0.25% bromophenol blue, 0.25% xylene cyanol, 
30% glycerol in water. Stored at -20°C.
Dulbecco’s MEM : purchased as a lx  sterile liquid from Gibco BRL.
EDTA (0.5M, pH 8.0): 186.1g. disodium ethylene diamine
teraacetate.2H20 added to 800ml. of distilled water. NaOH pellets 
(approximately 20g.) added to make the pH 8.0 (EDTA will then dissolve). 
Volume adjusted to 1 litre with distilled water and sterilised by 
autoclaving.
Ethidium bromide : ethidium bromide made to a working solution of 
3mg/ml. with distilled water in a fume cupboard. Stored away from light. 
Ficol-Hypaque: Purchased as a 100ml solution from Pharmacia Biotech, 
and stored at 4°C.
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Foetal calf serum :Virus screened, mycoplasma screened, bacteriophage 
screened. Purchased from Gibco BRL and heat inactivated at 57°C for 30 
minutes before storage at -20°C.
L-Glutamine: purchased as a 200mM (100X) aqueous solution from Gibco 
BRL.
Lysis solution: 25mM tris-HCL pH 8.0, lOmM EDTA, 50mM glucose. 
Lysozyme: purchased as a sterile powder from Sigma chemicals and used 
at a concentration of lOmg/ml in STET solution.
Phosphate buffered saline: 137mM NaCl, 2.7mM KC1, 4.3mM
Na2HPC>4.7H20, 1.4mM KH2PO4 (pH 7.3).
Protein gel loading buffer, made as a 2 x stock. lOOmM Tris-HCL (pH 
6 .8), 4% SDS, 20% glycerol, 0.1% Bromophenol Blue and 10% 2-p- 
mercaptoethanol.
R P M I1640: purchased as a lx  sterile liquid from Gibco BRL
SDS (10%): lOOg. sodium dodecyl sulphate made up to 1 litre with
distilled water and sterilised by filtration.
SDS-PAGE running buffer: 25mM Tris base, 250mM glycine, 0.1%SDS 
pH 8.3.
Semi-dry transfer buffer: 48mM Tris, 39mM glycine, 0.1% SDS and 20% 
2-P mercaptoethanol.
Sodium pyruvate: purchased as a lOOmM solution from Gibco BRL and 
stored at 4°C.
STET Solution: 5% Triton X-100, 50mM EDTA, 50mM tris-HCL, 8% 
sucrose.
TAE (50X): 242g. Tris base, 57.1ml. glacial acetic acid, 100ml. 0.5M 
EDTA (pH 8.0) made up to 1 litre with distilled water. Used at a final 
concentration of lx  (lxTAE pH 8.15 is 40mM tris-acetate, 2mM EDTA) 
TBE (10X/L): 89mM Tris base, 89mM boric acid, 2mM EDTA (pH 8.0). 
TBS: 25mM Tris base, 137mM NaCl, pH to 7.6 with HCL.
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TCI 00 Insect media: purchased from Gibco BRL as a sterile solution.
TE\ lOmM Tris HCL, ImM EDTA, pH adjusted as appropriate (made up 
as a lOOx solution and sterilised by autoclaving).
Trypsin/EDTA: purchased as a lOx solution from Gibco-BRL and stored at 
-20°C.
X-gal\ 5-bromo-4-chloro-3indolyl-P-D-galactosidase (Gibco BRL), stored 
dry at -20°C. and made to the required dilution using N,N- 
Dimethylformamide (Sigma)
2.0.12 BACTERIAL GROWTH MEDIA
L-agar: L broth containing 1.5% agar sterilised by autoclaving
LB medium (L-broth): lOg tryptone, 5g yeast extract and lOg NaCl made 
up to 1 litre with distilled water, and the pH adjusted to 7.5 with NaOH, 
followed by sterilisation by autoclaving.
SOC medium: L-broth, lOmM MgCl2, lOmM MgS0 4 , 20mM glucose.
2.1.0 GROWTH AND MANIPULATION OF 
MAMMALIAN CELLS
2.1.1 FEA CELLS
A feline embryonic cell line was used in the assay procedure for feline 
recombinant interferon. This is a cell line designated FEA and derived 
from feline embryonic cells.
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Maintenance: The cells were maintained in platicware at 37°C in 95% air, 
5% C02. The cells were grown as monolayer adherent cultures in 
0.2ml/cm2 surface area until they reached sub-confluence. Cells were then 
washed with trypsin/EDTA before replating in fresh medium at the correct 
density. The cells were split 1:3 approximately twice weekly.
Long term storage: Master and working cell banks were prepared of the 
FEA cells. Cells were trypsinised and washed in growth medium. After 
centrifugation, cells were resuspended at 5xl0^/ml in Dulbecco's MEM 
(supplemented with 20% FCS, 1% Glutamine, 1% Sodium pyruvate, 
penicillin/streptomycin and 10% w/v dimethyl sulphoxide (DMSO)). The 
cells were frozen in a cell freezer and stored under liquid nitrogen. After 
long term storage, frozen cells were rapidly thawed by immersion of their 
plastic container in sterile water at 37°C. Following thawing, the cells 
were washed in fresh medium. After centrifugation the cells were 
resuspended in growth medium and plated in plasticware at the appropriate 
density.
2.1.2 F422 CELL LINE
The F422 cells are an FeLV positive cell line derived from a naturally 
occurring lymphosarcoma (Rickard 1969). The cells were cultured in 
RPMI medium supplemented with 10% FCS and penicillin/streptomycin.
2.1.3 PRIMARY T CELL CULTURES.
A specific pathogen free (SPF) domestic cat was euthanased using 
intravenous pentabarbitone (euthatal). Using standard aseptic techniques 
the spleen and several mesenteric lymph nodes were removed and placed
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in modified RPMI medium (RPMI 1640, penicillin/streptomycin, lOmM 
Hepes buffer, 5xl0"^M (3-mercaptoethanol, 2% FCS, and 2mM glutamine) 
and placed on ice. The spleen and lymph nodes were diced in medium on 
a sterile 9cm plate using a sterile scalpel. The medium containing cells 
was transferred to a separate sterile receptacle. The dead cells and 
contaminating red blood cells were removed by layering 15ml of cells on 
top of 15ml of ficoll hypaque (Pharmacia) and centrifuging at 3000 rpm 
for 15 minutes. The interface cells were removed and diluted with an 
equal volume of fresh medium. The cells were pelleted for 5 minutes at 
1500 rpm, counted and used to make replicate 20ml suspension cultures at 
a concentration of 2.5x10^ cells/ml. The cultures contained 10% spleen 
derived lymphocytes and 90% lymph node derived lymphocytes. The 
cells were stimulated by the addition of the mitogen concanavalin-A at a 
concentration of 7.5ug/ml of culture medium and flushed with CO2 and 
incubated at 37°C.
2.2.0 GROWTH AND MANIPULATION OF INSECT CELLS
Spodoptera frugiperda (Sf9) cells (Invitrogen) were cloned from the 
parent line IPLB-SF 21 AE. The parent line was derived from pupal 
ovarian tissue of the fall armyworm (Spodoptera frugiperda). These cells 
are the host for the propagation of wild-type or recombinant Autographica 
californica multiple nuclear polyhedrosis virus (AcMNPV). Sf9 cells can 
be propagated as both adherent monolayers and as non-adherent 
suspension cultures.
Maintenance: Cultures were maintained in plasticware at 28°C in T C I00 
medium (Gibco) supplemented with 10% FCS and penicillin/streptomycin. 
There was no requirement to flush the cells with CO2 or maintain cells in a
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CC>2 incubator. For the most part, cells were grown as adherent monolayer 
cultures until sub-confluence. The cells were then removed from the flask 
my mechanical disruption, counted by trypan blue exclusion (see below) 
and plated in fresh medium at the appropriate density.
For protein production the cells were grown as suspensions cultures in 
spinner culture flasks in TCI00 complete medium. The cells were initially 
added to the spinner flasks at a concentration of 10  ^ cells /ml of medium. 
The cells were allowed to go through two doublings (to about 5x10  ^
cells/ml) before the addition of virus to the cells. It was essential that the 
cells were in a logarithmic growth phase when virus was added. The 
spinner flasks were not overfilled (max. 100ml in a 250ml flask) so that an 
adequate surface area for gaseous exchange was maintained. For 
maximum protein production the virus was added at 10 pfu/cell.
Trypan blue exclusion: Cells were removed from the flasks by mechanical 
disruption and resuspension in 20ml of fresh growth medium. One 
hundred microlitres of this suspension was added to an equal volume of 
trypan blue (Gibco BRL) in an eppendorf tube. The cells were then 
counted using a haemocytometer, the dead cells appearing blue.
Long term storage: Both master and working banks of cells were 
established and stored under liquid nitrogen. For long term storage, cells 
were washed in growth medium and, after centrifugation, resuspended at a 
concentration of 5x10^ cells/ml in TC I00 medium (supplemented with 
10%FCS, penicillin/streptomycin and 10% w/v DMSO). The cells were 
then stored for 24 hours at -70°C and transferred to liquid nitrogen. To 
revive cells, a vial was removed from the liquid nitrogen and thawed by
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rubbing the vial in the palm of the hand. The cells were washed, 
centrifuged and plated in plasticware at the appropriate density.
High Five™ CELLS (Invitrogen): this cell line was derived from
Trichoplusia ni egg cell homogenates. Culturing was performed as for the 
Sf9 cells.
2.3.0 GROWTH AND MANIPULATION OF VIRUSES
2.3.1 WILD-TYPE BACULOVIRUS STRAIN
The baculovirus strain used throughout the project was generously 
provided by Dr. Jones at the NERC institute of Virology. The virus has 
been designated BacPAK6. BacPAK6 was generated by co-transfection of 
linearized AcRP6-SC with a plasmid designated PAK6. PAK6 was 
generated to have two Bsu36l sites which flank a p-galactosidase gene 
(Kitts and Possee 1993), thus recombinant BacPAK6 viral plaques stain 
blue with X-gal. The orfl629 sequence required to rescue restricted 
BacPAK6 viral DNA are present in most transfer vectors.
2.3.2 TITRATION OF BACULOVIRUS BY PLAQUE ASSAY
The method for titration of viruses by plaque assay was taken from King 
and Possee (1992). Plaque assays are carried out to determine virus titres 
in terms of plaque forming units per ml (pfii/ml) so that standard amounts 
of virus can be used to infect cells during experimental work. Plaque 
assays are also used to separate and titrate recombinant and wild type virus 
after co-transfections. The BacPAK6 virus is lac-z positive and therefore 
plaques generated by this virus will stain blue with X-gal.
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Initially 35mm plates were seeded with 10^ Sf9 cells per plate in 2ml of 
medium. The plates were then left at 28°C for 3 hours to allow the cells to 
settle and form a monolayer. Before commencing the assays, the cells 
were viewed microscopically to ensure that the cells had settled down and 
had formed a fairly sparse, even monolayer (50% confluence). If the cells 
become confluent too soon then no plaques or very tiny plaques will form.
Working in a safety hood, serial log dilutions of the virus to be titred were 
prepared, using growth medium as the diluent. The dilutions made 
depended on the source of the virus to be titred. Wild-type virus and 
recombinant virus replicate to a titre of about 1-2 x 10& pfu/ml and so the 
dilutions made for these ranged from 10“5 to 10-8. Co-transfection 
supernatants contain virus between 10^ and 10^ pfu/ml and so dilutions 
ranging from undiluted to 10-4 were made. The aim was to obtain around 
10 to 30 plaques per plate that could be easily counted. In addition 
dilutions were always duplicated.
Once the cells had been allowed to settle, the medium was removed using 
a pasteur pipette. The cells were then overlaid with lOOul of the 
appropriate dilution of virus, by adding dropwise to the centre o f the dish. 
The dishes were then incubated at room temperature for one hour for the 
virus to adsorb to the cells.
During the 1 hour incubation period the agarose overlay was prepared. The 
agarose overlay consisted of 3% low gelling temperature agarose, which 
was autoclaved and maintained at 45°C in a water bath.
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After 1 hour, the inoculum was removed from the cells. Equal volumes of 
agar and T C I00 medium were mixed. 2ml of this was added to the sides 
of the 35mm dishes and allowed to set. All the inoculum was removed, as 
failure to do so may cause poor plaque formation or the agarose plug may 
fall out of the dish.
When the agarose overlay had set, this was then overlaid with 2ml of 
T C I00/10% FCS. It was essential to add a liquid overlay to allow the 
development of well defined plaques. The reason for this is that the liquid 
overlay provides additional nutrients to supplement the half strength 
T C I00 medium in the solid overlay (concentrated TC I00 medium can not 
be used in the overlay as the salts precipitate from solution.)
The cells were incubated at 28°C for 3-4 days. Plaques were visualised by 
staining with neutral red. 0.5 ml of 0.1% neutral red in PBS was added to 
each plate. The neutral red was prepared fresh. After preparing the 
solution it was heated in the microwave for 10 seconds and then filtered 
through a 0.45u filter. After the solution had cooled, X-gal was added to a 
concentration of 0.8mg/ml. The cells were left to stain for around 3 hours 
at 28°C. Following this, the dye was removed and the plates inverted. 
The plates were left overnight at 4°C to allow clearing and better 
visualisation of plaques. Live cells take up the neutral red stain so that 
plaques appear as blue plaques (wild-type) or clear plaques (recombinant).
To determine the titre of virus, the plates were examined to find the 
dilution which gives a countable number of plaques (10 to 30). The titre 
was calculated as follows:
no. plaques x dilution factor x 10 (only 0.1 ml added) PFU/ml.
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2.3.4 FELINE CALICIVIRUS
In the experiments described in this thesis a large plaque forming strain of 
calicivirus was used, designated FCV/G1/PR.
2.3.5 TITRATION OF CALICIVIRUS BY PLAQUE ASSAY
Titration of calicivirus was performed in a 24 well plate system. FEA cells 
were grown to sub-confluency in tissue culture flasks at 37°C/5% C02- 
The cells were subsequently trypsinised, counted and resuspended in 
Dulbecco's complete MEM at a concentration of 2 x 10$ cells/ml. One ml 
of the suspension was added to each well. The cells were allowed to 
incubate at 37°C/5%C02 for 24 hours before being examined 
microscopically to ensure a sub-confluent monolayer had been established. 
The medium was removed from the cells and wells were allocated cell and 
virus controls. Serial log dilutions of the calicivirus were made, and lOOul 
of each dilution was added drop wise to the centre of the cell monolayer in 
the appropriate well. The cells were allowed to incubate for 1.5 hours at 
37°C/5%C02. Following incubation, the virus inoculum was removed 
using a plastic pipette and the cells were overlaid with agar/medium mix. 
The agar medium mix consisted of equal volumes of 2% sterile agarose 
and complete BFIK21 medium (i.e. supplemented with 
penicillin/streptomycin, glutamine, and 10% FCS). Once the agar had set, 
the cells were incubated for 48 hours at 37°C/5% C02- Plaques were 
visualised after staining the monolayer with crystal violet/formalin. The 
titration of the virus was calculated by examination of the first well which
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gave a countable number of plaques. The titration was calculated as 
follows, and was expressed as plaque forming units/ml (pfu/ml.).
Titre = no. plaques x dilution factor x 10 (only lOOul added to cells)
2.3.6 VESICULAR STOMATITIS VIRUS
Vesicular stomatitis virus is a group 2 pathogen as defined in the 
Categorisation o f  Pathogens According to Hazard and Categories o f  
Containment 1990. In addition the organism is covered by the Specified 
Animals Pathogen Order 1993 which prohibits the holding or use of the 
organism unless a licence has been issued by the Scottish Office's 
Agriculture and Fisheries Department (SOAFD).
A licence was granted to use a mutant VSV and all assay procedures were 
carried out in a category II laboratory. The VSV mutant used in these 
assays was designated VSVteE2 and is derived from the New Jersey strain 
of VSV. This mutant strain contains two independent mutations within the 
NS gene (Rae and Elliott, 1986) and is incapable of producing diseases in 
domestic livestock. In addition, because it is temperature sensitive, it is 
unable to sustain a transmission cycle between animals. The primary virus 
stock was kindly provided by Dr. Richard Elliott of the MRC Institute of 
Virology.
2.3.7 TITRATION OF VSV BY PLAQUE ASSAY
The titration procedure for VSV was identical to that used for calicivirus. 
Flowever, the assay was performed at 31°C/5% CO2 because the VSV 
used was a temperature sensitive mutant.
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2.4.0 GROWTH AND MANIPULATION OF BACTERIA
2.4.1 TRANSFORMATION OF COMPETENT BACTERIA.
For transformation of the DH5a cells (Gibco BRL), l-4ul of a ligation 
reaction was added to 0.1ml of competent cells and the mixture was held 
on ice for 30 minutes. The cells were then "heat-shocked" at 42°C for 45 
seconds. The cells were placed on ice for two minutes. Following this, 
80ul of SOC medium was added to the cells and the cells incubated at 
37°C on an orbital shaker for 1 hour to allow for expression of plasmid- 
encoded antibiotic resistance. Following the incubation step the cells were 
plated out on appropriate selective culture plates at a volume of 1 OOul per 
plate.
For the transformation of the INVaF' cells (Invitrogen), much the same 
protocol was followed. However, the products of the ligation reaction 
were added to 50ul of cells, and, in addition, 2ul of 0.5M p- 
mercaptoethanol was added to improve transformation efficiency. After 
incubation and subsequent heat-shocking (described above), 450ul of SOC 
medium was added to the vials prior to incubation at 37°C on an orbital 
shaker.
2.4.2 SCREENING AND SELECTION
Transformed cells expressing antibiotic resistance were selected from non­
transformed cells by growth on appropriate selective (antibiotic
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containing) L agar plates. When a host/vector combination allowing 
blue/white selection of recombinant from non-recombinant plasmids on 
the basis of intact p-galactosidase activity was used, then X-gal (5-bromo, 
4-chloro, 3-indolyl p-D galactoside) was incorporated into the L agar. The 
X-gal is a substrate of p-galactosidase which produces a blue colour on 
hydrolysis. Cells transformed by non-recombinant plasmids have intact P- 
galactosidase function and grow as blue colonies. In cells transformed by 
recombinant plasmids, the lacZ gene fragment in the plasmid is disrupted 
by DNA insertion and the p-galactosidase activity is absent. These cells 
grow as white colonies and can be selected on this basis. Colonies were 
picked and each colony placed into universals containing 10ml of L broth 
(+100ug/ml ampicillin). These colonies were grown overnight in L-broth 
by vigorous shaking at 37°C.
2.4.3 ISOLATION OF PLASMID DNA
Recombinant plasmid DNA was isolated according to the alkaline lysis 
method introduced by Bimboim & Doly, (1979) involving the 
denaturation of E.coli DNA and selective renaturation of covalently closed 
circle DNA.
i) Small scale isolation
A single colony was inoculated into 10ml of L broth and incubated at 
37°C o/n. 1.5 ml of the o/n culture was pelleted, then resuspended in 
300ul o f STET (5% Triton X-100, 50mM EDTA, 50mM Tris-HCl, 8% 
sucrose) and 50ul of fresh lysozyme solution added (lOmg/ml in STET). 
The solution was boiled for 45 seconds, then the lysate cleared in a micro 
centrifuge (13,000xg). The pellet was removed and the DNA precipitated 
from the solution with 0.5 volumes 7.5M ammonium acetate and 2-3
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volumes ethanol in dry ice for 30 minutes. The precipitate was pelleted in 
a micro centrifuge, washed in 70% ethanol, dried and resuspended in 20ul 
dH20.
ii) Large scale purification.
High quality plasmid DNA was purified from a 500ml exponentially 
growing o/n culture. Cells were pelleted at 4000 rpm at 4°C for 10 
minutes and resuspended in 20mls of lysis solution (25mM Tris-HCl (pH 
8.0), lOmM EDTA, 50mM glucose). After 30mins on ice, 40mls of fresh 
0.2M NaOH/1% SDS was added and the mixture was left on ice for a 
further 5 minutes. The lysates were neutralised with 30ml o f potassium 
acetate (3M KoAc) solution for 15 minutes on ice. The lysates were 
clarified by centrifugation at 4000 rpm for 5 minutes at 4°C and the 
supernatant filtered through gauze swabs into a conical flask. DNA was 
precipitated by the addition of 0.6 volumes of isopropanol (54mls/500ml 
prep) for 30 minutes at room temperature and pelleted by centrifugation 
for 10 minutes at 4000 rpm and 4°C. The pellet was drained thoroughly 
and dried and then re suspended in 4ml of TE (lOmM Tris, ImM EDTA 
pH 8.0). Five g of caesium chloride were placed in a universal followed 
by the TE buffer containing the plasmid and 300ul of ethidium bromide. 
The refractive index was adjusted to 1.390 with CsCl or TE and the DNA 
separated on a density gradient by centrifugation at 55,000 rpm for 40 
hours at 20°C. Closed circular DNA (the lower band) was removed by 
syringe and needle and the ethidium bromide removed by repeated 
extraction with isopropanol until no trace of colour was left. The CsCl 
was removed by extensive dialysis in collodion bags against TE pH 8.0 
and the yield of DNA calculated on the basis that 50ug/ml solution of 
double stranded DNA would have an OD26O measurement of 1. The DNA 
was concentrated by extraction of the aqueous phase with butan-2-ol the
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precipitated with 0.1 volumes of 3M sodium acetate, and 2-3 volumes of 
ethanol.
Hi) Small scale preparation o f  sequencing grade plasmid.
1.5 ml of an o/n culture were decanted into an eppendorf tube and spun in 
a micro centrifuge at 14k for 2 minutes. The media was poured off and 
any residual media removed with a Gilson pipette. The pellet was re 
suspended in lysis solution and 300ul of fresh 1%SDS/0.2M NaOH added. 
The solution was thoroughly mixed by inverting several times and was 
placed on ice. After 5 minutes, 225ul of 3M KoAc was added to the tube, 
mixed and then placed on ice. After a further 5 minutes the solution was 
clarified by centrifugation at 14k for 5 minutes. 630ul of the supernatant 
was added to a fresh eppendorf tube and to this was added 630ul of 100% 
ethanol. The tube was shaken vigorously and the immediately centrifuged 
at 14k for 5 minutes. The ethanol was decanted and 1.5ml of 70% ethanol 
was added to the tube. The tube was vortexed and centrifuged at 14k for 2 
minutes. The ethanol was removed and the remaining pellet dried in a 
vacuum dessicator for 1 minute, followed by resuspension in 16ul of 
distilled water.
2.4.4 RESTRICTION ENZYME DIGESTION OF PLASMID DNA.
Restriction enzyme digestion of plasmid DNA was carried out to confirm 
the presence of inserts of the correct size within small scale plasmid preps 
or the correct insertion of a cDNA into an expression vector. Typically, 1- 
2ug of plasmid DNA was digested in a reaction volume of 15ul. 
Restriction enzymes were used at 5-10 units per 15ul reaction in buffer 
provided by the manufacturer. Samples were digested in the presence of 
lOOmM spermidine, which is reported to prevent endonuclease inhibition
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by polyanions (Bouch, 1981). When samples were to be subjected to 
electrophoresis, the reaction was terminated by the addition of 0.2 volumes 
of DNA gel loading buffer.
2.5.0 MANIPULATION OF NUCLEIC ACIDS
2.5.1 mRNA HARVEST AND PURIFICATION.
mRNA harvesting and purification was carried out using the Quick Prep™ 
mRNA purification kit (Pharmacia). This kit employs the disruptive 
properties of guanidinium thiocyanate to lyse the T cells and allows the 
direct isolation of polyadenylated RNA by the use of oligo(dt) cellulose 
chromatography. Messenger RNA was purified in accordance with the 
manufacturers protocol (Pharmacia).
By far the most important factor in RNA purification is avoiding or 
inactivating RNAses which are ubiquitous and highly stable. RNA 
manipulations were carried out in disposable, sterile plasticware, which is 
essentially free of RNases, or in glassware which had been treated with 
diethylpyrocarbonate (0.1% DEPC, 12 hours, 37°C) and then autoclaved.
The method for mRNA purification using this kit was divided into two 
parts. The first procedure involved the lysis of the cells and separation of 
total RNA from other cellular components by centrifugation. Cells were
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initially recovered from the flasks and subjected to centrifugation at 1500 
rpm for 5 minutes. Following centrifugation, the supernatant was 
discarded and 1.5ml of extraction buffer (a buffered aqueous solution 
containing guanidinium thiocyanate and N-lauroyl sarcosine) was added 
to the cells. This ensures the rapid inactivation of endogenous RNase 
activity and the complete dissociation of cellular components from the 
mRNA. The cells were homogenised using a 2ml syringe and a 21ga 
needle by repeatedly aspirating the mixture through the needle. Following 
this, 3ml of elution buffer (lOmM Tris-HCl (pH 4.4), ImM EDTA) was 
added to the mixture and again the mixture was homogenised. The 
mixture is diluted 3 fold with elution buffer to lower the concentration of 
guanidinium thiocyanate. The concentration was then low enough to 
allow efficient hydrogen bonding between poly-A tracts on mRNA 
molecules and the oligo-(dt) attached to cellulose, but high enough to 
maintain complete inhibition of RNases. In addition, the three fold 
dilution causes a number of proteins to precipitate, allowing them to be 
easily removed by centrifugation. The elution buffer was placed in a water 
bath set at 65°C and the mixture was subjected to centrifugation at 10,000 
rpm for 10 minutes at room temperature in a Beckman JA20 rotor.
The second part involved isolation of mRNA from total RNA using 
oligo(dt) cellulose spun columns. Initially, the column was inverted 
several times to resuspend the matrix. The top and bottom closures were 
removed and the column placed in a 15ml falcon tube. This was subjected 
to centrifugation for 2 minutes at 350g (1300 rpm in our bench top 
omnifuge). Following centrifugation the bottom closure was replaced and 
the column placed upright in a test tube rack. 4ml of the supernatant 
obtained from centrifugation of the lysed cells was added to the surface of 
the cellulose spun column. The top closure was replaced and the tube was
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inverted several times over a 10 minute period. This allows for the mRNA 
to bind to the column matrix. Prior to elution of the mRNA the column 
was washed 3 times in high salt buffer (lOmM Tris-HCl (pH 7.4), ImM 
EDTA, 0.5M NaCl) and twice in low salt buffer (lOmM Tris-HCl (pH 7.4), 
ImM EDTA, 0.1M NaCl). The mRNA was eluted from the column with 
three successive washes with elution buffer at 65°C, using 25ul of elution 
buffer for each wash. The entire procedure from cell lysis through to 
mRNA elution was carried out without pause.
Quantitation of mRNA was carried out using a spectrophotometer. The 
A26O value and the A260/280 rat °^ were recorded. The concentration of 
mRNA was determined using the following calculation:
RNA (ug/ml) = A26O x D x 40 were D = dilution factor
Following quantitation, the mRNA was precipitated by the addition of 
50ul of potassium acetate (2.5M potassium acetate (pH 5.0)) and lOul of 
glycogen (lOmg/ml glycogen in DEPC treated water) and 1ml of 95% 
ethanol. After incubation at -20°C for 1 hour the reaction was spun in a 
microcentrifuge at 13000 rpm for 15 minutes. The RNA was subsequently 
stored, precipitated, under ethanol at -70°C.
2.5.2 FIRST STRAND cDNA SYNTHESIS.
First strand cDNA synthesis was achieved using a First strand cDNA 
synthesis kit (Pharmacia) which employs Murine Leukaemia Virus (M- 
MuLV) reverse transcriptase to catalyse the reaction. For successful 
cDNA synthesis it was essential to use intact, undegraded RNA in the 
reaction. This was achieved by the use of the mRNA purification kit
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(Pharmacia) as described above. The conditions for first strand synthesis 
were also optimised by the use of a first strand cDNA synthesis kit 
(Pharmacia) which permits full-length transcription of RNA's 7 kilobases 
or more in length. The protocol for synthesis of a 33ul first strand reaction 
was followed. One ug of mRNA was diluted in 20ul of DEPC-treated 
water and then incubated at 65°C. for 10 minutes to heat denature it, and 
placed on ice. The mRNA was added to 1 lul of bulk first strand reaction 
mix (cloned, FPLCpure Murine Reverse Transcriptase, RNAguard, 
RNase/DNase-free BSA, dATP, dCTP, dGTP, and dTTP in aqueous 
buffer). In addition, lul of DTT (200mM aqueous solution) and lul of Nor 
I-d(T)ig primer (0.2ug) was added to the mixture. The mixture was 
incubated for 1 hour at 37°C. The completed first strand reaction then 
contained a library of mRNA:cDNA heteroduplexes which were ready for 
PCR amplification.
2.5.3 PCR AMPLIFICATION.
Amplification of cDNA was achieved using the Polymerase Chain 
Reaction (PCR), described by Mullis, 1986. PCR amplification of cDNA 
involves the enzymatic synthesis of specific cDNA target sequences using 
two oligonucleotide primers which flank the cDNA region of interest and 
hybridise to opposite strands. PCR was carried out using the Gene Amp 
DNA Amplification kit (Perkin Elmer Cetus) using AmpiTaq recombinant 
Taq DNA polymerase. In most instances the reaction was performed in 
0.5ml polypropylene microcentrifuge tubes and consisted of cDNA, 31 and 
5' primers, lOx reaction buffer (lOOmM Tris-HCl (pH 8.3), 500mM KC1, 
15mM MgCl2, 0.01% (w/v) gelatin), dNTP mix (200uM final 
concentration of each dATP, dTTP, dGTP, dCTP), AmpliTaq DNA 
polymerase (final concentration of 2.5u/50ul), and autoclaved, ultra-
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filtered water. The reaction was overlaid with mineral oil to prevent 
evaporation. The reactions were then subjected to thermal cycles of 
denaturation, annealing and polymerisation in an automated thermal cycler 
(Perkin Elmer). Upon completion of the PCR the products were visualised 
by either polyacrylamide gel electrophoresis or agarose gel electrophoresis 
before ligation into plasmid vector. A more detailed account of reaction 
conditions and PCR optimisation is given in the relevant chapter.
2.5.4 AGAROSE GEL ELECTROPHORESIS
DNA molecules of different sizes were separated by electrophoresis 
through 1% agarose in lxTAE. More often, the minigel kits were used 
along with varying number of sample wells. The cast agarose gel was 
immersed in TAE buffer in the minigel apparatus. Each DNA sample was 
mixed 5:1 (v/v) with DNA gel loading buffer {q.v.) and carefully loaded 
into one of the wells. This was repeated for all of the samples. 
Electrophoresis was carried out at 70 volts. Following electrophoresis the 
separated DNA fragments were stained with ethidium bromide and 
identified by direct examination of the gel using an ultraviolet 
transilluminator. Fragment sizes were determined by comparison with 
DNA markers. The markers used were X UNA/Hind III fragments (size 
range 125bp to 23 Kb) and DNAJHae III fragments (size range 72bp to 
1353bp). Both markers were obtained from Gibco BRL. Only the 
DNA/Hae III fragments were used in conjunction with PAGE. Gels were 
photographed using kodak film.
2.5.5 POLYACRYLAMIDE GEL ELECTROPHORESIS
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Polyacrylamide gel electrophoresis was used to separate and accurately 
measure the size of DNA molecules less than 1 kb in length. Acrylamide 
was used at concentrations between 3.5 and 8% w/v in TBE, depending on 
the size of DNA of interest. An acrylamide: A^A-methlynbisacrylamide 
ratio of 19:1 was used. Polymerisation was achieved by addition of 
ammonium persulphate (0.08%, w/v) and TEMED (N,N,N',N'- 
tetramethylethylenediamine, 0.08% v/v). 15 x 17cm gels were cast at a 
thickness o f 1.5mm between sealed, vertical, siliconised glass plates. 
Twenty well teflon combs were used. After removal of the comb and 
before the samples were loaded, the wells were thoroughly flushed with 
TBE to remove incompletely polymerised acrylamide. DNA samples were 
mixed 5:1 (v/v) with DNA gel loading buffer. A total volume of 1 Oul was 
loaded. Gels were run in TBE buffer at approximately 5V/cm until the 
marker dyes had run the desired distance. DNA bands were detected and 
photographed after staining with ethidium bromide for 15 minutes. 
Denaturing polyacrylamide gel electrophoresis using 6% acrylamide gels 
incorporating 7M (42% w/v) urea was used for DNA sequencing . This 
method is described below.
2.5.6 DNA LIGATION
All DNA ligations involved DNA molecules with either compatible 
cohesive or blunt-ended termini. Purified, precipitated insert DNA was 
resuspended in an appropriate volume of TE (pH 8.0) and mixed with 
vector DNA in TE. For plasmid vectors, the molar ratio of insert:vector 
was usually 10:1 and a reaction volume of 20ul was used. Included in the 
reaction was lOx reaction buffer, lul of T4 DNA ligase and water to make 
the volume to 20ul. The reaction was allowed to proceed overnight at
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14°C. The protocol for insertion of PCR product into the pCR-script 
vector is slightly different and is described in the relevant chapter.
2.5.7 EXTRACTION OF DNA FROM AGAROSE GELS
This was achieved using the Geneclean II kit (BIO 101 inc.). DNA was 
subjected to electrophoresis using 1% agarose gels in TAE. After 
electrophoresis the gels were stained with ethidium bromide and the DNA 
visualised using an ultraviolet transilluminator as described. The 
appropriate DNA band was cut from the gel using a scalpel blade and 
transferred to an eppendorf tube.
The Geneclean kit II contains a specially formulated silica matrix called 
Glassmilk that binds single and double stranded DNA without binding 
DNA contaminants. To the gel slice in the eppendorf tube was added three 
volumes of Sodium iodide (Nal). The addition of three volumes keeps the 
final concentration of Nal above 4 molar. The tube was then incubated at 
50°C for 10 to 15 minutes or until all of the agarose had melted. The tube 
was transferred to ice and the glassmilk added. The amount of glassmilk 
added depends on the mass of DNA contained in the Nal solution. 
Generally 5ul of glassmilk was added to solutions containing 5ug of DNA 
or less, lul of glassmilk was added for every 0.5ug of DNA above 5ug. 
Following the addition of glassmilk the tube was vortexed and incubated 
on ice for 15minutes to allow the DNA to bind to the silica matrix. After 
the incubation step the silica matrix was pelleted along with its bound 
DNA. The pellet was washed four times using the NEWWASH solution 
(NaCl, Ethanol and water), provided in the kit. After a final centrifugation 
the supernatant was discarded and the pellet dried for about 2 minutes in a 
vacuum dessicator. The bound DNA was eluted from the silica matrix by
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the addition of lOul of TE to the pellet, and after mixing, incubating for 15 
minutes at 50°C. The solution was centrifuged for 1 minute and the 
supernatant containing the DNA removed, lul of the eluted DNA solution 
was subjected to agarose gel electrophoresis to estimate the concentration 
of DNA eluted.
2.5.8 SEQUENCING OF DNA
Sequencing of DNA was carried out according to the chain termination 
method of Sanger et al (1977) using the reagents and protocol of the 
"Sequenase" version 2.0 reagent kit (United States Biochemical). Plasmid 
DNA was first denatured by the addition of 4ul of IN NaOH to 16ul of 
plasmid DNA solution. The reaction was incubated at 37°C for 15 
minutes. The solution was neutralised with 8ul of 5M NH40Ac and 
precipitated under lOOul of ethanol at -70°C. The resulting precipitate was 
centrifuged at 14k for 15 minutes and then the ethanol removed and the 
precipitate dried in a vacuum dessicator for around 5 minutes. The pellet 
was resuspended in 7ul of distilled water. Following the denaturation step 
the protocol provided by the kit was followed.
The protocol for the sequencing reaction involves an annealing reaction, a 
labelling reaction and a termination step.
Annealing reaction:
For each of the four sequencing lanes, a single annealing reaction was 
used. The 7ul of DNA obtained in the denaturation step was combined 
with 2ul of reaction buffer (200mM Tris-HCL, pH 7.5; lOOmM MgCl2; 
250mM NaCl) and lul of the appropriate sequencing primer, giving a total 
volume of lOul. The reaction was incubated for 2 minutes at 65°C. The
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reaction was allowed to cool to room temperature over a period of around 
30 minutes. Slow cooling was achieved by placing a beaker of water at 
65°C on the bench. Once the temperature was below 35°C, annealing was 
complete and the tubes were placed on ice. The annealed template was 
used within 4 hours.
Labelling reaction:
In the labelling reaction, the following was added to the annealed 
template/primer: lul of 0.1 M DTT; 2.0ul of dilute labelling mix (dGTP); 
0.5ul [a-35S]dATP and 2.0ul of diluted sequenase enzyme. The reaction 
was prepared on ice and the enzyme was always added last. For standard 
reactions (reading sequences up to 500 or so bases from the primer), the 
labelling mix was diluted 5 fold (i.e. 4ul of mix combined with 16ul of 
water). The sequenase enzyme was diluted 1:8 in ice cold enzyme dilution 
buffer.
After the reaction had been set up the contents of the tube were mixed 
thoroughly and incubated for 2 to 5 minutes at room temperature.
Termination reactions:
Four tubes were labelled G, A, T and C. 2.5ul of the ddGTP termination 
mix was added to the tube labelled G. Similarly the A, T and C tubes were 
filled with 2.5 ul of the ddATP, ddTTP and ddCTP termination mixes, 
respectively. The tubes were then pre-warmed to 37°C for at least 1 
minute. When the labelling incubation was complete, 3.5ul o f the reaction 
was added to each of the tubes labelled G, A, T and C. The reactions were 
mixed and incubated at 37°C for 3-5 minutes. Following the incubation 
step the reaction was terminated by the addition of 4ul o f termination 
solution to each tube. The tubes were stored on ice until ready to load on
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to the gel. Samples labelled with 35s can be stored at -20°C for up to 1 
week. When the gels were ready for loading, the samples were heated to 
75-80°C for 2 minutes and loaded onto the gel immediately using 2-3ul in 
each lane.
Six percent denaturing acrylamide gels were used to separate the labelled, 
terminated fragments and gels were run at 1400V. Aliquots of each 
reaction were run for 2 and 4 hours, usually allowing the reading of 250- 
300 bp of DNA sequence per primer.
After electrophoresis, the gel plate with the gel bonded to it, was prised 
from the gel apparatus. Urea was removed from the gel by immersion of 
the glass plate, with the gel attached, in 10% acetic acid and methanol for 
15 minutes. The gel was transferred to paper and dried using a vacuum gel 
dryer. The dried gel was transferred to the dark room where it was 
overlaid with autoradiography film and placed in a light proof film cassette 
and exposed for 24 hours at room temperature. The following day the film 
was developed using a Kodak automatic processor. The sequencing film 
was read manually and the sequence data analysed.
Sequence analysis was carried out using the University of Wisconsin 
genetics computer group (G.C.G) sequence analysis software programmes. 
These programmes are run using the VAX computer and the VMS 
operating system. BESTFIT, which employs the "local homology" 
algorithm of Smith and Waterman (1981), was used to find the best 
homology between the sequences of PCR derived DNA and that of 
published interferon-y sequences for other species.
2.6.0 PROTEIN ANALYSIS
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2.6.1 SDS-POLYACRLAMIDE GEL ELECTROPHORESIS
One-dimensional gel electrophoresis under denaturing conditions ( i.e. in 
the presence of 0.1% SDS), initially described by Laemmli (1970), 
separates proteins based on molecular size as they move through the 
polyacrylamide gel matrix towards the anode. For the most part, 12 % 
gels were used as they resolve proteins in the size range 10 to 55 KDa. 
The gels were cast in minigel vertical gel units (Bio-Rad Mini-Protean II) 
which incorporate rectangular glass plates separated by 0.75mm spacers. 
Initially, a resolving gel was prepared (3.3ml H2O, 4.0ml acrylamide mix, 
2.5ml 1.5M Tris (pH 8.0), and 0.1ml 10% SDS). Polymerisation was 
achieved by the addition of 0.1ml 10% ammonium persulphate (APS) and 
4ul of Temed (A/A,A', A'-tetramethylethylenediamine) and the mixture was 
poured between the glass plates. The upper interface of the poured gel was 
covered with butanol to allow the development of an even surface. The 
resolving gel was allowed to set for 30 minutes while the stacking gel was 
prepared. The stacking gel consisted of 2.1 ml H2O, 0.5ml acrylamide 
mix, 0.38ml 1.0M Tris (pH 6.8) and 30ul of 10% SDS. Polymerisation 
was achieved by the addition of 30ul of 10% APS and 3ul of Temed. Prior 
to the addition of the stacking gel to the plates, the butanol was poured off 
and the interface thoroughly washed with distilled water. After the 
addition of the stacking gel, an 8 space teflon comb (Bio-Rad) was 
inserted into the plates to create the protein wells. The gel was allowed to 
set for around 20 minutes.
Protein loading buffer was added to each of the protein samples in a 1:2 
v/v ratio and the samples boiled for 5 minutes prior to being loaded into 
the gel wells. The protein samples were subjected to electrophoresis at
100
200V in SDS-PAGE running buffer. Typically the electrophoresis was 
carried out for 30 to 45 minutes. Subsequently, the gels were subjected to 
electroblotting as described below.
2.6.2 WESTERN BLOT ANALYSIS OF PROTEIN GELS
Western blot analysis was carried out using the ECL™ method. This is a 
light emitting non-radioactive method for detection of immobilised 
specific antigens, conjugated directly or in-directly with horseradish 
peroxidase-labelled antibodies. Following SDS-PAGE, proteins were 
transferred from the gels to nitrocellulose membranes by the process of 
electroblotting. The gel was first removed from the electrophoresis glass 
plates and immersed in semi-dry transfer buffer. In addition, the 
nitrocellulose membrane (Hybond™-ECL) was soaked in transfer buffer 
for 5 minutes prior to the commencement of the blotting procedure. Two 
sheets of blotting paper were cut and soaked in transfer buffer. One sheet 
of the blotting paper was arranged on the blotting apparatus, over which 
was placed the nitrocellulose membrane. The gel was placed over this and 
the second sheet of blotting paper arranged over the gel to create a 
sandwich. Air bubbles were removed from the sandwich by rolling a glass 
tube over the upper sheet of blotting paper. The electoblotting was 
performed at 15V for 45 minutes.
Following the electroblotting, the nitrocellulose was removed and rinsed in 
IX TBS. The non-specific binding sites were blocked by incubation of the 
membrane with non-fat milk powder (0.5% Marvel, 0.5% Tween in TBS) 
for 30 minutes on a shaker apparatus at room temperature. Subsequently, 
the primary antibody was added at a predetermined concentration, in 3% 
Marvel, 0.5% Tween in TBS. Following a two hour incubation at room
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temperature, the membrane was subjected to 3 X 10 minute washes with 
3% Marvel, 0.5% Tween in TBS. The secondary antibody (HRP labelled) 
was then added, again in 3% Marvel, 0.5% Tween in TBS, and incubated 
at room temperature for 1.5 hours. The membrane was washed 3 times for 
10 minutes in TBS/0.5% Tween and subsequently developed.
Proteins were detected by chemiluminescence using ECL Western blotting 
reagents (Amersham life science). The entire detection procedure was 
carried out in a dark room. Equal volumes of ECL detection solution 1 
and 2 were mixed to give sufficient volume to cover the membrane (1ml/ 
membrane). Excess buffer was drained from the membrane and the ECL 
solution added dropwise to the entire protein side of the membrane 
surface. The membrane was allowed to incubate for 1 minute without 
agitation. Excess solution was drained from the membrane by holding the 
comer next to some blotting paper. The membrane was sandwiched in 
cling film, any air bubbles removed and placed in a film cassette (protein 
side up). A sheet of autoradiography film (Hyperfilm-ECL, Amersham) 
was placed over the membrane and the cassette closed for, typically, 15 
seconds. The film was developed using an automated processor
102
CHAPTER 3
CLONING AND SEQUENCING OF CDNA 
ENCODING FELINE INTERFERON-y
3.1 INTRODUCTION
3.2 mRNA PURIFICATION
3.3 CDNA SYNTHESIS
3.4 PCR AMPLIFICATION
3.5 PCR PRIMER DESIGN
3.6 PRODUCTS OF PCR AMPLIFICATION
3.7 DISCUSSION
3.1 INTRODUCTION
This chapter describes the cloning and sequencing of cDNA encoding 
feline interferon-y. The ultimate aim of the project was to produce a 
biologically active protein that could eventually enter into clinical trials. 
Before the advent of recombinant DNA techniques the only way to obtain 
such biological agents was to purify them to homogeneity directly from 
animal tissue or from tissue culture supernatants. This is a time consuming 
procedure which gives low yields of product. This procedure is further 
disadvantaged by the potential contamination of the product with other 
agents. Many of the early clinical trials in the late 1970's and early 1980's 
involving interferon were conducted using a partially purified interferon-a 
species, which was later replaced with the recombinant product (reviewed 
by Gutterman 1994). Recombinant DNA techniques allow the actual 
coding sequence of the gene of interest to be cloned and subsequently 
expressed. The advantages of cloning the gene include increased yield of 
product and less problems with contamination. One of the major problems 
with proteins derived from laboratory based expression systems is that the 
product may not be identical to the native protein in terms of its post- 
translational modification. Differences in glycosylation and 
phosphorylation may alter the biological half-life of the protein and, in 
addition, it is now well recognised that animals can develop antibody 
responses to recombinant proteins, even if  those proteins are species 
specific. However, the advantages of gene cloning far out weigh any 
disadvantages when compared to obtaining the protein directly from the 
animal.
There are several approaches one can take towards the cloning of genes. 
Several human cytokines were purified to homogeneity in sufficient
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quantities to allow partial amino acid sequence to be determined. For 
human tumour necrosis factor-(3, (Gray et al 1984), the complete amino 
acid sequence was derived and chemical synthesis of the entire gene from 
oligonucleotides was performed, prior to the natural gene being isolated. 
More often, however, determination of partial amino acid sequence has 
allowed the generation of degenerate oligonucleotides that could then be 
used to screen libraries of cDNA or genomic clones for the entire cytokine 
coding region. Many human cytokines were cloned by this approach, e.g., 
human interleukin ip  (March et al, 1985); human interleukin-6 (Hirano et 
al 1986); and human interleukin-12 (Gubler et al 1991; Wolf et al 1991).
Similar methodology has been used to detect cytokines from other species 
(e.g. mice, domestic animals and non-human primates), with the additional 
stage of cross-species screening of animal cDNA libraries with human 
DNA probes. Such approaches have been successful for Bovine 
Interferon-y (Cerreti et al 1986), and Rat interferon-y (Dijkema et al 1986).
Prior amino acid sequence may not be required if a specific and sensitive 
bioassay is available, or if the cytokine to be cloned is very highly 
conserved between species. Many of the first cytokine genes to be cloned 
were detected using a combination of hybrid selection of mRNA to cloned 
cDNA sequences followed by expression in Xenopus oocytes or rabbit 
reticulocyte lysates, e.g human interferon-y (Devos et al 1982). The 
procedures were later modified so that mRNA was prepared from cloned 
cDNA using in-vitro RNA polymerase reactions prior to oocyte injection. 
Hybridisation selection and oocyte injection fell out of favour because of 
the inherent instability of the RNA preparations and the time taken for 
oocyte injection. As an alternative, expression of cDNA in monkey COS-7 
cells became more widely used and many cytokines have been cloned by
105
expression cloning in COS-7 cells including human GM-CSF (Lee et al
1985); mouse interleukin-4 (Lee et al 1986), and Murine interferon-y 
(Gray and Goeddel 1983)
A more powerful tool for cloning genes has now been provided by the 
introduction of the polymerase chain reaction (PCR) (Mullis, 1986) and 
this has been incorporated into the approach described here to clone cDNA 
encoding feline interferon-y. This procedure initially involves the isolation 
of RNA from appropriate tissues and subsequent synthesis o f a panel of 
RNA:cDNA heteroduplexes which represent all the genes expressed by the 
cells at the time of RNA harvest. The cDNA is synthesised using the 
enzyme reverse transcriptase which is an RNA dependent DNA 
polymerase. PCR is then used to amplify the cDNA encoding interferon-y 
by using specific primers which flank the coding sequence. The use of 
PCR to amplify a specific cDNA sequence from RNA is termed Reverse 
Transcriptase PCR (RT-PCR). Because the actual feline interferon-y 
sequence was unknown, primers had to be designed according to regions 
of homology between published sequences from other species. The basic 
experimental approach is shown schematically in figure 3.1.
Interferon-y genes have now been cloned from a number of species 
including human (Gray et al 1982), murine (Gray and Goeddel 1983), 
equine (Curren et al, 1994), canine (Zucker et al, 1992), bovine (Ceretti et 
al 1986), porcine (Roger et al 1990) and ovine (Radford et al 1991), rabbit 
(Samudzi et al, 1991), and rat (Dijkema et al, 1986). The ovine and equine 
interferon-gamma genes were cloned following amplification by the 
polymerase chain reaction.
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Figure 3.1: The sequence of events in the experimental procedure.
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3.2 ISOLATION OF mRNA FROM STIMULATED LYMPHOCYTE 
CULTURES
The human interferon gamma gene contains 3 introns and is 6kb in size 
(Taya, 1982). Since the aim of the project was to determine the amino acid 
sequence and produce recombinant interferon it was technically easier to 
amplify the coding sequence from mRNA rather than chromosomal DNA.
For the whole experiment to proceed satisfactorily it was essential that the 
starting material, i.e. the mRNA, was full length and of high quality. The 
difficulty in isolating RNA is the ubiquity of ribonucleases which are very 
stable, active enzymes which require no co-factors to function. To 
eliminate ribonuclease contamination all the glassware used in the 
experimental procedure was DEPC treated and the mRNA isolation was 
carried out in a tissue culture fume hood and sterile surgical gloves were 
worn throughout the procedure.
Fresh lymph node tissue was used to establish T cell cultures as described 
in the materials and methods. The lymphocyte cultures were stimulated 
with the T cell mitogen concanavalin-A. Concanavalin-A is toxic to cells 
in high doses and the amount used in this experiment (7.5ug/ml) was taken 
from reported experimental data (Nagata et al 1987). Addition of the 
mitogen causes the enhancement of gene transcription and induces the 
cells to proliferate. Concanavalin-A is a plant derived non-specific 
polyclonal activator. Both concanavalin A and phytohaemaglutinin (PHA) 
are equally active in inducing interferon-gamma gene transcription (Kiener 
and Spitalny 1987). There is a time lag between addition of the mitogen 
and maximum RNA production and so the difficulty in these experiments 
is knowing when to harvest the mRNA as the time lag is unknown. To
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optimise the yield, mRNA was harvested at 6, 12 and 18 hours. It was 
found that maximum mRNA harvest was achieved after 6 hours of 
stimulation. This correlated with the report of Nagata et al (1987)
mRNA was harvested using an mRNA purification kit from Pharmacia, as 
described in the materials and methods. The concentration and purity of 
the mRNA was determined from spectrophotometric readings. In the 
experiment described here, 5ug of mRNA was harvested from 
1 (^ stim u la ted  T cells. The mRNA sample had an OD A 260/280 reading 
of 1.95, indicating high purity mRNA.
3.3 FIRST STRAND cDNA SYNTHESIS
First strand cDNA synthesis was carried out as described in the Materials 
and Methods. The reaction was catalysed by Molony murine reverse 
transcriptase and the primer used was a NoM-d(T)18 primer provided in 
the kit. lug of mRNA was diluted to a volume of 20ul with DEPC treated 
water and incubated at 65°C. for 10 minutes. Following incubation, the 
20ul of mRNA was added to llu l of the bulk first strand reaction mix, 
along with lul of DTT and lul of the primer and the contents of the tube 
thoroughly mixed by pipetting. The reaction was allowed to proceed for 1 
hour at 37°C., after which, lOul of the sample was included in the PCR 
reaction, while the remainder was stored at -20°C. It was found that the 
best PCR results were obtained when the cDNA was used directly after 
preparation.
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3.4 PCR AMPLIFICATION
Amplification of cDNA was achieved using the polymerase chain reaction 
(PCR) as described by Mullis, (1986). PCR amplification of cDNA 
involves the enzymatic synthesis of specific cDNA target sequences using 
two oligonucleotide primers which flank the cDNA region of interest and 
hybridise to opposite strands. In addition to the DNA to be amplified and 
the oligonucleotide primers, there are appropriate deoxyribonucleoside 
triphosphates (dNTP's), buffer and a thermostable DNA polymerase 
included in the reaction.
The primers are added in vast excess compared to the DNA to be 
amplified. They hybridise to opposite strands of the DNA and are oriented 
with their 3' ends facing each other so that synthesis of DNA by Taq 
polymerase (which catalyses the extension of DNA in the 5' to 3' direction) 
extends across the DNA between them. Repeated thermal cycles of 
denaturation, annealing and extension allow amplification of the DNA of 
interest.
Using the newly synthesised cDNA as template, PCR was carried out to 
amplify cDNA encoding feline Interferon-y. The basic protocol is outlined 
in materials and methods and is shown schematically in figure 3.2.
3.5 DESIGN OF PCR PRIMERS
The most common cause of PCR failure is primer design. Primer design is 
the least predictable PCR parameter and it should be noted that some 
primers just do not work. For many PCR applications, primers are 
designed to be exactly complementary to the template. However, in this
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Figure 3.2: Diagrammatic representation of the Polymerase Chain Reaction
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Figure 3.3 Line up of upstream (A) and down stream (B) feline primers with 
equivalent regions in the interferon sequence for other species.(-) indicates 
areas of homology.
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instance the template sequence was unknown and so primers were selected 
from regions of homology between published sequences of other species.
To try and optimise the amplification the following general rules were 
followed in design of the PCR primers:
1) Primers were selected based upon regions of high degrees o f homology 
between sequences published for other species.
2) Primers were designed to be 20-30 bases in length.
3) Primers were made which had a GC:AT ratio of around 1:1 and runs of 
polypurines or polypyrimidines were avoided where possible.
4) The ends of the primers consisted of a C or G to improve anchorage of 
the primer.
5) The calculated melting temperatures (Tms) for a given primer pair were 
balanced. In order to achieve this, the Tm was predicted from the general 
calculation of 2°C. for A or T and 4°C. for G and C (Thein and Wallace
1986).
The following 23 base long primers were used in the amplification 
process:
Upstream: 5' CTA CTG ATT TCA ACT TCT TTG GC 3’ Tms 70<>C 
Downstream: 5’ CAA ATA TTG CAG GCA GGA CAA CC 3’ Tms 68°C
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Other primers were used in an attempt to amplify the feline Interferon 
gamma cDNA but were all unsuccessful. The above primers were found to 
be the most efficient. , The most important primer is the 3’ primer as 
mismatches in this primer are more likely to prevent extension. It is worth 
noting that computer programs are now available to aid in primer design. I 
had no access to such programs in these initial stages of the project and all 
primers used were designed manually.
3.6 PRODUCTS OF PCR AMPLIFICATION
PCR was carried out using the Gene Amp DNA Amplification kit (Perkin 
Elmer Cetus) using AmpiTaq recombinant Taq DNA polymerase. It was 
ensured that all reagents used were of a high purity. This was aided by the 
use of a PCR amplification kit (Cetus) in which all of the reagents were 
provided. The setting up of the PCR reaction was carried out in a separate 
laboratory away from the normal working space and under strict sterile 
conditions to avoid any contamination. A separate pipetteman was used in 
setting up the reactions which was set aside for PCR use only. In addition, 
aerosol resistant tips were used throughout the experiment.
The reaction was performed in 0.5ml polypropylene microcentrifuge tubes 
and consisted of lOul of the cDNA reaction, 200pm of each primer, 5ul of 
lOx reaction buffer (lOOmM TRIS-HC1 (pH 8.3), 500mM KC1, 15mM 
MgCl2, 0.01% (w/v) gelatine), 5ul of dNTP mix ( 200uM final 
concentration of each dATP, dTTP, dGTP, dCTP), 5ul of AmpliTaq DNA 
polymerase (final concentration of 2.5u/50ul) and autoclaved, ultra-filtered 
water to bring the final volume to 50ul. The reaction was overlaid with 
mineral oil to prevent evaporation. The reactions were then subjected to
113
thermal cycles of denaturation (94°C, 1 min), annealing (52°C., lmin) 
and polymerisation (72°C., lmin) in an automated thermal cycler (Perkin 
Elmer). A positive and negative control was included in the reaction. The 
positive control was provided in the kit, and consisted of control template 
and appropriate control primers. The negative control consisted all the 
components of the PCR reaction without the addition of cDNA template. 
The positive control demonstrated that the reaction had proceeded 
satisfactorily and the negative control was used as an indicator of 
contamination.
After 30 PCR cycles, the products of the reaction were visualised on a 1% 
agarose gel by staining with ethidium bromide and using an ultraviolet 
transilluminator (figure 3.4). The reaction had generated a specific product 
of around 600kb which was then cloned into the S r f 1 site of the plasmid 
vector pCR scripttm SK+ (Stratagene). The pCR-Script SK(+) cloning 
system utilises blunt-ended ligation of PCR fragments without the need for 
post PCR treatment. The ligation was carried out using the protocol 
provided by the manufacturer. 4ul of the PCR product was added to the 
ligation reaction containing pre-digested vector DNA (lul), T4 DNA ligase 
(lul), lul of the rare 8-base recognising restriction enzyme S r f  I (5' 
GCCCGGGC 3'), lul of pCR-script 10 x reaction buffer, 0.5ul of lOmM 
rATP and 1.5ul of ultra-pure water. Using the restriction enzyme in the 
ligation reaction maintains a high steady-state concentration of the 
digested vector DNA. The reaction was allowed to proceed at room 
temperature for 1 hour before heat treating at 65°C for 10 minutes. 2ul of 
the ligation reaction was used to transform DH5a competent bacteria as 
described in chapter 2. The resulting white colonies were screened for 
insert after small scale plasmid preparation and subsequent digestion with 
Bam HI and Sst I restriction endonucleases.
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Sequencing plasmid preparations were made of the resulting positive 
clones from the PCR ligation and these clones were then sequenced. DNA 
sequencing was performed on both strands of DNA from three independent 
clones using a standard di-deoxy chain termination method employing the 
Sequenase version 2.0 kit (United States Biochemical) as described in the 
Materials and Methods. The PCR product was found to be 568 base pairs 
in length which included the PCR primers. In one of these clones there 
appeared to be a base change at nucleotide no. 143 (T Instead o f A). 
However, two further clones were sequenced in this region and the 
consensus nucleotide was found to be A. In addition, one of the clones 
demonstrated third base wobble at nucleotide numbers 507 (T as compared 
to C in other clones) and 525 (A compared to C in other clones). Large 
scale caesium chloride preparations of recombinant plasmid were made 
for subsequent sequence analysis as described in materials and methods.
Sequence analysis was carried out using the university of Winconsin 
genetics computer group (G.C.G) sequence analysis software programmes. 
These programmes are run using the VAX computer and the VMS 
operating system. BESTFIT, which employs the "local homology" 
algorithm of Smith and Waterman (1981), was used to find the best 
homology between the sequences of PCR derived DNA and that of 
published interferon-gamma sequences for other species.
Figure 3.5 shows the primers used in the sequencing of feline interferon-y. 
Figure 3.6 shows the nucleotide and predicted amino acid sequence for 
feline interferon-gamma. The sequence codes for a protein of 167 amino 
acids with a predicted molecular weight of 19.6 kd.
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234
194
310
271/281
1,353
1078
872
603 ~600bp: corresponding 
to the size
of interferon coding sequence
Figure 3.4: 1% Agarose gel showing lane 1, DNAJHae III marker; lane 2, 
negative control, and lane 3, product of cDNA amplification reaction. The 
feint band corresponds to a 600bp molecule.
T3 PRIMER: 5' AATTAACCCTCAGTAAAGGG 3’
T7 PRIMER: 5' GTAATACGACTCACTATAGGGC 3' 
PCR PRIMER 1: 5’ CTACTG ATTTCAACTTCITTGGC 3’ 
PCR PRIMER 2: 5’ CAAATATTGCAGGCAGGACAACC 3’ 
SEQUENCE PRIMER 1: 5’ GTAATCCAGATGTAACAG 3' 
SEQUENCE PRIMER 2: 5’ CCATCAAGGAAGACATG 3' 
SEQUENCE PRIMER 3: 5’ GCAGATCATTCACAGGG 3’ 
SEQUENCE PRIMER 4: 5' CACTCTCCTCTTTCCAGTTC 3'
Figure 3.5 Primers used to sequence Feline interferon-gamma
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M N * Y T S 
1 ctactgatttcaacttctttggcctaactctccgaaacq atg aat tac aca agt
F I F A F Q L c I I L C S S G
55 ttt att ttc get ttc cag ctt tgc ata att ttg tgt tct tct g g t
Y Y C Q A M F F K E I E E L K
100 tat tac tgt cag gcc atg ttt ttt aaa gaa ata gaa gag eta aag
G Y F N * A S N P D V A D G G S
145 gga tat ttt aat gca agt aat cca gat gta gca gat ggt g g g teg
L F V D I L K N W K E E S D K
190 ctt ttc gta gac att ttg aag aac tgg aaa gag gag agt gat aaa
T I I Q S Q I V s F Y L K M F
235 aca ata att caa age caa att gtc tcc ttc tac ctg aaa atg ttt
E N L K D D D Q R I Q R S M D
280 gaa aac ctg aaa gat gat gac cag ege att caa agg age atg gac
T I K E D M L D K L L N *r T S S
325 acc ate aag gaa gac atg ctt gat aag ttg tta aat acc age tcc
S K R D D F L K L I Q I P V N
370 agt aaa egg gat gac ttc etc aag ctg att caa ate cct gtg aat
D L Q V Q R K A I N E L F K V
415 gat ctg cag gtc cag ege aaa gca ata aat gaa etc ttc aaa gtg
M N D L S P R S N L R K R K R
460 atg aat gat etc tea cca aga tct aac ctg agg aag egg aaa agg
S Q N L F R G R R A S K stop
505 age cag aat ctg ttt cga ggc cgt aga gca teg aaa taa tgg_ ttq
550 tcc t a c ctg caa tat ttg
Figure 3.6, The above shows the nucleotide and predicted amino acid 
sequence for feline interferon-gamma. The nucleotides underlined 
represent the PCR primers. The amino acid sequence is shown to start at 
the first methionine. With the human equivalent the first 20 amino acids 
represent a leader sequence which is cleaved from the mature protein.
* Indicates possible sites for N-glycosylation.
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3.8 DISCUSSION
PCR provides a rapid means to amplify cDNA's of interest and it has been 
employed to amplify several cytokine genes, including ovine (Radford et 
al 1991) and equine (Curran et al, 1994) interferon-gamma. This chapter 
has described the use of PCR to amplify cDNA encoding feline interferon- 
gamma and has outlined the importance of high quality template and PCR 
optimisation. Initial experiments using different primers and conditions 
were unrewarding and thus a great deal of time and effort went into 
optimising conditions. Each element of PCR can effect its outcome and 
thus all steps in the process were optimised.
The deciding factor in the success of PCR reactions for amplification of 
unknown sequences seems to hinge on primer design. The primers were 
selected according to high degrees of homology between published 
sequences of other species. In evolutionary terms, the feline sequence was 
likely to be more closely related to the human sequence than the murine 
sequence (This has been demonstrated at the karyotypic level where the 
feline and human organisation is more similar than that o f the 
murine/feline of murine/human (O'Brien, 1986) and so the primers used 
were more closely related to the human sequence than the murine 
sequence. Radford, (1990), used bovine primers to amplify the ovine 
sequence with great success and found that the ovine and bovine sequences 
to be highly homologous (93%) and the protein is actually cross reactive in 
these species. Conservation of cytokine gene sequences across species 
improves the ability to amplify unknown sequences by the polymerase 
chain reaction.
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Other conditions of the PCR reaction which were optimised included the 
concentration of Taq polymerase, dNTP's, Mg2+ and primers, and also the 
various parameters of the thermal cycling. The enzyme Taq DNA 
polymerase, from Thermophilus aquaticus, has the ability to withstand the 
repeated heating and cooling conditions which are inherent in PCR. 
However, it is not totally resistant to heat and should not be put through 
unnecessary denaturation steps. The enzyme's catalytic ability gradually 
diminishes when heated repeatedly and it has little activity following 30 
cycles of template denaturation.
Increasing the amount of Taq polymerase above 2.5U per reaction can 
sometimes increase PCR efficiency, but only up to a point. Adding more 
enzyme can sometimes increase the yield of non-specific PCR products at 
the expense of the product of interest. In the experiment described here, 
Taq polymerase was used at 2.5U/reaction.
The differences in sequence in certain clones may have been a result of the 
lack of proof-reading capacity of the Taq polymerase used. More clones 
had to be sequenced in these anomalous regions to establish a consensus 
sequence. Proof-reading polymerases are now commercially available and 
should be considered in further amplification reactions. While the 
introduction of mutations by the Taq polymerase is possible (Taq 
polymerase has an error rate estimated at 2x10_4 nucleotides per cycle 
(Saiki, 1988), another explanation of differences between clones may be 
that, because the PCR was performed on cDNA which was presumably 
derived from more than one interferon-gamma mRNA molecule, it is 
possible that variations in mRNA transcripts or reverse transcription 
reaction products could have contributed to the differences between certain 
clones. Cerretti et al, (1986), found one base difference between the
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sequence of two cDNA clones of bovine interferon-gamma, and two 
variations with the bovine interferon-gamma sequence of Demyck (1983), 
which was also derived from a cDNA clone. Both of the latter variations 
altered the inferred amino acid sequence.
dNTP's were provided with the manufactures kit and, in this experiment, 
were used at the recommended concentration, i.e. in excess, and at a final 
concentration of 200uM for each dNTP. The concentration of dNTP's 
should not be increased in an attempt to increase the efficiency of the PCR 
reaction. When each dNTP is 200uM, there is enough to synthesise 12.5ug 
of DNA when half of the dNTP's are incorporated. dNTP's chelate 
magnesium and thereby change the effective optimal magnesium 
concentration. Moreover, dNTP concentrations > 200uM increase the 
error rate of the polymerase. Millimolar concentrations of dNTP's actually 
inhibit Taq polymerase (Gelfand 1989).
It is beneficial to have an optimum magnesium concentration because this 
can affect all of the following parameters: primer annealing, strand 
dissociation temperatures of both template and PCR product, product 
specificity, formation of primer dimer artefacts, the enzyme activity and 
fidelity. Taq polymerase requires free magnesium on top of that bound by 
template DNA, primers and dNTP's. Accordingly, PCR reactions should 
contain dNTP concentrations of 0.5 to 2.5 mM over the total dNTP 
concentration. The presence of EDTA or other chelators in the primer 
stocks or template DNA may disturb the apparent magnesium 
concentration.
In the experiment described here, PCR buffer (lOx), supplied by the 
manufacturer, was used which contained free magnesium at a
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concentration of 15mM, i.e. the final concentration in the PCR reaction 
was 1.5mM. While conducting preliminary experimental PCR reactions to 
optimise the process, it was found that varying the concentration of 
magnesium between 0.5 and 2.5 mM had little effect on improving PCR 
efficiency of feline interferon-y amplification.
Primer concentrations of 10 to 50 pM per reaction are generally optimal 
for PCR reactions. Primers at higher concentration may promote 
mispriming and accumulation of non-specific products. However, for the 
amplification of the feline interferon-y sequence, the optimal primer 
concentration was found to be 200pM per reaction, based upon standard 
spectrophotometric determination.
In thermal cycling, each step in the cycle requires a minimal amount of 
time to be effective while too much time at each step may be wasteful and 
deleterious to the Taq polymerase. The shortest possible times at each step 
are used. For templates less than 1Kb in length, 1 minute per cycle is 
adequate for synthesis of complete copies of the DNA stands.
It is critical in the denaturation stage that the double strands are completely 
separated. For PCR from genomic DNA it is generally required that the 
sample be heated to 95°C+ for approximately 5 to 10 minutes prior to the 
addition of the Taq polymerase due to the viscosity of the template. For 
the amplification of feline interferon cDNA, from first strand cDNA, the 
Taq polymerase was added to the reaction tube prior to the addition of the 
tubes to the thermal cycler as, in this type of reaction, it is less important to 
heat denature the DNA for long periods of time. In general the length of 
time for the denaturation process was taken to be 1 minute/kb. Thus, in 
this experiment, the denaturation step was 94°C for 1 minute.
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It is critical that the primers anneal to the template in a stable fashion. 
Specificity is improved by raising the annealing temperature towards 
60°C. However, where there may be primer/template mismatch the 
temperature needs to be lower to promote annealing of these degenerate 
primers. In the amplification of interferon-y cDNA, the annealing 
temperature was varied between 45°C and 55°C, in preliminary 
experiments, to determine optimum annealing conditions. The optimum 
temperature for annealing was found to be 52°C and the annealing time 
was set at 1 minute.
The extension temperature was set at a standard 72°C and the time was set 
at 1 minute and 30 cycles of denaturation, annealing and extension were 
performed.
The PCR primers used in the reaction amplified a product o f 568 base 
pairs (which included the PCR primers). The predicted coding sequence is 
504 base pairs and codes for a protein of 167 amino acids. The mature 
protein may be smaller than this because, as in human interferon-gamma, 
the first twenty three amino acids may represent a leader or signal peptide 
sequence which is cleaved from the mature protein before secretion. The 
signal sequence is thought to develop a conformation that is recognised by 
channel proteins in the endoplasmic reticulum and thus serves to transport 
the protein through the ER to be ultimately secreted. The signal peptide is 
cleaved from the mature protein by a signal peptidase on the luminal side 
of the endoplasmic reticulum. It can be difficult to predict the site of 
signal peptide cleavage, but signal sequences do exhibit some common 
features (Stryer, 1987). They range in length, from 13 to 30 residues; the 
amino terminal part of the signal contains at least one positively charged
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residue; a highly hydrophobic stretch forms the centre of the sequence and 
the cleavage site at the carboxyl-terminal end is preceded by a sequence of 
about 5 residues that is more polar than the hydrophobic core. However, 
the residues one before (-1 on the amino-terminal side) and three before (- 
3) the cleavage site have small neutral side chains. Alanine is most 
common but cysteine, threonine, serine and glycine can be found at the -1 
and -3 positions. From these general rules one can predict that the 
cleavage of the signal sequence of the feline recombinant interferon- 
gamma would be at amino acid 23.
The feline nucleotide sequence shows significant homology o f 78% to the 
human sequence and 63% homology to the murine sequence (Gray et al 
1982 and Gray and Goeddel 1983). At the amino acid level the feline 
interferon-gamma shares 63% and 43% homology with the human and 
murine homologs respectively. A comparison of cDNA sequences and 
amino acid sequences is given in figure 3.7. There are three potential 
glycosylation sites in the feline sequence, between amino acids 2 and 4, 39 
and 41 and between 107 and 109. These glycosylation sites are predicted 
from the amino acid sequence of the mature protein. Sugars can be linked 
onto the protein through the amide groups of asparagine in the short 
peptide sequence Asn-X-Ser/Thr. Whether these predicted glycosylation 
sites are a true reflection of the actual in-vivo glycosylation is a matter for 
debate. The glycosylation sites do appear to be highly conserved between 
species.
The three dimensional structure of human interferon-y has been described 
by Ealick et al, (1991). The protein is primarily a  helical, with 6 helices 
(designated A to F) in each subunit that comprise -62%  of the structure 
(figure 3.7). There is no p sheet structure. The mature protein is a dimer
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and the dimeric structure of the human recombinant protein is stabilised by 
the intertwining of helices across the sub-unit interface with multiple 
intersubunit interactions
The amino acid sequence of interferon-y derived from a number of species 
is given in figure 3.7. The diagram shows the helical assignment and the 
highly conserved regions between species. Based on this homology, one 
could predict that the feline interferon-y molecule would have similar 
tertiary structure to the human recombinant protein (figure 3.8). Three of 
the most conserved regions in the sequence occur in helices C and F, 
which are the most buried helices in the dimer, and a short basic stretch at 
the beginning of the COOH terminal tail. The NH2 and COOH termini of 
the mature molecule are thought to be critical for receptor binding or 
triggering of biological responses (Ealick et al 1991). One of the most 
variable regions between species is the loop between helices A and B. It 
has been suggested by Ealick et al ( 1991), that this region may account for 
receptor affinity i.e. IFN-y from one species generally displays poor 
affinity for the receptor of another species.
In conclusion, PCR was used successfully to amplify cDNA encoding 
feline interferon-gamma and may provide a powerful tool to amplify other 
feline cytokine genes. The following chapters will discuss how this cDNA 
was then introduced into an expression system to produce recombinant 
feline interferon-y protein.
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1 50
Fe MNYTSFIFAF QLCIILCSSG YYCQAMFFKE IEELKGYFNA SNPDVADGGS
Hum MKYTSYILAF QLCIVLGSLG CYCQDPYVKE AENLKKYFNA GHSDVADNGT
Hum2 MKYTSYILAF QLCIVLGSLG CYCQDPYVKE AENLKKYFNA GHSDVADNGT
Bov MKYTSYFLAL LLCGLLGFSG SYGQGQFFRE IENLKEYFNA SSPDVAKGGP
She MKYTSSFLAL LLCVLLGFSG SYGQGPFFKE IENLKEYFNA SNPDVAKGGP
Cer MKYTSYILAL QLCVLLGFSG SYGQGPFFKE IENLKEYFNA SNPDVAEGGP
Eq MKYTSFILAF QLCAILGSST YYCQAAFFKE IENLKEYFNA SNPDVGDGGP
Pig MSYTTYFLAF QLCVTLCFSG SYCQAPFFKE ITILKDYFNA STSDVPNGGP
RabbitMSYTSYILAF QLCLILGSYG CYCQDTLTRE TEHLKAYLKA NTSDVANGGP 
Rat MSATRRVLVL QLC.LMALSG CYCQGTLIES LESLKNYFNS SSMDAMEGKS
Mur MNATHCILAL QL.FLMAVSG CYCHGTVIES LESLNNYFNS SGIDVEEKS.
51 100
Fe LFVDILKNWK EESDKTIIQS QIVSFYLKMF ENLKDDDQRI QRSMDTIKED
Hum LFLGILKNWK EESDRKIMQS QIVSFYFKLF KNFKDD.QSI QKSVETIKED
Hum2 LFLGILKNWK EESDRKIMQS QIVSFYFKLF KNFKDD.QSI QKSVETIKED
Bov LFSEILKNWK DESDKKIIQS QIVSFYFKLF ENLKDN.QVI QRSMDIIKQD
She LFSEILKNWK EESDKKIIQS QIVSFYFKLF ENLKDN.QVI QRSMDIIKQD
Cer LFIEILKNWK EESDRKIIQS QIVSFYFKLF ENFKDN.QVI QRSVDIIKQD
Eq LFLDILKNWK EDSDKKIIQS QIVSFYFKLF ENLKDN.QVI QKSMDTIKED
Pig LFLEILKNWK EESDKKIIQS QIVSFYFKFF EIFKDN.QAI QRSMDVIKQD
RabbitLFLNILRNWK EESDKKIIQS QIVSFYFKLF DNLKDH.EVI KKSMESIKED 
Rat LLLDIWRNWQ KDGNTKILES QIISFYLRLF EVLKDN.QAI SNNISVIESH
Mur LFLDIWRNWQ KDGDMKILQS QIISFYLRLF EVLKDN.QAI SNNISVIESH
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Fe MLDKLLNTSS SKRDDFLKLI
Hum MNVKFFNSNK KKRDDFEKLT
Hum2 MNVKFFNSNK KKRDDFEKLT
Bov MFQKFLNGSS EKLEDFKKLI
She MFQKFLNGSS EKLEDFKRLI
Cer MFQKFLNGSS EKLEDFKKLI
Eq LFVKFFNSST SKLEDFQKLI
Pig MFQRFLNGSS GKLNDFEKLI
RabbitIFVKFFNSNL TKMDDFQNLT 
Rat LITNFFSNSK AKKDAFMSIA
Mur LITTFFSNSK AKKDAFMSIA
151 168
Fe RKRKRSQNLF R.GRRASK*
Hum GKRKRSQMLF Q .GRRASQ*
Hum2 GKRKRSQMLF R.GRRASQ*
Bov RKRKRSQNLF R .GRRAST*
She RKRKRSQNLF R.GRRASM*
Cer IKRKRSQNLF R.GRRASM*
Eq RKRKRSQNPF R.GRRALQ*
Pig RKRKRSQTMF Q.GQRASK*
RabbitKKRKRSQTLF R .GRRASKY*
Rat RKRKRSRC*
Mur RKRKRSRC*
Figure 3.7 Line up of known interferon gamma amino acid sequences. 
Bold text indicates areas of conservation.
QIPVNDLQVQ
NYSVTDLNVQ
NYSVTDLNVQ
QIPVDDLQIQ
QIPVDDLQIQ
QISVDDMQIQ
QIPVNDLKVQ
KIPVDNLQIQ
RISVDDRLVQ
KFEVNNPQIQ
KFEVNNPQVQ
RKAINELFKV
RKAIHELIQV
RKAIHELIQV
RKAINELIKV
RKAINELIKV
RKAINELIKV
RKAISELIKV
RKAISELIKV
RKAVSELSNV
HKAVNELIRV
RQAFNELIRV
150
MNDLSPRSNL
MAELSPAAKT
MAELSPAAKT
MNDLSPKSNL
MNDLSPKSNL
MNDLSPKSNL
MNDLSPKANL
MNDLSPRSNL
LNFLSPKSNL
IHQLSPESSL
VHQLLPESSL
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Figure 3.7 Schematic drawing of recombinant human interferon-y dimer 
(from Ealick et a l, 1991)
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4.0 INTRODUCTION
4.0.1 GENERAL INTRODUCTION
This chapter describes the expression of recombinant feline interferon-y 
protein. The options for protein expression include those based on 
bacterial, yeast and mammalian cell systems, and systems utilising 
baculovirus to express genes in insect cells. The system which is chosen 
to express a gene of interest should reflect the desired end result. For this 
project a fully functional interferon-y protein was required that had 
sufficient in-vivo half-life so that it could eventually be used as a 
therapeutic agent. Post-translational glycosylation of expressed genes 
occurs in both mammalian and baculovirus based systems. While 
glycosylation is unimportant for the biological function of interferon-y, it 
may be important in extending biological half-life. In addition a system 
was required that would be highly efficient at protein expression, and a 
system that would not be difficult to scale up to producing large amounts 
of protein. For these reasons the Baculovirus system was chosen.
The lifecycle and applications of baculoviruses have been reviewed by 
Bishop (1992); King and Possee (1992), and Luckow and Summers
(1988). Autographica californica nuclear polyhedrosis virus (AcMNPV), 
a member of the family Baculoviridae, has a wide host range and infects 
more than 30 species of Lepidopteran insects. The genome of AcMNPV 
consists of double stranded, circular, supercoiled DNA approximately 130 
kb in length. During AcMNPV infection two forms of viral progeny are 
produced: extracellular viral particles (ECV) and occluded virus particles 
(OV). The latter are embedded in proteinaceous viral occlusions called
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polyhedra. The polyhedrin protein is the major viral encoded structural 
protein of the virus and, in infected Spodoptera frugiperda cell cultures, 
accumulates to high levels.
The viral occlusions are an important part of the natural virus life cycle 
providing a means for horizontal transmission. When infected larvae die, 
the occlusion protein protects embedded viral particles from the 
environment. Ingestion of contaminated plant material by larvae then 
causes release of the virus particles in the gut to allow the life cycle to 
continue. Virus particles enter the cell by endocytosis or fusion and the 
viral DNA is uncoated at the nuclear pore or in the nucleus. DNA 
replication occurs around 6 hrs post infection but viral occlusions are not 
detected until 18 to 24 hpi. Extracellular virus particles reach a maximum 
between 36 and 48 hpi but the polyhedrin protein continues to accumulate 
for 4-5 days until the infected cells lyse. The natural baculovirus life cycle 
is represented diagrammatically in figure 4.1.
4.0.2 BACULOVIRUS GENE EXPRESSION AND REPLICATION
Baculovirus gene expression and replication has been reviewed by King 
and Possee 1992. The bi-phasic production of ECV and polyhedra 
observed in insect larvae is also found in cell culture and, in general, the 
processes are similar. The budded or ECV form of AcMNPV enters insect 
cells in culture by the process of adsorptive endocytosis. The 
nucleocapsids serve to translocate the DNA to the nucleus of the cell 
where virus replication is initiated. Baculovirus genes are expressed in a 
regulated fashion in infected cells. For convenience, virus gene expression 
has been divided into four phases. These are: immediate early (a), delayed 
early (p), late (y) and very late (5). In general, the expression levels
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Figure 4.1. Diagrammatic representation of the life cycle of a baculovirus in
insect larvae and the insect cell (P, polyhedra; ECV, budded extracellular
virus; PDV, polyhedra-derived virus; NC, nucleocapsid).
(from King and Possee, 1992) /
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attained in each succeeding phase is higher than that of the preceding one. 
This is shown diagrammatically in figure 4.2.
A description of these genes has been reviewed by King and Possee
(1992). Immediate, early genes are defined as those genes which can be 
transcribed in the presence of inhibitors of protein synthesis (e.g. 
cycloheximide). Two examples have been described, namely IE-1 and IE- 
N. Evidently, these virus genes are transactivated by host transcriptional 
factors and do not require de novo synthesis of other virus gene products.
The 39k delayed early gene is first detected in infected cells between 3 and 
6 hours post infection (h.p.i.). It has been concluded that the early- 
immediate gene products are required to transactivate the delayed early 
genes.
The late genes are expressed in infected cells at around 6 h.p.i which 
coincides with the onset of virus DNA replication. The virus genes which 
are expressed during this period include, the basic protein, the capsid 
protein and the virus membrane glycoprotein.
The very late genes are transcribed at a time when the virus is assembling 
occlusion bodies within the nucleus of the infected cell (from about 15 
h.p.i). The very late gene products include the polyhedrin gene, which 
forms the matrix of the occlusion body, and the p i 0 protein, which is most 
likely involved in polyhedra formation. Both polyhedra and plO genes are 
not involved in the formation of infectious virus particles. These two very 
late genes have certainly been the major focus for development of 
baculovirus expression vectors, since their promotors are extremely
132
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efficient and can result in their combined proteins accounting for up to 
50% of the total cell protein mass in the terminal stages of infection.
The polyhedrin gene of AcMNPV has been mapped and sequenced (cited 
by King and Possee 1992). This gene is non essential for replication or for 
the production of extracellular virus in cell culture. Deletion or insertional 
inactivation of the polyhedrin gene results in the production o f occlusion 
negative viruses, which form plaques which are distinctively different 
from those of wild type, occlusion positive viruses. This provides a way of 
visually screening for recombinant viruses. The nonessential nature, the 
high levels of expression of the polyhedrin gene and the ease of visual 
screening make the promoter of this gene particularly suitable for 
engineering as an expression vector (Lucklow and Summers, 1988).
4.0.3 POST-TRANSLATIONAL PROCESSING OF 
FOREIGN PROTEINS
The insect cell appears to be capable of undertaking many of the 
processing events that are required for the formation of biologically active, 
heterologous proteins. The following processing events have been 
reported: glycosylation, phosphorylation, fatty acid acetylation, amidation, 
and proteolytic processing, including signal peptide cleavage (Reviewed 
by King and Possee, 1992).
While it is evident that recombinant proteins expressed in baculovirus 
systems undergo glycosylation, there are differences in the nature of the 
added oligosaccharides in insect cells as compared to mammalian cells. 
Mammalian cell extensively trim and modify the core oligosaccharide in 
terminal glycosylation events. These events usually result in the addition
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of fucose, glucosamine-galactose and sialic acid residues to form complex, 
branched oligosaccharides. Insect cells lack, or only have very low levels, 
of the necessary fucose, galactose and sialic acid transferases. They also 
appear to lack the ability to process the core oligosaccharide which has 
been shown to contain a high proportion of mannose residues.
While post-translational modifications occur to proteins expressed from 
baculovirus vectors in insect cells, in some cases the efficiency of 
modification is not 100% (Bishop 1992). This is probably not unexpected 
for polyhedrin or plO based expression vectors, since these are late 
promotors and at this stage of infection the cell is in a terminal state and 
the machineries involved in post-translational modification may be 
becoming increasingly inefficient.
Proteins synthesised by baculovirus vectors appear to be translocated in 
the insect cell in a manner corresponding to its own host cell. Most signal 
peptides are recognised and cleaved in the endoplasmic reticulum and the 
resulting protein is targeted to the membrane or is secreted, as appropriate. 
Amino-terminal sequence analysis has confirmed the correct signal peptide 
cleavage for, among others, human interferon-a (Maeda et al, 1985), and 
human interleukin-2 (Smith et al, 1985).
4.0.4 GENERAL PRINCIPLES IN BACULOVIRUS EXPRESSION
A consequence of the size of the baculovirus genome (around 150 kb) is 
that it cannot be directly manipulated to insert foreign DNA. To express a 
foreign gene in baculovirus, the gene of interest is cloned in place of the 
viral coat protein gene in a plasmid transfer vector carrying a small potion 
of the viral genome. The recombinant transfer vector is co-transfected into
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Figure 4.3 Sequence of events in baculovirus gene expression 
(from Watson et al, 1992)
AcMNPV DNA AcMNPVJacZ DNA
Trans fe r  Vector
Linear DNA
T T
Co—transfect ion
Reccmnina tfcnRecomcnatlon
2-3 Cays
ta c u e - a  a s  ay
+  X-
Recomblnant  virus
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insect cells with wild type baculovirus DNA. At low frequency, the 
transfer vector plasmid and the viral DNA's recombine through 
homologous sequences, resulting in the insertion of the foreign gene into 
the virus genome. Recombinant viral plaques develop which are visually 
different from wild-type viral plaques. The recombinant virus can then be 
put through several rounds of plaque purification and the expanded and 
used to infect fresh insect cells, resulting in high expression of the foreign 
protein, Watson et al (1992)
4.0.5 ADVANTAGES AND DISADVANTAGES OF THE 
BACULOVIRUS EXPRESSION SYSTEM
There is no ideal protein expression system and bacterial, yeast, 
mammalian and baculovirus systems all have advantages and 
disadvantages. The method chosen to express the gene of interest is based 
upon the nature of the recombinant protein and its final use. The 
advantages and disadvantages of the baculovirus system are given in table
4.1
4.0.6 TRANSFER VECTORS.
Most transfer vectors reported contain sequences from AcMNPV including 
the promoter of the polyhedrin gene and varying amounts of 5! and 3' viral 
DNA flanking the polyhedrin gene cloned into a high copy number 
bacterial plasmid (Lucklow and Summers 1988).
The transfer vector used in this experiment was a polyhedrin promotor 
based expression vector termed pAcCL29-l, Livingstone and Jones
(1989). This is described in Materials and Methods.
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ADVANTAGES OF BACULOVIRUS 
EXPRESSION
1) The products o f  the late expression o f  both the 
polyhedrin and plO genes are not essential for 
replication o f  the virus and may, therefore, be 
replaced with foreign genes.
2) The polyhedrin and plO genes have very strong 
prom oters which allows expression o f  protein at 
very high levels.
3) The expression o f  very late gene promoters 
occurs in cells after the maturation o f  budded, 
infectious virus particles. Thus, if a cytotoxic 
protein is to be expressed it will not adversely 
affect virus replication.
4) The virus can accom m odate large am ounts o f 
foreign DNA without affecting normal replication 
and DNA packaging; the nucleocapsid simply 
extends lengthways to accom m odate the extra 
DNA.
5) The baculovirus replicates in eukaryotic cells 
which allows for post-translational m odification. 
However, there may be differences in the patterns 
o f  glycosylation.
6) Baculoviruses replicate only in invertebrates 
and there is no risk to the user o f  the system.
7) Protein production is relatively easy to scale up.
Table 4.4
DISADVANTAGES OF BACULOVIRUS 
EXPRESSION
1) Baculovirus infection o f  insect cells results in the 
death o f  the host and hence the necessity to reinfect 
fresh cultures o f  Sf9 cells. This m ay be inefficient 
on a com mercial scale.
2) Post-translational processing is different in insect 
cells. Insect cells produce glycoproteins with 
sim ple, unbranched side-chains with a high mannose 
content.
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4.0.7 WILD TYPE BACULOVIRUS
Success with the baculovirus expression system is dependent on being able 
to infect cells efficiently with Autographica californica multiple 
nucleocapsid nuclear polyhedrosis virus (AcMNPV), thus obtaining 
maximum virus replication and optimum production of the desired protein 
King and Possee (1992). During co-transfection of plasmid transfer vector 
with circular wild-type baculovirus the recombination frequency is around 
0.1 to 1%. Because of this, new ways of improving recombination 
frequency so as to make screening plaques more efficient have been 
developed, Kitts and Possee (1993), Bishop (1992).
In yeast and mammalian cells DNA molecules containing double-strand 
breaks are highly recombinogenic and in these systems linearization of the 
incoming DNA is routinely used to promote recombination with 
homologous systems. In insect cells, linear fragments of AcMNPV DNA, 
produced by restriction enzymes, have been used to map mutations in the 
virus genome by marker rescue, but linear baculovirus DNA is generally 
regarded as non-infectious. It was proposed that a linearized virus genome 
might be non-infectious but still be able to recombine with homologous 
sequences introduced into the host cell. If the homologous sequences 
spanned the two ends of the linearized baculovirus DNA, then the genome 
would be recircularized and restored to full infectivity.
This hypothesis was tested when it was discovered that a restriction 
enzyme (2fcz/36I, Ms til, Saul ) did not digest AcMNPV DNA. This site 
could be inserted using synthetic oligonucleotides. Circular and linearized 
viral DNA’s were compared in terms of their infectivity and 
recombinogenicity. It was confirmed that linear DNA co-transfected alone
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reduced the yield of progeny virus to 93% and infectivity was reduced 15- 
150 times that of circular DNA. However, co-transfection of linearized 
virus with an appropriate transfer vector demonstrated that the linear DNA 
was proficient at recombination and that upto 30% of the progeny virus 
were recombinant. The use of linearized virus DNA in co-transfections 
represented a considerable improvement over previous methods for 
selecting recombinant virus. The system was refined further by the 
discovery that the Bsu36l RE site is also present in the bacterial lac-Z gene 
coding sequence. A virus AcMNPV/ac-Z has been constructed with this 
coding sequence in place of the polyhedrin gene. After linearization any 
recombinant plaques that develop after homologous recombination should 
be colourless after staining with X-gal. King and Possee (1992) and Kitts, 
Ayres and Possee (1993).
The process described above can improve the proportion of recombinant 
viral progeny to around 30%. In the experiments which demonstrated this, 
the background of non-recombinant viruses came from two sources: 1) 
viral DNA molecules that did not get cut by the restriction enzyme (a small 
proportion of uncut virus can make a large difference because uncut virus 
is 15 to 150 times more infective than linearized virus) and 2) linearized 
viral DNA that has recircularised inside the insect cell without 
recombination with the transfer vector. To remove background caused by 
the second factor, another approach was developed by Kitts and Possee
(1993).
The new approach involved the construction of a virus such that restriction 
of the viral DNA would separate part of the essential gene downstream of 
the polyhedrin expression locus from the remainder of the viral genome. 
Even if the virus recircularised, the resulting virus genome would lack
140
essential sequences and would not produce viable progeny, whereas a 
double recombination between the linearized viral DNA and the transfer 
vector would generate a circular viral genome with an intact copy of the 
essential gene that would produce viable viruses. In addition, the 
incorporation of two or three restriction sites into the viral genome would 
reduce the background created by virus escaping restriction enzyme 
digestion. This is because the fraction of molecules that had not been cut 
at least once would be extremely small.
In the experiment described below (4.1), a wild type virus with two Bsu36l 
sites, designated BacPAK6, was used and was kindly provided by NERC 
institute of virology and environmental microbiology, Oxford. BacPAK6 
had been generated by co-transfection of linearized AcRP6-SC with a 
plasmid designated PAK6. PAK6 was generated to have two Bsu36\ sites 
which flank a p-galactosidase gene (Kitts and Possee 1993), thus 
recombinant BacPAK6 viral plaques would stain blue with X-gal. It was 
demonstrated by the group in Oxford, that the use of restricted BacPAK6 
viral DNA to generate recombinant AcMNPV expression vectors yields a 
higher proportion of recombinant viruses than existing methods. This 
system has the additional advantage of being compatible with a wide range 
of existing vectors. The orfl629 sequence required to rescue restricted 
BacPAK6 viral DNA are present in most transfer vectors.
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4.1 EXPERIMENT TO EXPRESS THE rFelFN-y 
PROTEIN IN A BACULOVIRUS SYSTEM
4.1.1 LIGATION OF THE INTERFERON-GAMMA 
GENE INTO pAcCL29-l.
The amplified cDNA encoding feline interferon-gamma was originally 
cloned into the pCR script™ SK+ plasmid vector and sequenced (chapter 
3). As previously described, five clones were sequenced, and one of these 
clones, designated clone 2, was found to have an interferon-y cDNA insert 
in an orientation that would ^allow directional cloning into the Sstl and 
BamHl sites of pAcCL29-l. Caesium chloride plasmid preparations were 
made of both interferon clone 2 and also pAcCL29-l. Both plasmids were 
then independently digested with Sstl and BamHl. The digested 
interferon clone 2 was subjected to electrophoresis using a 1% agarose gel. 
The band corresponding to the interferon insert was excised and purified as 
described in materials and methods. One microlitre of the product of gene 
cleaning was then subjected to agarose gel electrophoresis to check for the 
presence, purity and to estimate the concentration of insert. The insert was 
then included in a ligation reaction with the pre-digested pAcCL29-l 
vector. The ligation was set up at a molar ratio of 1:10, vector:insert, i.e. 
lOOng of vector and 50ng of insert. The ligation reaction was incubated 
for 12 hours at 14°C and was then used to transform the E.coli bacterial 
strain INVaF' (Invitrogen) as described in Chapter 2. Twenty white 
bacterial colonies were screened for insert using the standard plasmid 
miniprep technique and subsequent digestion with Sstl and BamHl 
restriction endonucleases. Six out of the 20 colonies had plamid clones 
which were positive for an insert of the correct size. One of these clones, 
designated clone 20, was grown in culture and purified on a caesium
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1 2  3 4
23,130
9,416
2,027
PAcCL29-l
IFN Insert
Figure 4.5 1% Agarose gel showing : lanel, X DNA/Hind III marker; lane 2, 
DNAJHae III marker; lane 3, lul of pAcCL29-l digested vector, and lane 4, 
lul of digested, gene cleaned clone 2 interferon insert.
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chloride gradient. The clone was then sequenced again using previously 
described primers and, in addition, primers which were designated 58 and 
59 (see below), which confirmed that the insert was in the correct 
orientation. Sequencing of clone 20 demonstrated that there had been no 
alteration in the coding sequence. Primer 58 and 59 were synthesised 
according to published primer sequences o f King and Possee (1992). 
Primer 58 is a 5' upstream primer which sequences through the promotor 
region of the polyhedrin gene. Primer 59 is a 3' downstream primer which 
sequences through the terminal 3' end of the polyhedrin gene.
Primer #58: 5’ TGA TAA CCA TCT CGC AA 3'
Primer #59: 5? AGC GAG ATT GTA TGG TG 3’
These primers can be used to sequence across the cloning junction in any 
polyhedrin promotor based transfer vector. The 3' primer is only 
applicable to transfer vectors where the polyhedrin coding region has been 
deleted e.g. pAcYMl.
4.1.2 ISOLATION OF INFECTIOUS AcMNPV DNA
A large stock of AcMNPV (BacPAK 6) was grown up in Sf9 cells using 
500ml spinner culture flasks. The cells were pelleted at low speed and the 
virus particles from the medium were then pelleted at 13k and 4°C 
overnight in a 6 x 250 MSE rotor. The pellets were soaked overnight in a 
small volume of TE. Following this the pellets were resuspended by 
vortexing and then spun at low speed (3k/10mins/chillspin) to remove 
large debris. The virus was layered on to a 10-50% (w/v) sucrose gradient 
(in TE). This gradient consisted of a 10% layer of sucrose on top of a 50%
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cushion. Seven ml was used in each of two tubes (topped up with paraffin) 
and spun at 4°C/24k for 1 hour. The virus forms a tight band at the 
interface and was harvested in the usual way. The diluted virus was then 
pelleted at 30k for 1 hour and soaked overnight in TE (2ml). The virus 
was then stored at 4°C.
4.1.3 PURIFICATION OF INFECTIOUS VIRUS DNA
This method was used to prepare very pure, infectious virus DNA for co­
transfections. The starting material was purified virus. Sterile solutions 
and aseptic technique was used throughout, as the DNA prepared would 
eventually be used to infect cells in culture. The method used was as 
follows: Four hundred ul of purified virus was taken, to which was added 
lOOul of 20% sarkosyl solution. This was incubated at 60°C for 30 
minutes to lyse the virions. The lysed virions were then layered onto a 
cushion of caesium chloride (50% w/v in TE buffer) containing 12.5ul of 
ethidium bromide (lOmg/ml). The sample was spun at 35000 rpm for 18 
hours at 20°C. After centrifugation, the virus DNA appeared as two 
orange bands. The lower band corresponded to supercoiled DNA and the 
upper band was open circular DNA. Both bands were harvested as they 
are equally infectious.
The tube was placed in a retort stand and a beaker placed beneath the tube 
to catch any drips. A hole was bored into the base of the tube and both 
DNA bands were collected in a bijou. The ethidium bromide was removed 
by adding equal volumes of butanol and shaking gently. The phases were 
allowed to separate and the upper phase was discarded. This was repeated 
until all the ethidium had been removed. The sample was then dialysed 
against TE buffer at 4°C overnight to remove the caesium chloride. The
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buffer was changed several times during this procedure. Following 
dialysis, the sample was transferred to a sterile bijou and stored at 4°C. 
Baculovirus should not be stored frozen and will remain infectious for in 
excess of one year at 4°C. In addition, viral DNA should never be ethanol 
precipitated as this destroys infectivity.
The concentration of viral DNA was determined by UV 
spectrophotometery. An OD reading was taken at 260nm and the 
concentration of DNA was calculated as follows:
DNA conc.= OD26O x 50 x dilution factor.
In this experiment, after TE dialysis, the concentration of DNA was found 
to be 8.5ug/ml with an A260/280 of 2.0067.
4.1.4 LINEARIZATION OF WILD-TYPE VIRUS
The amount of linearized virus required for 1 calcium phosphate co­
transfection is around 0.7-lug (King and Possee 1992). Thus, enough 
virus was linearized for two reactions, namely the true co-transfection and 
a control. One hundred and fifty ul (lug) of the above wild-type DNA was 
included in two restriction enzyme digestion reactions. Each reaction 
included 150ul of viral DNA, 18ul of buffer #3, 2ul of Bsu36l, 1.8ul of 
acetylated BSA, and 8.2ul of water to give a final volume of 180ul. The 
reaction was digested overnight at 37°C. One ul of each reaction was 
electrophoresed on a 1.5% agarose gel against uncut DNA and high 
molecular weight markers to ensure digestion had taken place. In both 
reactions there appeared to be full digestion (figure 4.7).
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Figure 4.6 1% agarose gel: lanes 1-6 correspond to the 6 positive clones of 
pAcCL29-l containing interferon cDNA insert after digestion with S s t l  and 
B a m H l ; lane 7, DNA/H ae  III marker, and lane 8, XDNAJHind III marker.
Linearized virus
Figure 4.7 1.5% agarose gel showin-linearized wild-type virus (lane 1), 
uncut virus (lane 2), DNA/H ae  III marker (lane 3) and >JDNA/H ind  III 
marker (lane 4)
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4.1.5 CO-TRANSFECTION OF INSECT CELLS
Co-transfection of insect cells with linearized virus and transfer vector was 
achieved using the calcium phosphate co-precipitation method. The 
success of this method depends very much on forming the correct size of 
precipitate. To facilitate the success of this procedure, a standard calcium 
phosphate co-precipitation kit (Stratagene) was used. This kit employs 
two solutions, #1 and #2. #1 is 2.5M CaCl2 and #2 is 2xBBS (pH 6.95) 
consisting of 50mM N,N-bis (2-hydroxyethyl)-2-aminoethanesulphonic 
acid and buffered saline, 280mM NaCl and 1.5mM Na2HPC>4 .
Enough 35mm dishes containing 10^ Sf9 cells were prepared and allowed 
to settle for around 2-3 hours. Three co-transfection reactions were set up, 
namely, linearized viral DNA plus Transfer vector, linearized viral DNA 
alone and uncut wild-type virus alone, the latter two acting as controls. 
The reactions were set up as follows: lug of linearized viral DNA and 5ug 
of transfer vector were diluted with distilled, deionized water to 450ul to 
which was added 50ul of solution #1. Five hundred ul of solution #2 was 
added slowly and mixed gently by flicking the reaction tube with the index 
finger. The mixture was allowed to incubate at room temperature for 20 
minutes. After incubation the medium was removed from the 35mm 
dishes and 1ml of each co-transfection mixture added to the appropriate 
plates. The cells were incubated for 1 hour at room temperature. 
Following this incubation, a further 1ml of TC 100 medium was added to 
the plates, which were then allowed to incubate overnight at 28°C. The 
following day, the medium was removed and the monolayer washed with 
calcium free phosphate buffered saline. Two ml of medium was then 
added to each plate and the plates allowed to incubate at 28°C for a further
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48 hours. After 48 hours the co-transfection mixtures were harvested, 
filtered through a 0.45u filter and stored at 4°C. The next step was to 
separate recombinant and wild-type virus.
4.1.6 SEPARATION OF PARENTAL AND RECOMBINANT 
VIRUSES BY PLAQUE ASSAY
A detailed protocol for plaque assay has already been described (chapter 2) 
and this method follows much the same principles. The required number 
of 35mm dishes were prepared, as described, using 10^ Sf9 cells /dish. 
The required dilutions of the co-transfection mixtures were then made in 
T C I00 growth medium, viz: neat, 10“ 1, 10*2 and 10"3. The medium from 
the SF9 cells was removed and lOOul of each dilution was added to the 
appropriate dish. The dishes were allowed to incubate at room temperature 
for 1 hour. Following this incubation step, the inoculum was removed and 
replaced with a 2ml agarose/TClOO overlay. The dishes were then 
incubated at 28°C for 3 days and stained as described in Chapter 2.
Recombinant plaques are lac-Z negative and appear as white/clear plaques 
when dual stained with neutral red and X-gal. From the actual plaque 
assay performed, a total of 6 white plaques were visualised on the plates 
containing harvested co-transfection mixtures incorporating transfer vector 
and linearized virus. No blue plaques were observed on these plates. The 
linearized virus alone gave no plaques, either blue or white, and the wild- 
type virus alone gave a diffuse lawn of blue plaques alone on the stained 
plates. The 6 white plaques were picked into 1 ml of T C I00 medium. 
lOOul of each of the plaque dilutions was re-plated onto Sf9 cells in 35mm 
dishes to begin plaque purification. In addition 400ul of each plaque pick 
solution (labelled #1 to #6) was added to 10^ cells (in a 24 well plate). 0.5
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Figure 4.8 Separation of parental and recombinant viruses by plaque assay, 
upper plate (left) is the control plate; lower plate (left) contains wild-type 
virus showing diffuse blue colouration after X-gal staining; right upper and 
lower plates demonstrate clear staining recombinant viral plaques.
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ml of TC I00 medium was added to these wells and they were allowed to 
incubate for 3-4 days at 28°C.
After a four day incubation period the cells in the 24 well plates were 
microscopically examined. In each of the six wells that had been plated 
the cells had lysed and had floated off the base and into the medium. This 
indicated that viral replication was occurring. The supernatants from these 
cells were removed and clarified by centrifugation. The supernatants were 
then included in a standard cytopathic effect reduction assay to check for 
expression of interferon. In this crude assessment the individual 
supernatants (# 1 to #6) were incubated with FEA cells, as described below, 
and subsequently challenged with feline calicivirus. 5x10^ FEA cells were 
used to seed each well in a 12 well assay plate. The cells were incubated 
overnight at 37°C/5%C02 and examined microscopically the following 
day to ensure that the cells had become just sub-confluent. Wells were 
assigned virus and cell controls. The medium was removed from the cells 
and lOOul of neat supernatant from samples #1 to #6 was added to the 
appropriate wells and allowed to incubate with the cells for 1 hour at 
37°C/5%CC>2. Following this incubation, the virus innoculum was 
removed and replaced with an agarose overlay. The plates were then 
incubated for 48 hours at 37°C./5%CC>2 prior to staining with crystal 
violet/formalin (0.2% crystal violet in 10% formalin). The results o f this 
assay are given in Table 4.2. All of the supernatants appeared to have 
some protective effect against calicivirus challenge in the assay, except for 
perhaps #4 and #6, but protection appeared to be stronger when 
supernatant #3 was used. As a consequence, the original plaque-pick #3 
was used in subsequent plaque purifications.
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No. Recombinant virus challenge with FCV
Plaque pick #1 ~10 plaques
Plaque pick #2 ~6 plaques
Plaque pick #3 ~2 plaques
Plaque pick #4 >20 plaques
Plaque pick #5 '■'TO plaques
Plaque pick #6 >20 plaques
cell control >20 plaques
wild-type viral control >20 plaques
Table 4.2 Results of the crude CPER assay to assess whether recombinant 
virus was producing a biologically active protein.
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4.1.7 PLAQUE PURIFICATION OF RECOMBINANT 
VIRUS STOCKS
As described above the original plaque-pick #3 was replaqued in a second 
assay and six plaques from this plate were picked into 1ml of T C I00 
growth medium. These plaques were put through a second round of 
plaque purification. Crude evidence of expression was then looked for 
using the same procedure, as described above. The virus from each plaque 
pick was expanded in 24 well plates over a 4 day period and the 
supernatants harvested and clarified by centrifugation. To test for 
expression, neat supernatant was used to protect feline fibroblasts in a 
standard cytopathic effect reduction assay (Maeger, 1987). However, 
before adding virus it was noted that the cells which had been incubated 
with neat supernatants had rounded up and floated into the medium. This 
effect was not seen in control cells which had been incubated with medium 
alone, medium + neat medium harvested from uninfected Sf9 cells and 
cells which had been incubated with medium + wild-type baculovirus 
PAK6. It was concluded that the baculovirus recombinants were indeed 
producing a product that was appearing to cause cytostasis. The greatest 
effect was observed in the assay wells containing final plaque-pick #6, and 
lOOul of this was used to infect 5x10^ cells in a medium sized flask in an 
attempt to amplify recombinant viral stocks.
4.1.8 AMPLIFICATION OF THE INTERFERON-y CODING 
SEQUENCE FROM RECOMBINANT VIRUS USING PCR
PCR was used to establish that the recombinant viruses contained the 
interferon gene. lOul of each of the 6 final plaque-picks were taken and
155
boiled for 10 minutes to lyse the viral particles. One ul of each of the 
boiled viruses was then included in a PCR reaction, using the original PCR 
primers described in chapter 3. Prior to adding the Taq polymerase the 
reactions were boiled again for a further 10 minutes to separate double 
stranded viral DNA. A total of 30 cycles were used of 94°C for 1 min; 
55°C for 1 min and 72°C for 1 min. All six of the final plaques were 
positive for interferon-gamma cDNA. The results from the PCR 
amplification are given in Figure 4.10.
4.1.11 THE GENERATION OF RECOMBINANT VIRUS STOCKS
High titre working stocks of virus were generated to enable efficient, high 
multiplicity of infection during the production cycle. As described above 
lOOul of final plaque-pick #6 was used to amplify virus stocks. 5 x 1 0 ^  
Sf9 cells were plated in a T75 medium sized flask and allowed to settle for 
around 3 hours. The medium from the cells was then removed and lOOul 
of plaque pick #6 and 1ml of medium was added to the flask. Following a 
1 hour incubation period, this medium was removed and replaced with 
15ml of fresh medium. The cells were then incubated for 7 days at 28°C. 
Following the incubation, the supernatant was harvested and clarified by 
centrifugation. The supernatant was then included in a plaque assay to 
determine the viral titre (described in Chapter 2). This stock of virus had 
an apparent titre of 5 x 1 0 ^  PFU/ml and was subsequently designated the 
master stock of recombinant virus. This stock was then used to prepare a 
working stock of virus. Initially 10^ Sf9 cells were seeded into a 500ml 
spinner culture flask containing 100ml of T C I00 medium. The cells were 
allowed to go through two doublings (i.e. they were in logarithmic growth) 
and were subsequently infected with 0.1 pfu/cell of the master stock 
recombinant virus. The cells were incubated at 28°C for 1 week. The
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medium was then clarified by centrifugation and filtered through a 0.2u 
filter and was then assayed for virus using the standard plaque assay 
technique as described. This virus stock had a titre of 3 x 10& PFU/ml and 
was used as the working stock of virus for subsequent protein expression. 
Figure 4.11 shows the sequence of events in generating virus stocks.
4.1.10 TIME COURSE STUDY OF INTERFERON 
PROTEIN PRODUCTION
For this experiment It was necessary to establish to optimum time (peak 
interferon concentration) to harvest supernatants from the baculovirus 
cultures. This would allow a set protocol for protein production to be 
established which would reduce variation between subsequent protein 
batches. Sf9 cells were grown to a sufficient density and used to seed a 
100ml spinner flask at a density of 1 x 10^ cells/ml. After seeding the 
cells in spinner culture, they were allowed to go through two doublings (as 
determined by cell counting) and then recombinant virus was added at a 
concentration of 10 pfu/cell when the cells were at 5 x 10^ cells/ml and 
were still in logarithmic growth. The high pfu was used to ensure that the 
cells were all infected at the same time. 5ml aliquots were removed at 24 
hour intervals and the protein production estimated by the standard CPER 
assay using calicivirus and feline fibroblasts (see below).
4.1.11 PRODUCTION OF RECOMBINANT PROTEIN
Following the time course study, a set protocol for protein production was 
established to minimise any variations between supernatant batches. The
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271/281
~600bp
Figure 4.10 6% Polyacrylamide gel showing amplification of the interferon-y 
coding sequence from recombinant virus using PCR. DNAJHae III marker 
(lane 1), negative control (lane2), positive control (lane 3) and amplification 
from plaques 1 to 6 (lanes 4 to 9).
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PLAQUE PURIFICATION
Nr LOW MOI
MASTER STOCK OF VIRUS
LOW MOI
WORKING STOCK OF VIRUS
Nr HIGH MOI
PROTEIN PRODUCTION
Figure 4.11 The generation of recombinant virus stocks
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protocol consisted of infecting cells which were in logarithmic growth 
(cell viability>98%) and at a concentration of 5 x 10^ cells per ml. For the 
production of the first batch of interferon protein, 1 x 10? Sf9 cells were 
used to seed 100ml of TC I00 medium in a 500ml spinner culture flask. 
The cells were allowed to go through two doublings before being counted 
and subsequently infected with recombinant virus. The cells were infected 
when they had reached a concentration of 5 x 10^ cells/ml (after 48 hours) 
and the infecting dose of virus used was 10 pfu/cell. The supernatant was 
harvested 5 days post infection and was subjected to centrifugation (1500 
rpm/lOmins) to remove cell debris. The product was then filtered through 
a 0.2um filter and stored at -20°C. This first batch of crude interferon 
protein was designated DAI and was subsequently used in the bioassays 
described below.
In addition to the production of DAI, a second batch of crude interferon 
was produced, designated DA2. The conditions for production were as 
described above but the protein was produced by the infection of High 
Five (Invitrogen) insect cells (described in Chapter 2). These cells are 
reported to increase protein production 10 fold.
4.2 EXPERIMENT TO DEMONSTRATE BIOLOGICAL ACTIVITY 
OF RECOMBINANT INTERFERON-y PROTEIN
4.2.1 INTRODUCTION
Interferons are related by their ability to induce the anti-viral state in cells, 
they are not themselves anti-viral agents. The cellular response to 
interferon and the subsequent inhibition of replication of an infecting 
virus, which can be measured, forms the basis o f the cytopathic effect
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reduction assay for interferon (CPER). The degree of inhibition o f virus 
replication is related to the potency of the interferon preparation or sample; 
that is a measure of the degree to which an individual interferon 
preparation is able to protect cells of a particular type against productive 
infection by a virus of a certain type. Potency measurements are relative, 
not absolute, and depend on: the proportion of interferon molecules in a 
particular preparation which are biologically active in the antiviral assay; 
the sensitivity of the cell line to interferon; and the sensitivity o f the virus 
to the anti-viral state established in the assay cells. Cell culture media and 
conditions add a further dimension to the complexity and variability of the 
antiviral assay. The potency of interferon preparations has therefore been 
quantified by the arbitrary assignment of anti-viral units defined in 
particular cell-virus systems, usually where some kind of end point can be 
observed, and expressed as the reciprocal of the dilution of an interferon 
preparation required to produce the end-point. The World Health 
Organisation (WHO) has established a number of human IFN international 
reference preparations (standards), the use of which allows individual 
laboratories to calibrate their assays in relation to the assigned potencies of 
these international reference preparations (IRP's) and thus to compare the 
results of their assays with other laboratories.
4.2.2 THE CYTOPATHIC EFFECT REDUCTION (CPER) ASSAY
This is by far the cheapest and most common form of assay to demonstrate 
biological activity of interferon preparations. In this type of assay cells are 
protected with serial dilutions of the interferon preparation and then 
challenged with a cytopathic virus. The cells are then cultured until 
maximum cytopathic effect is seen in virus control cells. At that point, the 
end point for the interferon sample, usually assigned to be the well in
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which 50% of the cells are living, is either determined microscopically or 
following staining with a vital dye. Such assays produce sharply increased 
CPE as the interferon is diluted out and thus it is not always easy to 
construct a satisfactory dose-response curve. Often, only two or three 
points are on the rectilinear portion of the dose response curve. A 
modification of the CPER assay is the plaque reduction assay. This is a 
similar assay but is carried out using a reduced multiplicity of infection 
(moi) of the challenge virus and a suitable overlay material. The end-point 
chosen for this type of assay is usually 50% plaque reduction compared to 
the virus control. Other assays to measure the antiviral action of 
interferons rely on the measurement either of infectious virus or particular 
viral components. The plaque reduction assays were not used in our 
experimental work.
In this experiment to measure the antiviral action of the baculovirus 
supernatant derived from the time course study, a CPER assay was used. 
This CPER assay was used to demonstrate protection of feline embryonic 
fibroblasts (FEA cells) against challenge with Feline calicivirus after their 
incubation with supernatants.
Initially a stock of feline calicivirus was prepared in FEA cells and the titre 
determined as described in Materials and Methods. In parallel, a working 
bank and master bank of FEA cells were grown in tissue culture and 
subsequently stored under liquid nitrogen. A working stock vial of cells 
was thawed and revived, as described in Chapter 2, and amplified to be 
used in the assay. In the 24 well plate system, FEA cells were harvested 
and counted from tissue culture flasks. Wells were assigned cell controls 
and virus controls. The cells were used to seed 24 wells at a concentration 
of 2 x 105 cells/well in 1ml of medium (Dulbecos MEM/
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10%FCS/glutamine/NaHCO3/penecillin/streptomycin and they were 
allowed to incubate for 24 hours at 37°C/5% C02- Following the 
incubation step the cells were examined microscopically to ensure that 
they had formed a sub-confluent monolayer. Subsequently, dilutions of 
the interferon preparations derived from days 2 through 5 in the time 
course study were then added to the appropriate wells. The cells were 
then allowed to incubate at 37°C for a further 24 hours. The control wells 
were incubated with medium alone or wild-type baculovirus. Following 
incubation, the challenge calicivirus was added to the medium overlaying 
the cells and the cells were incubated for a further 1 hour at 37°C/5% CO2 . 
The concentration of virus added was sufficient to cause 100% CPE, as 
determined when the virus was titrated, and, in this experiment, both 1 
PFU and 4PFU per cell were used. Following the 1 hour incubation step, 
the medium was removed and replaced with fresh medium. The cells were 
examined daily until maximum cytopathic effect was seen in the virus 
controls (this was 48 hours). The medium was then removed and the cell 
layer stained using crystal violet/formalin (0.2% crystal violet in 10% 
formalin). The results of the time course study are given in Table 4.3. The 
assay was repeated for the day 5 preparation and, for this assay, the dye in 
the stained wells corresponding to dilutions of the day 5 harvest was eluted 
using 0.5% NaCl in 50% ethanol, and the optical density at 595nm was 
measured spectrophotometrically. The results of this are shown in table 
4.4 and represented graphically in Figure 4.12.
An identical assay procedure was performed for the sample DAI using the 
24 well system. However, the assay was difficult to reproduce for this 
sample.
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4.2.3 CPER ASSAY USING VESICULAR STOMATITIS VIRUS
Virtually all cells and cell lines will show some sensitivity to interferon- 
gamma of the appropriate species, but not all are suitable for use in an 
assay system (Meager, 1987). Interferon-gamma is highly species specific 
and thus, for this experiment, the feline FEA cell line was used with, 
initially, feline calicivirus as the challenge virus, in the CPER assay. The 
choice of viruses which are sensitive to interferon induced protection is 
wide but, for the anti-viral assays, only a few viruses have proved suitable. 
This has been established by interferon researchers who have developed 
the antiviral assay for the human and murine interferon systems. The three 
most common viruses used in the human and murine assays are: 
Encephalomyocarditis virus (EMCV), Vesicular stomatitis virus (VSV), 
and Semliki Forest virus (SFV). All three viruses are known to work well 
in the interferon assay system. Previously, Zack, 1986(cited in Khan, 
1992) had reported the successful determination of interferon-y titres using 
the CPER assay utilising VSV and feline embryonic fibroblasts.
Vesicular stomatitis virus is a rhabdovirus and causes a disease in 
ungulates and horses which is clinically indistinguishable from Foot and 
mouth disease. As a consequence, the use of vesicular stomatitis virus is 
restricted and is confined to laboratories which have special licence and 
category II facilities. Three serotypes of the virus are recognised: VSV- 
Indiana (VSV-1), VSV-New Jersey (VSV-NJ) and VSV-Algoas (VSV-A). 
VSV is capable of replicating in a wide range of cells derived from 
vertebrate and invertebrate hosts and serological surveys have shown that 
it infects man and arboreal and semi-arboreal hosts in addition to domestic 
animals (Reif et al, 1987). Vesicular stomatitis virus is a group 2 pathogen 
as defined in the Categorisation o f  Pathogens According to Hazard and
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Categories o f  Containment 1990. In addition the organism is covered by 
the Specified Animals Pathogen Order 1993 which prohibits the holding or 
use of the organism unless a licence has been issued by the Scottish 
Office's Agriculture and Fisheries Department (SOAFD).
In the initial stages of the expression work there was no licence to use the 
VSV, and thus the calicivirus system was used. There was no evidence at 
this stage that any interferon preparation would protect FEA cells against 
challenge with calici virus. The calicivirus assay was used in a rather 
crude manor to initially assess whether the baculovirus system was 
producing interferon, and then used it to assess the profile of interferon 
production with time from Sf9 cells infected with recombinant virus. The 
advantage of the system was that it did not require category II facilities. 
While initial assays showed protection, the assay system became rather 
variable and it was difficult to reproduce a working assay for the sample 
DAI. As a consequence, it was decided to use the VSV assay system with 
FEA cells to try and standardise the assay procedure.
A licence was granted to use a mutant VSV and all assay procedures were 
carried out in a category II laboratory. The VSV mutant used in this assay 
was designated VSVtoE2 and is derived from the New Jersey strain of 
VSV. This mutant strain contains two independent mutations within the 
NS gene (Rae and Elliott, 1986) and is incapable of producing diseases in 
domestic livestock. In addition, because it is temperature sensitive, it is 
unable to sustain a transmission cycle between animals. The primary virus 
stock was kindly provided by Dr. Richard Elliott o f the MRC Institute of 
Virology.
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The assay procedure was essentially the same as that described for the 
calicivirus assay. The optimum temperature for virus replication is 31°C 
and, initially, FEA cells were cultured at this temperature to ensure that 
they would still grow. The cells appeared to double normally and were 
subsequently infected with the VSV mutant at a rate of 0.1 PFU/cell to 
amplify virus stocks. The stock of virus was subsequently titrated using a 
standard plaque assay procedure as described in materials and methods. 
The 24 well plate assays system was set up as described for the calici virus 
assay. The only differences being that, after incubation with interferon 
dilutions of DAI, the cells were challenged with VSVtsE2 at a rate of 4 
PFU/cell and incubation was carried out at 31°C/5%C02 in a category II 
laboratory.
Subsequently, the assay procedure was repeated using a 96 well format for 
the sample DAI and DA2. The assay procedure for the 96 well format was 
essentially identical to the 24 well system. The only difference being that 
the cells were added to the wells at a concentration of 2 x 10^ cells/well in 
lOOul of medium. VSV virus was added at a concentration of 4pfu/cell 
and the assay was carried out in triplicate. Staining was carried out by the 
addition of lOOul of Amido Blue Black (0.05% solution in 9% acetic acid 
with 0.1M sodium acetate) to each well and leaving them for 1 hour. The 
cells were fixed for 1 hour by the removal of the well contents and the 
addition of lOOul of formalin acetate (10% formaldehyde solution in 9% 
acetic acid with 0.1M sodium acetate. After 1 hour, dye elution was 
carried out by the removal of the well contents and the addition of lOOul of 
0.38% sodium hydroxide to each well. After a further hour of mixing, the 
optical density at 595nm was measured spectrophotimetrically. The O.D. 
measurements are shown in table 4.5 and are represented graphically in 
figure 4.13. The staining, fixing and elution protocols were taken from 
Balkwill, 1991.
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Dilution day2 day3 day4 day5
1:4 +++ +++ +++ unreadable
1:16 ++- ++- +++ unreadable
1:64 ------ ------ ++- unreadable
1:256 ------ ------ ------ unreadable
1:1024 ------ ------ ------ unreadable
Table 4.3 Results of the time course study of recombinant protein 
production. (+) indicates protection against challenge with calicivirus 
where (+++) = 100% protection.
No. Dilution Day 5 Sample (O.D.)
1 1:2 3.0
2 1:4 2.179
3 1:8 3.0
4 1:16 3.0
5 1:32 0.968
6 1:64 0.745
7 1:128 0.659
8 1:256 0.568
9 1:512 0.893
10 1:1024 0.755
Table 4.4. O.D.(595) readings from the day 5 calicivirus assay in the time 
course study.
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4.2.4 RESULTS OF THE TIME COURSE STUDY
The results of the time course study are shown in Table 4.3. Protein 
production was evident from day 2 but maximum effect was seen on day 
five. From these results it is evident that the protein production begins 
early in infection, i.e. from 24-48 hours, and the protein is accumulating in 
a stable fashion through to day 5. The results from the day 5 wells were 
not included in Table 4.3 because, before addition of virus to these cells, 
the cells were rounded and had floated from the monolayer. As a 
consequence, this day 5 assay was repeated and the results plotted as O.D 
measurements. The O.D. measurements for the day 5 dilutions are shown 
graphically in Figure 4.12. The variability in O.D. measurements at high 
concentrations of interferon may be due to the toxic effects of interferon 
causing cytostasis. There is a sharp cut off point between protection and 
non-protection in the dilutions shown, with few points on the rectilinear 
portion of the graph. From the graph, the dilution which gave 50% 
protection was 1:32.
4.2.5 RESULTS OF THE VSV CPER ASSAY
The mean optical density measurements of the 96 well VSV assays 
performed for DAI and DA2 are given in table 4.5 and are shown 
graphically in figure 4.13. The maximum O.D measurement shown was 
obtained from the cell controls and the minimum value was obtained from 
the virus controls. For both samples, DAI and DA2, there is a gradual cut 
off between protection and non-protection with more points on the 
rectilinear portion of the graph than in the calici virus assay. For the 
sample DAI the dilution which gave 50% protection was found to be 
1:8583 and, for DA2, the value was 1:1968. Thus, for sample DAI and
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No IFN Dilution DAI (O.D) DA2 (O.D)
1 1:10 2.732 2.256
2 1:100 2.559 2.279
3 1:1000 2.405 2.059
4 1:10000 1.817 2.006
5 1:100000 1.563 1.250
CELL CONTROL: O.D 2.888 
VIRUS CONTROL: O.D 0.994
Table 4.5 O.D (595) measurements for samples DAI and DA2 in the 96 
well VSV assay.
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Fig. 4.13 Graph showing the results of the VSV based CPER assay for 
sample DAI
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Figure 4.14: VSV/Interferon assay using 24 well format. Row A and B, 
Column 1 are cell controls. Row C and D, column 1 are virus controls. 
The remainder of row A is the assay using Interferon sample DAI showing 
doubling dilutions from columns 2 to 6 (1:4 to 1:64). Row B is a duplicate 
of Row A. Rows C and D are as for A and B but using the sample DA2. 
It is clearly demonstrated that the interferon samples are protecting the 
cells from VSV challenge at these dilutions.
171
using this assay protocol, the concentration of interferon, in terms of 
laboratory reference units, was 8583/ml. Therefore, the Sf9/baculo virus 
system produced 8.583 x 10^ LRU of feline recombinant interferon per 
litre. The High Five/ baculovirus system appears to have produced a lower 
value of 1.968 x 10^ LRU/litre.
4.2.6 MHC CLASS II ANTIGEN INDUCTION ASSAY
As discussed in Chapter 1, one of the most important biological functions 
of interferon-gamma is the up-regulation of MHC class II antigens. This 
assay was used to demonstrate that the baculovirus derived recombinant 
feline interferon gamma, was able to up-regulate MHC class II antigens on 
the feline continuous T cell line, designated F422. The assay has been 
described in Current Protocols in Immunology (1994), and King and Jones 
(1983). The F422 cell line is discussed in Materials and Methods.
Initially F422 cells were grown in tissue culture and subsequently 
centrifuged, washed and resuspended in complete medium to a 
concentration of 3x10^ cells/ml. Two fold serial dilutions of the interferon 
preparation DAI were made in 12 well tissue culture plates. Wells were 
also assigned to virus and cell controls. 1ml of the cell suspension was 
added to each well and the cells were allowed to incubate at 37°C/5%C02 
for around 48 hours.
Following incubation, the cells in each well were divided in two to give a 
test (+) and negative control (-) for the subsequent flow cytometry 
analysis. The test cells were labelled with MHC class II anti-cat 
monoclonal antibodies (IgGj) and the negative control cells were labelled 
with CD8 anti-cat monoclonal antibodies (IgGi). The MHC class II
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antigen is inducible on F422 cell lines (Willett-unpublished results) 
whereas the cells are CD8 negative.
Following incubation, the cells were transferred to labelled 5ml falcon 
tubes. To each tube was added 2ml of PBS/0.1%BSA/0.01% Sodium 
azide to wash the cells. The tubes were then centrifuged at 1500 rpm for 5 
minutes at 4°C. and the supernatant discarded. 50ul of MHC class II 
monoclonal antibody was then added to the (+) cells and 50ul of CD8 
monoclonal antibody was added to the (-) cells. Both the anti-cat MHC 
class II monoclonal antibody and the anti-cat CD8 monoclonal antibody 
were derived as supernatants from hybridoma cells and the amount used in 
this experiment was that advised by Willett, personal communication. The 
cells were incubated on ice for 15 minutes. Following incubation, The 
cells were washed again using 2ml PBS/BSA/azide, centrifuged and the 
supernatant discarded. 50ul of sheep anti-mouse IgG FITC conjugate 
(Sigma) was then added to each tube and the tubes allowed to incubate on 
ice for 15 minutes. The cells were then washed with 2ml of 
PBS/BSA/azide, centrifuged and the supernatant discarded. Subsequently, 
cell analysis was carried out using flow cytometry (EPICS cell sorter 
(Coulter Electronics, Luton), or the cells were fixed using 1% 
paraformaldehyde and analysed at a later stage. Isotype matched controls 
were used to set an analysis gate such that <1% were positive. Five 
thousand events were collected in LIST mode and percentage positive 
were calculated relative to isotype matched negative controls.
4.2.7 RESULTS OF MHC CLASS II INDUCTION ASSAY
The MHC Class II induction assay was performed on the baculovirus 
interferon preparation designated DAI. This is the same preparation that
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had been used in the VSV assay described above and had titrated to give a 
value of 8583 laboratory units per ml in this assay. The results of the flow 
cytometry analysis is given in Figures 4.15 to 4.19. The gate labelled H in 
the figures represents background fluorescence, while the gate labelled L 
represents the percentage of cells which are demonstrating MHC class II 
up-regulation. The anti-cat MHC class II monoclonal antibody was used 
to demonstrate any changes in MHC class II expression on the cell line. 
The anti-cat CD8 monoclonal antibody was used to measure non-specific 
binding of mouse monoclonal antibody. The cell controls had been 
incubated in the absence of interferon-gamma. The virus controls were 
cells which had been incubated with Sf9 cell supernatants containing wild- 
type PAK6 baculovirus at a 1:32 dilution. Both of these controls were 
labelled with anti-cat MHC class II and anti-cat CD8 monoclonal 
antibodies in the same manner as the cells incubated with the interferon 
preparations. The results of the flow cytometry analysis are shown in 
Table 4.6. The assay procedure was carried out in duplicate and the 
figures shown in Table 4.6 are mean values.
All of the cells which were labelled with the anti-cat CD8 monoclonal 
antibody showed negligible fluorescence. Cell controls and wild-type 
virus controls showed base line fluorescence when labelled with the anti­
cat MHC Class II monoclonal antibody indicating that there is some 
expression of MHC Class II antigen on these cells in the absence of 
interferon-gamma. However, incubation of the cells with interferon 
dilutions clearly enhances the expression of this antigen on these cells. 
This is shown by the marked shift in fluorescence as shown in Figure 4.17. 
Interestingly, at high concentrations of interferon ( 1:4 to 1:32), while 
MHC Class II was still up-regulated, the degree of up-regulation was less 
than for those cell incubated with lower dilutions. This may be because at
174
higher concentrations there is a higher concentration of T C I00 medium 
which may be altering the pH or nutrient concentrations and thus the cells 
will not be growing under optimum conditions. The MHC class II 
induction assay seem to be very sensitive and up-regulation is still seen at 
dilutions of interferon DAI of 1:4096.
In addition to measuring the degree of expression of MHC Class II 
antigens, the flow cytometry also allowed the analysis of cell populations. 
Figure 4.19 shows the forward and side scatter analysis of the cell 
populations in each sample which is a distribution analysis based upon cell 
size (forward scatter) and cell granularity (side scatter). With increasing 
dilution of the interferon sample the population of cells in gate L appears 
to alter. At higher concentrations of interferon (1:4, 1:8), the majority of 
the cells show low forward scatter and increased side scatter which may 
indicate that there may be a high proportion of non viable cells or cells 
undergoing apoptosis (cell granularity but small size) in these samples. As 
the interferon is increasingly diluted, the population of cells appears to 
shift to form a majority of cells showing increased forward scatter and 
decreased side scatter. This suggests that this is a more viable, activated 
population of T cells and correlates with the increased MHC Class II 
expression at lower interferon dilutions. In one study by Novelli et al 
(1994), the level of interferon-gamma receptor expression on the surface of 
a T cell population, was shown to influence whether interferon-gamma 
caused proliferation or apoptosis. High level expression of the receptor 
appears to be a marker for apoptosis. One can hypothesise that, in this 
experiment, a high concentration of interferon-gamma has increased 
receptor expression on the T cells and is promoting apoptosis. At higher 
dilutions, the level of receptor expression may be lower, and here the 
interferon-y is promoting proliferation and activation. This system may be
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Dilution %fluorescence %fluorescence
MHC II CD8
1:4 31.1 negligible
1:8 38.9 negligible
1:16 44.9 negligible
1:32 63.55 negligible
1:64 69.9 negligible
1:128 68.85 negligible
1:256 69.3 negligible
1:512 66.95 negligible
1:1024 67.6 negligible
1:2048 70.55 negligible
1:4096 71.6 negligible
cell control 1.1 0.7
virus control 1.75 0.5
Table 4.6 Results of FACS analysis for the MHC Class II induction assay 
performed on the sample DAI.
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Fig. 4.15 FACS analysis of cell control: Cells incubated without interferon 
and subsequently labelled with anti-cat MHC Class II antibody. All of the 
cells are in gate H.
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Fig. 4.16 FACS analysis of cells, incubated with interferon, but labelled with 
anti-cat CD8 antibody. The cells are FITC negative.
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Fig. 4.17 FACS analysis of cells, incubated with 1:32 dilution of interferon, 
and subsequently labelled with anti-cat MHC Q ass II antibody. A clear 
shift of cells from gate H to gate L is demonstrated as compared to cells 
which have not been exposed to interferon.
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Fig. 4.18 FACS analysis of cells, incubated with interferon at 1:4096 
dilution, and subsequently labelled with anti-cat MHC Qass II antibody.
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Figure 4.19 FACS analysis of ceil poulations in the MHC Q ass II 
induction assay. The change in ceil population in gate L, with increasing 
dilution of interferon is clearly demonstrated.
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further complicated by environmental factors such as the higher 
concentration of T C I00 medium in the wells which contained higher 
concentrations of interferon.
4.3 DISCUSSION
This chapter has described how cDNA encoding feline interferon-y was 
cloned into the Baculovirus genome and stably expressed to produce a 
biologically active protein. Several expression systems have been used to 
express interferon-y from other species. In man, interferon-y was 
originally cloned in an expression system involving xenopus oocytes 
(Devos 1982) and, in the murine system, interferon-y was originally cloned 
by the expression of the protein in COS cells and was subsequently 
expressed in E.coli (at a level of 5x10^ U/ml).
Since the original cloning experiments for human interferon-y were 
performed, the protein has been expressed in a number of systems which 
include Yeast (Demyk et al 1983), E.coli based systems (Simons et al 
1984) giving levels of 0.5-2.5x10^ U/ml and 5x10^ U/ml, respectively, 
and CHO cells (Scahill et al 1983) and (Mory et al, 1986) which gave 
levels of expression in the order of 1-2 x 10& units/mg of protein.
The original interest in baculoviruses was based upon their potential as 
pesticides. However, studies involving gene replication by the virus and, 
in addition, the demonstration that removal or replacement of the very late 
polyhedrin gene did not affect replication, lead to an interest in 
baculoviruses as expression systems for cloned genes. The polyhedrin 
protein is produced at high levels and thus it was assumed that replacing 
the polyhedrin gene with another cloned gene would result in high levels
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of transcription of the new gene and high levels of protein expression. 
These initial theories have been realised in recent expression experiments.
The first reports of the use of baculovirus as expression systems were 
published by Smith et al (1983) and Pennock et al (1984) who used 
AcMNPV to produce p-interferon and P-galactosidase, respectively, in 
SF9 cells. Maeda et al (1985) also expressed p-interferon using BmNPV 
system in the silkworm. In the succeeding years a wide variety of 
recombinant proteins have been expressed using this system (reviewed by 
King and Possee, 1992), including feline interferon-a (Sakurai et al, 1992) 
and human interleukin-2 (Smith et al 1985). Smiths original experiments, 
in which he expressed human interferon-P, were very encouraging. 
Interferon-P had already been expressed in an E.coli-based system and in 
mammalian cells. The highest levels of p-interferon production in these 
systems were 1x10^ U/ml and 5x10^ U/ml, respectively (cited in Smith et 
al, 1985). However, in Smith's baculovirus system the interferon was 
secreted at levels of 5x10^ U/ml. In addition the protein was glycosylated 
and the data indicated that the signal peptide at the amino terminal end of 
the primary translation product was removed. In addition, the interferon 
had no anti-viral effect on the Baculovirus.
The high levels of expression of foreign genes reported for baculovirus 
systems, the fact that foreign genes undergo post translational 
modification, and the ability to scale up protein production encouraged the 
use of this system for expression of feline recombinant interferon-gamma. 
The ultimate aim for the project was to take the recombinant protein 
towards clinical application. While glycosylation is unimportant for the 
biological activity of the interferon protein, it may be important in terms of 
extending the biological half-life of the protein. This is obviously an
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important factor when considering therapeutic potential. Thus, 
baculovirus expression could potentially yield a product with high specific 
activity, potentially greater in-vivo half-life than yeast or E.coli derived 
proteins, and be easily scaled up to producing large amounts of protein for 
clinical use.
In this experiment, the cDNA encoding feline interferon-y was 
successfully cloned into the transfer vector pAcC129-l and subsequently 
transferred into the baculovirus genome by the process of homologous 
recombination. The major problems in baculovirus expression systems 
have been concerning the yield of recombinant viruses and the screening 
process for recombinant viruses. The use of linearized PAK 6 wild-type 
virus and neutral red/x-gal in the screening process greatly facilitated the 
isolation of recombinant virus.
The subsequent establishment of master and working stocks of 
recombinant virus is a time consuming process and initially it was 
necessary to screen for expression and demonstrate that the protein product 
was biologically active before establishing these stocks. To do this, a 
fairly crude antiviral assay based around the protection of FEA cells 
against calicivirus infection was used. There was no evidence that even a 
biologically active interferon preparation would work in this system but, at 
this stage there was no licence to use VSV. These crude initial screening 
assays were encouraging, and, although the interferon preparation was not 
quantified, the baculovirus system appeared to be producing a biologically 
active protein. Subsequently, protein production was optimised in spinner 
cultures by infecting the cells while they were in logarithmic growth and 
using a high multiplicity of infection of the recombinant virus (lOpfu/cell). 
The results from the time course study indicated, in the calicivirus system,
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that protein could be detected 18 to 24 hours post infection (h.p.i) but 
stably accumulated to maximum protein production by day 5. Following 
five days incubation, the addition of the infected Sf9 supernatant to FEA 
cells seemed to cause the cells to lose adherence and shrink. It was 
concluded that this may be a toxic effect of high concentrations of 
interferon-gamma leading to cytostasis. Despite the fact that the 
calicivirus assay system seemed to be working, it required concentrated 
interferon preparations to cause protection, and it appeared that the assay 
was quite variable and difficult to reproduce. Initially, It was thought that 
this may have been due to poor protein yield or an inappropriate 
concentration of calicivirus in the assay. Attempts to further optimise the 
assay conditions (viz, altering the dose of challenge virus) were 
unrewarding and it was decided to carry out the same assay procedure but 
to use vesicular stomatitis virus as the challenge virus.
The vesicular stomatitis virus assay was performed on the sample DAI and 
DA2, as described above, and gave more meaningful, reproducible results. 
In addition, the assay was performed in a 96 well plate format which could 
potentially facilitate assaying large numbers of interferon samples. The 
interferon preparation was quantified as the reciprocal of the dilution of 
interferon which gives 50% protection. This value was expressed in terms 
of laboratory reference units (LRU). Interferon-gamma is highly species 
specific and thus it is impossible to standardise these units in terms of 
international units (as described by WFIO). At the beginning of this 
discussion the expression of interferon-gamma from other species is 
described. It is difficult to compare yields according to units o f interferon 
between these systems for the reasons outlined. This is exemplified by the 
results gained by Mory et al (1986) compared to those gained by Zucker et 
al (1993). Mory expressed the human interferon-gamma molecule in CHO
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cells and the resulting cell clones gave interferon levels which had a 
specific activity of 1-2 x 10^ units/mg of protein using a VSV bases CPER 
assay. Zucker expressed the canine interferon-gamma molecule in E.coli 
and measured specific activity using the VSV-based CPER assay and using 
MDCK cells as the host cells. Zucker's results revealed a specific activity 
of canine recombinant interferon gamma of 640,000 laboratory reference 
units/mg of protein. No real comparisons can be drawn from these two, 
very different apparent specific activities because the assays were 
performed under different conditions and using different host cells. It is 
thus important to standardise a particular IFN-y assay so that subsequent 
titrations can be referenced according to laboratory units. In this 
experiment, it is difficult to define the titration in terms of specific activity 
until an absolute value for interferon-y production is gained in terms of mg 
of interferon/litre of baculovirus supernatant. However, it can be 
concluded from this experiment that the FEA/calicivirus assay system is a 
poor system for measuring biological activity of feline recombinant 
interferon-gamma and the FEA/VSV assay is a more reproducible assay.
The results of the VSV assay for sample DA2 demonstrated an apparent 
lower titre of interferon-y production from the High Five cells. The High 
Five cells were cultured as described for the Sf9 cells but were more 
difficult to culture and appeared to have slower population doubling times. 
This may account for a sub-optimal protein production compared to that 
claimed by the supplier.
The expression of feline recombinant interferon-a(tau) in the 
baculovirus/silkworm system has recently been reported by Ueda, Sakurai, 
and Yanai (1992). Interestingly, this group demonstrated that their 
interferon preparation protected feline cells (Crandell feline kidney-CRFK)
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against challenge with 10^-5 TCID50/ml/Feline herpesvirus (FHV) or 
105-5 TCID50/ml/Feline calicivirus (FCV). About 30 or 80 units/ml of 
rFeIFN-a decreased 50% of the number of plaques by FHV or the 
cytopathic effect (CPE) by FCV, respectively. Interferon-a is a far more 
potent antiviral cytokine than interferon-gamma (Farrar and Shreiber 
1993). This may explain the poor reproducibility of the antiviral assay 
based upon FCV in our system compared to the assays carried out using 
feline recombinant interferon-alpha.
The MHC Class II induction assay appeared to be as sensitive as the anti­
viral assays, especially at low concentrations, for the detection of 
biologically active recombinant protein. This is in accordance with 
reported assay performances being up to 10 times more sensitive than the 
antiviral assays (Current Protocols in Immunology, 1991). This is an easy 
assay to perform and may be more practical on a day to day basis 
considering the need for containment facilities for the use of VSV. The 
confirmation that the recombinant protein up-regulates MHC Class II is 
encouraging, considering that it is envisaged that the protein may be useful 
as a vaccine adjuvant.
Although it is difficult to quantify the baculovirus derived interferon, other 
than in terms of laboratory units, it can be concluded that recombinant 
interferon-gamma can be stably expressed in the baculovirus system and 
that the protein product appears to be biologically active. It is difficult to 
assess accurately the level of expression from the baculovirus system. 
During the plaque purification stages, recombinant plaques were chosen 
which appeared to give the highest level of expression in the crude anti­
viral assays. These apparent differences in levels of expression of different 
phenotypes may not actually represent variations in the phenotype but may
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be reflecting variations in experimental conditions. However, It has been 
advised that several alternative recombinant isolates are screened in case 
there are differences in the expression phenotype, although this is a rare 
occurrence (Bishop 1992). Usually the expression level of a foreign gene 
does not vary from experiment to experiment, provided the infection 
conditions are optimal (cell viability of >98%, cells in exponential growth, 
use of high titred virus stocks to establish one-step growth). Thus, for this 
experiment, infection conditions were set at: infection of cells in 
logarithmic growth at a rate of 10 pfu/cell o f recombinant virus and 
subsequent harvest of the supernatant at 5 days post infection.
Many genes have now been expressed using the baculovirus system 
employing both the plO and polyhedrin promotor system. Using either 
promotor system has resulted in high levels of expression in both tissue 
culture and larvae. The levels obtained often approach or exceed those of 
the polyhedrin or plO proteins. By analysis of stained preparations of cell 
extracts, expression levels of 50% or more of the total cell protein have 
been frequently obtained (Bishop 1992). The reasons for low level 
expression of foreign genes may be many and varied and have been 
reviewed by King and Possee (1992) and by Bishop (1992). The gene 
product may directly or indirectly alter the rate o f gene transcription by its 
effects on other functions of the host cell (although this is unlikely for 
species specific interferon-y). In addition, there may be differences in 
mRNA translation efficiency for different genes. The latter may be due to 
codon usage, or due to the primary or secondary structure of the mRNA 
species in the vicinity of the translation initiation codon, or the secondary 
structures within the body of the mRNA that affect the speed of 
translation. No studies have been carried out to address these issues. 
Other, more obvious reasons for apparent low levels o f protein production
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include, infecting cells which are not in logarithmic growth or are o f poor 
viability, using a low multiplicity of infectious virus or by mis-timing the 
harvest of baculovirus supernatants.
As described in Chapter 3, the first 23 amino acids represent a leader 
sequence which is cleaved from the mature protein. No protein sequence 
analysis is available for the feline recombinant protein, but the 
demonstration of biological function indicated that the protein had 
undergone post-translational processing, i.e. there was secretion of a 
functional protein which indicated that the signal sequence may be cleaved 
and homodimers formed.
The following chapter will discuss the immunological detection of the 
protein and subsequent partial purification.
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5.0 INTRODUCTION
While conducting the cloning and expression experiments, the only way of 
demonstrating the presence of recombinant interferon in the baculovirus 
supernatants was to conduct biological assays as described in Chapter 4. 
An alternative to measuring biological function is to detect the presence of 
recombinant protein by the use of labelled antibodies. The only 
commercially available antibodies were monoclonal antibodies for human 
and murine interferon-y, and there was no evidence that they would be 
cross-reactive in the feline system. However, once the amino acid 
sequence could be predicted from the cDNA sequence, an analysis was 
performed to predict immunogenic peptides for synthesis and eventual use 
as immunogens. The immunogens were used to raise polyclonal antisera 
for eventual use in protein detection systems.
The production of antibodies that could recognise the feline recombinant 
protein, in addition to the biological assay, then aided in the purification of 
recombinant protein from the baculovirus supernatants. This chapter 
describes the processes of peptide design, synthesis and immunisation and 
finally discusses how immunological techniques and biological assays 
were used in the purification process.
5.1 AMINO ACID SEQUENCE ANALYSIS
Choosing an appropriate peptide is critical in obtaining an antibody that 
will cross react with the recombinant protein. Initially, the amino acid 
sequence was predicted from the cDNA sequence using G.C.G sequence 
analysis software programmes. These software programmes also allow 
analysis of the predicted protein structure to determine critical regions
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which are important in peptide design. The critical parameters in peptide 
design have been reviewed in Harlow and Lane (1988), Current Protocols 
in Molecular Biology (1994) and Current Protocols in Immunology
(1994), and include regions of hydrophilicity, predicted antigenicity, 
secondary structure and the presence of glycosylation sites. The use o f the 
Peptide Structure and Peptide Plot commands allow predictions of 
secondary structure (according to the Chou-Fasman method), 
hydrophobicity (according to the Kyte-Doolittle or Hopp-Woods method) 
and surface probability (according to the Emini method). Antigenicity, 
(expressed as an antigenic index according to the Jameson-Wolf method), 
is a cumulative index based upon all the variable antigenic parameters. 
Plot Structure plots these measurements in the output file from Peptide 
Structure. The measurements are then shown as parallel panels on a graph 
(Figure 5.1). The methods used for predicting these parameters were cited 
in the GCG sequence analysis software package programme manual 
(1991).
The results of the peptide structure analysis are shown in Figure 5.1. From 
these predictions peptides were selected which could be potentially 
immunogenic. Peptides were selected according to areas of high surface 
probability, hydrophophilicity and antigenic index. The premise is that an 
antibody raised against a peptide from a surface area or flexible area of the 
protein is more likely to represent a B cell epitope on the native protein. 
Areas of increased hydrophilicity indicate surface exposure and thus are 
more likely to be immunogenic. Potential glycosylation sites were avoided 
as glycosylated sites on the native protein may cause stearic hindrance of 
the antibody. An added parameter in peptide selection was the degree of 
homology between chosen peptide sequences for the recombinant feline 
interferon-y and the peptide sequence of the rabbit interferon-y protein.
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Peptides are more likely to be immunogenic if they differ from the native 
protein of the experimental animal which is raising the antisera. Taking 
these factors into consideration, two peptides were selected. The first was 
an internal peptide based on the protein region between amino acids 80 
and 100, and the second was a peptide designed according to a region in 
the protein close to the carboxy terminus (amino acids 145 to 165). 
Several workers have noted that the carboxy-terminal sequences are often 
exposed and can be targeted for anti-peptide sequences. Both the amino 
termini and the carboxy termini are recognised as good immunogenic sites 
(reviewed in ab book). While analysis of the inferred amino acid sequence 
allows the prediction of the most suitable peptides for antibody production, 
it must be borne in mind that these are only predictions and the design of 
suitable peptides is still largely empirical. Figure 5.2 shows the sequence 
of the peptides chosen. The peptides were 20 amino acids in length. The 
size of peptide used can vary between about 6 and 20 amino acids. While 
short peptides are likely to be more soluble, they are usually less 
immunogenic than larger peptides.
Peptide 34 differs from the rabbit sequence by 8 amino acids and peptide 
33 differs from the rabbit sequence by 3 amino acids. A line up of the two 
peptide sequences is given in figure 5.3.
5.2 PEPTIDE SYNTHESIS
Peptide synthesis was carried out using the 432A Protein Synthesiser 
(Applied Biosystems). In the conventional approach for preparing anti 
peptide antibodies, small peptides are conjugated to larger proteins to 
render them immunogenic. This method has several disadvantages which 
have
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PRSNLRKRKRSQNLFRGRRA 3 3
ENLKDDDQRIQRSMDTIKED 34
Figure 5.2. Amino-acid sequence of peptide 33 and 34. Both peptides are 
20 amino acids in length.
PRSNLRKRKRSQNLFRGRRA Fe 
-K  K----- T------- Ra
ENLKDDDQRIQRSMDTIKED Fe 
D H IKK- -ES Ra
Figure 5.3. Amino acid line-up of peptide 33 and 34 with the rabbit 
equivalents. Peptide 33 shares 85% homology and peptide 34 shares 60% 
homology with the rabbit equivalents.
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been reviewed in Current Protocols In Immunology, 1995. Firstly, the 
peptide represents only a fraction of the total molecular weight of the 
immunogen and thus antibodies to the peptide will only represent a 
fraction of the total antibody response. Secondly, the amount of peptide 
conjugated to the carrier is unknown and may be randomly distributed 
along the length of the carrier. Finally, the process of conjugation may 
alter immunological determinants on the peptide.
In this experiment, the multiple antigen peptide system (MAP) was used in 
the peptide synthesis in order to overcome the above difficulties and to try 
and optimise antibody production. This system was originally described 
by Tam (1988) and is reviewed in Current Protocols in Immunology
(1995). The MAP system replaces the carrier protein by the arrangement 
of several copies of the peptide around an inner amino acid core. The core 
is quite small and the bulk of the complex is formed by up to 16 peptide 
antigens layered around the inner core matrix which is composed of lysine. 
The MAP core is oligimeric and contains non-cationic peptidyl and 
isopeptidyl lysine amide on both the Na  and N8 termini of the lysine. As a 
result the core is not immunogenic. It is the dendritic peptide antigen 
chains on the MAP core that are likely to be mobile and contribute to the 
enhanced immunogenicity of the MAP system.
Following synthesis and purification, the peptides were lyophilised and 
stored at 4°C.
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5.3 PREPARATION OF PEPTIDES FOR IMMUNISATION
To obtain a good immune response the peptide antibodies were introduced 
into the animals along with an adjuvant. Adjuvants are non-specific 
stimulators of the immune response and, in general, incorporate two 
components. The first component is a substance which allows the 
formation of a deposit and protects the antigen from rapid degradation. 
The second component is a non-specific stimulant of the immune response. 
These stimulators raise the local level of cytokines which stimulate antigen 
presenting cells and cause a local inflammatory response. In this 
experiment, a Non Ulcerative Freunds Adjuvant (NUFA) was used, which 
contains mineral oil for the formation of the antigenic deposit, and Bacillus 
Calmette Guerin (BCG) vaccine was used as a local immuno-stimulator. 
The NUFA was supplied in the incomplete form and was made complete 
for priming immunisations by the addition of Mycobacterium tuberculosis 
in the form of BCG vaccine. The BCG was added to the aqueous phase of 
the immunogen prior to emulsification with NUFA. The BCG preparation 
used was that of Evans Medical, formulated for intradermal rather than 
subcutaneous use (BCG vaccine BP). The subcutaneous formulation 
causes skin ulceration. The vial of BCG vaccine was reconstituted 
according to the manufacturer's instructions and 0.1ml was added to each 
0.9ml of aqueous immunogen. The aqueous phase was then mixed with 2 
volumes of adjuvant to produce a stable water-in-oil emulsion (see below). 
The BCG was only used for the primary vaccination and, for subsequent 
booster vaccinations, the aqueous immunogen was mixed with 2 volumes 
of adjuvant alone to form a stable emulsion.
Initially, the aqueous phase of the peptide was made up to the appropriate 
concentration using ultra pure, autoclaved water. The total volume
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injected in to each rabbit was 1ml at each immunisation (0.5ml into each of 
the quadriceps muscle). The volume of immunogen prepared for each 
rabbit was slightly larger than this to account for losses during the mixing 
or immunisation process. The peptide/NUFA was made up in a ratio of 
2:1 as described above. The mixing process was carried out using two 
syringes attached via twin luer-hubbed, syringe connector with a fine 
connecting channel, the connector allowing the contents to pass between 
the syringes to facilitate thorough emulsification. To check that the 
adjuvant and peptide were sufficiently mixed, a small amount was allowed 
to drip on to the surface of some water, if the drop dispersed then mixing 
was incomplete. However, if a discrete droplet was formed on the surface 
of the water then the mixture was ready for injection.
5.4 IMMUNISATION PROTOCOL
The animals chosen to raise the anti-sera were New Zealand rabbits. Two 
rabbits were used for each peptide and the intramuscular route was chosen 
for the immunisation. The dose of immunogen required to elicit the 
optimum immune response is empirically determined. Much of the 
immunogen injected may be degraded before it reaches the target cells and 
so the amount of immunogen injected does not necessarily reflect that 
which is going to be active. General guide lines on the dose used were 
taken from Harlow and Lane (1988) and Current Protocols in Immunology 
(1994). For the initial priming dose, lOOug of immunogen per rabbit was 
used. Subsequently, this was reduced to lOug per rabbit for booster 
injections. While reducing the subsequent doses to lOug may have the 
effect of reducing the yield of antibody, their tends to be an increase in 
antibody affinity.
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Following primary immunisation, the rabbits were boosted at 3 weeks and 
subsequently every six weeks. 14 days following the third boost, the 
animals were bled to check for the presence of antibody by ELISA (see 
below).
5.5 COLLECTION AND PREPARATION OF SERUM
Blood was collected between 10 and 14 days after boosting with 
immunogen. The blood was collected from the marginal ear vein in to 
sterile glass bijou bottles. 10-15ml. of blood was collected, allowed to clot 
and the serum removed and aliquoted in to 1ml tubes and stored at 
-20°C.
5.6 ELISA TO DETERMINE ANTIBODY RESPONSE
To establish that the rabbits had developed an antibody response to the 
injected peptides, and to measure the level of antibody response, an 
indirect antibody Enzyme Linked Immunosorbent Assay (ELISA) was 
performed. For the ELISA experiment, an ELISA starter kit (Pierce) was 
used which provided all the reagents for the assay apart from antigen and 
primary antibody. The procedure was carried out using the protocol, 
provided by the manufacturer, for a two dimensional serial dilution assay. 
The primary antibody was serially diluted across the plate and the 
secondary antibody was diluted down the plate. Initially, each antigen 
(peptide 33 and 34) was prepared as a solution at lOug/ml using coating 
buffer (BupH™ Carbonate in distilled water). Plates were assigned for 
either peptide 33 or peptide 34. One hundred ul of antigen solution was 
added to each well of the microtitre plate and allowed to incubate for 1 
hour at room temperature. The plates were emptied and washed 3 times
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with lOOul of wash buffer (prepared by adding 2.5ml of Surfact-Amps™ 
Tween 20, 5ml of Blocker™ BSA in PBS and 1 pack of BupH™ 
Dulbecco's PBS in 500ml of distilled water). The plates were incubated 
for 30 minutes with lOOul of blocking buffer (to block irrelevant antigenic 
sites), after which the plates were emptied. lOOul of wash buffer was 
added to each well and 1 OOul of the appropriate serum sample was added 
to all the wells in row A (see Figure 5.4). The primary antibody was 
serially diluted 2 fold from rows A through G (H was used as a control) 
and the plate was incubated for 1 hour followed by 3 washes with 1 OOul of 
wash buffer. The alkaline phosphatase labelled secondary antibody was 
diluted 1:3000 with blocking buffer. One hundred ul of wash buffer was 
added to each well and lOOul of the secondary antibody added to each well 
in column 1 (see Figure 5.4). This antibody was then serially 2 fold 
diluted across from column 1 through column 11 (12 was used as a 
control). The plates were incubated for 30 minutes and subsequently 
washed 3 times with lOOul of wash buffer. One hundred ul of wash buffer 
was then added to each well and allowed to incubate for a further 5 
minutes. The wells were emptied and lOOul of the phophatase enzyme 
substrate added to each well ( substrate was made by the addition of 1 5mg 
PNPP tablet to 10ml of DEA substrate buffer). The plates were incubated 
for 30 minutes and the optical density measured at 405nm using an 
automated ELISA reader.
The results of the ELISA for both peptide 33 and 34 are given in Tables
5.1 and 5.2. A minimal response was seen with peptide 33 (using serum 
designated T710) but a strong response was seen with peptide 34, using 
serum designated T711. A two fold serial dilution assay was performed in 
order to establish optimum concentrations for the primary and secondary 
antibodies when used in combination. The optimal combination of the
199
1:1 1:2 1:4 1:8 1:16 1:32 1:64
•1 . -41 . 1 •
1 :2 •
1 A •
1:8 •
:16 •
:32 ©
:5^ ©
T o
•  •  •
 •  •  •
9 0 0 0 0
0  © © O G 
© G O O O O G O O O O  
O O O O O O O O O
A
£
c
D
G
1 2 3 -  5 6 7 S 9 1 0 1 1
Figure 5.4.Schematic representation of ELISA protocol.
1 2 4 5 6 7 8 9 10 11
A .374 .150 .111 .119 .096 .088 .085 .082 .077 .075 .040
B .512 .237 .147 .120 .101 .101 .088 .084 .082 .087 .038
C .773 .323 .196 .136 .108 .100 .090 .083 .082 .080 .046
D .786 .305 .194 .136 .116 .106 .102 .082 .081 .078 .040
E .615 .267 .185 .125 .103 .094 .091 .078 .078 .082 .039
F .568 .276 .182 .157 .115 .117 .091 .083 .086 .077 .040
G .469 .245 .177 .130 .100 .094 .090 .084 .084 .078 .042
H .085 .097 .096 .096 .085 .087 .089 .092 .084 .080 .035
Table 5.1 ELISA O.D.(405) readings for peptide 34 and serum sample 
T711. Column 11 is the control for the primary antibody and row H is the 
control for the secondary antibody.
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1 2 3 4 5 6 7 8 9 10 11 12
A .094 .089 .085 .086 .118 .082 .079 .076 .074 .076 .042 .045
B .099 .089 .088 .093 .086 .089 .091 .083 .082 .082 .041 .041
C .094 .143 .107 .149 .095 .088 .086 .081 .080 .082 .045 .038
D .090 .092 .093 .096 .087 .086 .084 .092 .094 .078 .040 .040
E .081 .086 .093 .107 .099 .119 .103 .074 .073 .074 .044 .038
F .084 .087 .124 .111 .095 .088 .084 .081 .081 .096 .041 .040
G .083 .086 .087 .088 .081 .084 .083 .080 .079 .077 .039 .038
H .088 0.93 .088 .085 .076 .085 .088 .082 .081 .078 .041 .037
Table 5.2 ELISA O.D (405) measurements for peptide 33 and serum sample 
T710. Column 12 is the control for the primary antibody and row H is the 
control for the secondary antibody.
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primary and secondary antibodies was defined as the one which gives half 
the maximum reading on the microtitre plate reader. For the antigen 34, 
this was using the primary antibody at 1:4 and the secondary antibody at 
1: 12000 .
5.7 WESTERN BLOT ANALYSIS OF RECOMBINANT 
BACULOVIRUS PRODUCTS
Western blot analysis was conducted, as described in Chapter 2, on both 
Sf9 supernatants containing recombinant protein and Sf9 cell lysates 
following reducing (SDS) polyacrylamide gel electrophoresis (SDS- 
PAGE). Ten ul of each of the cell lysate suspension, supernatant 
containing recombinant protein and supernatant containing wild-type 
baculovirus (BacPAK 6) were loaded on to the polyacrylamide gel as 
described in chapter 2. Electrophoresis was carried out at 200v for 45 
minutes. The gel was then subjected to electroblotting (Materials and 
Methods), after which western blot analysis was performed. The primary 
antibody used in this procedure was rabbit anti-cat IFN-y polyclonal 
antibody raised against peptide 34 and designated T711. The secondary 
antibody used was a horseradish peroxidase (HRP) labelled, sheep anti­
rabbit antibody (Sigma). Primary antibody was used at a concentration of 
1:3000 and the secondary antibody was also used at a concentration of 
1:3000. Blots were visualised using the ECL process as described in 
materials and methods. The results of the Western blot analysis is give in 
Figure 5.5.
The autoradiographs demonstrate that the primary antibody is binding to a 
protein of around 20kDa in both the lanes containing Sf9 supernatant and 
the lanes containing cell lysates. This appears to be the only product
2 0 2
1 2 3
50kDa
20kDa
Figure 5.5 Western blot analysis of baculovirus derived IFN-y. Supernatant 
(lane 1); cell lysate (lane 2), and wild-type virus supernatant (lane 3).
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detected by this antibody, there is, however, a feint band corresponding to 
55KDa which may represents non-specific binding to serum proteins. The 
negative control lane consists supernatant from Sf9 cells infected with 
wild-type PAK6 baculovirus. No protein bands were detected in this lane 
when blotted with antibody T711.
5.8 PARTIAL PURIFICATION OF RECOMBINANT PROTEIN
In order for the production of expressed protein to progress towards 
clinical application it was necessary to design a purification protocol for 
the protein. To achieve this, the purification method described for the 
murine interferon-g, Nagata et al (1987), was followed for the feline 
equivalent. This group used a combination of ion exchange 
chromatography and gel filtration following an ammonium sulphate 
precipitation step. Because of time constraints, only, ammonium sulphate 
precipitation and ion exchange chromatography have been conducted, but 
it is planned to complete the purification process using gel filtration. Ion 
exchange chromatography was carried out utilising FPLC.
Initially, 20ml of Sf9 supernatant, designated DAI (as described in chapter 
4), was subjected to filtration using a 0.2u filter. Solid ammonium 
sulphate was added to the supernatant to create a 30% solution (176g/l). 
This mixture was subjected to centrifugation at 10,000 r.p.m in a JA 10 
rotor, and the precipitate discarded. Solid ammonium sulphate was added 
to the supernatant to make 85% saturation (400g/l), centrifugation carried 
out at 10,000 r.p.m, and the supernatant discarded. Ammonium sulphate 
precipitated all the protein in the mixture, including the serum proteins in 
the T C I00 medium.
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The resulting precipitate was dissolved using 5 volumes of buffer B 
(20mM Tris-HCL, 5mM benzamidine, 2mM dithiothreitol (DTT), 10% 
(v/v) glycerol, pH 8.0). The solution was then subjected to dialysis against 
buffer B to remove the salt. To do this in a small scale preparation, the 
solution was added to a collodian bag and dialysed using 8 volumes of 
buffer B. The dialysis was carried out at 4°C over a 24 hour period. 
Following dialysis, the solution was degassed by filtration using a 0.45u 
filter and stored at 4°C prior to addition to the chromatography column.
Ion exchange chromatography was carried out using a Mono Q HR 5/5 
anion exchange chromatography column (Pharmacia). This type of 
column has been specifically designed for FPLC (Fast Protein Liquid 
Chromatography) of proteins and peptides. FPLC is a variant of High 
Pressure Liquid Chromatography (HPLC) and has been developed for the 
fast separation of biomolecules. Ion exchange chromatography depends 
upon the reversible adsorption of charged solute molecules to an 
immobilised ion exchange group of opposite charge. Initially, the ion 
exchanger is equilibrated with buffer which allows the binding of the 
desired solute molecules. The solute molecules adsorb by displacing 
exchangeable counter ions. Unbound substances are washed out from the 
exchanger bed using starter buffer and then solute molecules are eluted 
from the column using an increasing salt concentration gradient. 
Molecules are released from the column in the order of their strengths of 
binding, the most weakly bound substances being eluted first. The column 
is then washed, re-equilibrated and is ready for the next sample.
The FPLC controller was first programmed to carry out the following 
tasks: to equilibrate the column with 3 volumes of buffer B, to load the 
sample (in a 2ml volume), to wash the column, then to elute molecules
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using an increasing salt gradient over 30ml, and then to wash and re­
equilibrate the column. The salt gradient was provided by buffer A (buffer 
B + 0.3M NaCl). Both buffer B and buffer A were degassed by filtration 
using a 0.45u filter.
Fractions from the column were collected using a standard fraction 
collector (Pharmacia) and the elution profile was recorded graphically. 
The graphical representation of the column output is given in figure 5.6. 
From the profile we can see a major, narrow protein peak corresponding to 
55% of the salt gradient. Subsequently, there is a larger, homogenous set 
of peaks. The protein mixture added to the column contained, not only 
interferon and serum proteins, but also viral proteins derived from the 
baculovirus.
Twenty fractions from the column were then taken and 200ul of each 
fraction was dialysed against PBS and glycerol (10% v/v) to remove any 
of the buffer components which could have interfered with subsequent 
bioassays. The samples were dialysed using micro collodian bags 
(Sartorius) and 8 volumes o f the PBS/glycerol. These dialysed samples 
were then subjected to both a CPER assay (as described in chapter 4) and 
SDS-PAGE electrophoresis and subsequent western blotting using 
antibody T711.
5.9 BIOLOGICAL ASSAY OF FPLC PRODUCTS
The fractions collected from the column were numbered 1 to 20 and each 
were incorporated into a 96 well format CPER assay, as described in 
chapter 4, utilising VSV. The samples were incubated for 24 hours with 
the FEA cells at a dilution of 1:3 prior to the addition of virus. The virus
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Fraction O.D.(595nm) Fraction O.D.(595nm)
Cell Control 0.868 9 0.443
Virus control 0.095 10 0.238
1 0.118 11 0.164
2 0.095 12 0.125
3 0.103 13 0.123
4 0.112 14 0.137
5 0.132 15 0.124
6 0.259 16 0.162
7 0.416 17 0.184
8 0.525 18 0.136
Table 5.3 Results of CPER assay for FPLC fractions
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was added at 4 pfu/cell and incubated at 31°C/5%C02. Following a two 
day incubation, the cell layers were stained, as described in chapter 4, and 
a visual assessment of the monolayers performed. In addition, the dye in 
the assay wells was eluted an the O.D. measurements at 595nm recorded 
using an automated ELISA reader. The results are shown in Table 5.3 and 
depicted graphically in Figure 5.7. From the assay, it appeared that 
fractions 6, 7, 8, and possibly 9 were giving protection to the FEA cells 
against challenge with VSV. It would appear, therefore, that these are the 
fractions which contain the eluted interferon. This finding was further 
substantiated by western blotting.
5.10 WESTERN BLOT ANALYSIS OF FPLC PRODUCTS
lOul of each of Fractions 1 to 14 were subjected to SDS-PAGE 
electrophoresis, as described, and subsequent western blotting using 
antibody T711 as the primary antibody and HRP labelled sheep anti-rabbit 
antibody as the secondary antibody. The antibodies were used at the same 
concentrations as those described for previous western blots i.e. both were 
used at a concentration of 1:3000. Blots were visualised using the ECL 
method (Chapter 2). The results of the western blot are given in Figure 
5.8.
It can be seen from the autoradiographs that the primary antibody is 
binding to a protein in fraction 7, and 8. The majority of the protein seems 
to be in fraction 7 as only feint bands can be seen in lanes corresponding to 
fractions 8 and 9. The size of the protein detected appears to be around 
20KDa which is the same size as the protein detected in crude DAI using 
the same antibodies and conditions.
2 0 9
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20kDa
8 9 10 11 12 13 14
-20 kDa
Figure 5.8 Western blot analysis of fractions 3 to 14, derived from FPLC.
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Once the bioassay and western blots were complete, the graphical output 
from the FPLC was analysed to determine the peaks which corresponded 
to fractions 6 through 9. These fraction exactly corresponded to the first 
major protein peak (Figure 5.6). From this, it can concluded that 
interferon-y protein is being eluted from the ion exchange column over a 
period of 3 to 4 fractions at a concentration ofNaCl of around 0.15M.
5.11 DISCUSSION
This chapter describes how polyclonal antibodies were raised against 
synthetic peptides of interferon-y and how these, along with the bioassay, 
were used to partially purify the interferon protein. Two peptides were 
synthesised for eventual immunisation of rabbits. However, it would 
appear that only one of the peptides, peptide 34, elicited a strong immune 
response in the rabbit. This may be because either the epitope chosen for 
peptide 33 was weakly immunogenic and/or that there was insufficient 
heterogeneity between the rabbit and feline equivalents to elicit an immune 
response (the feline peptide shared 85% homology to the rabbit 
equivalent). To determine the presence of antibody to the appropriate 
peptides, an ELISA was performed as described. The ELISA results for 
peptide 33 were very poor and indicated a poor response by the host. 
Despite this, a western blot of sample DAI was performed, using 
polyclonal antisera to peptide 33. Unfortunately, the autoradiographs 
appeared blank (results not shown) and it was decided not to continue with 
antisera to peptide 33.
No available human or murine interferon-gamma antibodies, either mono 
or polyclonal, cross react in the feline system, and so the use of antibody 
T711 greatly facilitated detection of the recombinant protein. The
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potential value of this antibody is that it would be possible to detect 
protein far faster than using the bioassay alone. Subjecting Sf9 
supernatants to SDS-PAGE and comassie blue staining, without 
subsequent western blotting, is usually unrewarding. This is because after 
staining there are multiple bands corresponding, not only to the 
recombinant protein and serum protein in the T C I00 medium, but also 
other viral proteins expressed by the recombinant virus. Even if a 
comparison is made against supernatants containing recombinant virus and 
supernatants containing wild-type virus it is often difficult to draw any 
conclusions about differences in the protein bands observed. This is 
because insertion of foreign genes in to the baculovirus genome will alter 
the pattern of expression of other viral, non recombinant proteins (King 
and Possee (1992).
Ion exchange chromatography was successfully performed on the sample 
DAI to produce a partially purified interferon molecule. The conditions 
for chromatography were reproduced as described for the purification of 
murine recombinant interferon-y (Nagata et al, 1987). The interferon 
appears to be eluted at a salt concentration of 0.15M which is in 
accordance with that observed for the murine equivalent which was eluted 
at a salt concentration of between 0.05M and 0.15M. The use of antibody 
T 711 and western blot analysis, along with the sensitive bioassay, greatly 
facilitated the FPLC analysis. The interferon appears to be eluted in one 
single peak, but one could consider improving purification conditions by 
eluting over a greater volume (i.e. reducing the slope o f the salt gradient) 
to improve separation of the interferon from irrelevant proteins.
A further extension to improving conditions for protein purification would 
be to produce the protein in serum free conditions. This would remove any
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irrelevant serum proteins from the FPLC equation. The production of 
protein in serum free conditions can often be a difficult process. Initially 
the cells have to be adapted to serum free conditions by subsequent 
passage in reducing serum concentrations (King and Possee 1992). When 
the cells are growing under optimal conditions, they are then infected with 
recombinant virus as described in chapter 4. An alternative approach is to 
grow the cells in serum and subsequently infect the cells under the same 
conditions. Following a 24 hour incubation period the cells are harvested 
by centrifugation and resuspended in spinner culture using serum free 
medium (M. Harris personal communication). Both sets of serum free 
conditions were experimented with but the yield of protein fell using these 
procedures and it is possible that more work needs to be carried out on this 
approach to try and optimise conditions. One of the problems in using the 
latter method for serum free protein production is that, after a relatively 
long incubation period the non-adapted cells may lose viability and the 
capacity for post-translational modification of the recombinant protein.
Time has limited the experiment to only the partial purification of the 
recombinant protein, but it is planned to continue the process by using an 
additional gel filtration step, described by Nagata et al (1987) for the 
murine IFN-y.
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CHAPTER 6
GENERAL DISCUSSION
6.1 INTRODUCTION
6.2 THE TREATMENT OF RETROVIRUS INFECTIONS
6.3 INTERFERON AS A VACCINE ADJUVANT
6.4 INTERFERON IN THE TREATMENT OF NEOPLASIA
6.1 INTRODUCTION
At the outset, the aim of this project was to clone, sequence and express 
feline interferon-y with to aim of examining the potential of this cytokine 
in the treatment and prevention of diseases in felidae. The amplification of 
feline specific cDNA encoding interferon-y was achieved using the 
polymerase chain reaction, utilising primers selected according to highly 
conserved regions in sequences published for other species. This method 
had previously been adopted in the cloning of other cytokines genes 
including ovine and equine interferon-y, and canine and feline IL-2. While 
this approach offers simplicity, care is required in the design of primers 
and PCR optimisation.
Expression in the baculovirus system was greatly facilitated by the use of 
the BacPAK 6 wild-type virus which allowed rapid isolation of 
recombinant virus. Subsequent expression studies were initially hampered 
by the lack of a reliable biological assay, but the use of the CPER assay, 
utilising vesicular stomatitis virus, eventually proved more reliable than 
the calicivirus based assay. The MHC class II induction assay was found 
to be as sensitive as the viral assays and may be more practical, 
considering the need for category II facilities when working with VSV.
The future aim of the project is to take feline recombinant interferon-y into 
a clinical setting. Before this can happen, a phase I clinical trial needs to 
be conducted to assess the toxicity of interferon in experimental animals. 
It is intended to conduct this trial in experimental cats using three 
escalating doses of interferon-y. Various clinical parameters, including 
temperature, presence of anorexia, weight changes, haematology, 
biochemistry and possibly cardiovascular signs, will be monitored
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throughout this phase I trial. If the protein is then to be taken into the 
veterinary clinic as a therapeutic agent, an Animal Test Certificate (ATC) 
must be obtained. An ATC is used to assist in the development of a new 
veterinary product in the target species by providing data on efficacy. In 
addition, data is required on the safety and quality of the product. Non- 
clinical safety tests have to be conducted under the principles of Good 
Laboratory Practice (GLP) and quality depends on manufacture under 
good Manufacturing Practice (GMP).
Since their discovery, interferons have been extensively researched in the 
hope that they would prove beneficial in the treatment of human diseases, 
notably cancer and viral infections. The emergence of recombinant DNA 
techniques have allowed sufficient quantities of a variety cytokines to be 
produced and enter into clinical trials. At present, interferon-a has proved 
to be the most beneficial of the interferon species in terms of the treatment 
o f neoplasia and chronic viral infections. Interferon-p has recently entered 
clinical trials for the treatment of multiple sclerosis, with encouraging 
results, while Interferon-y has found a niche in the treatment of chronic 
granulomatous disease in humans (reviewed by Johnson et al (1994). 
Interferon-y is also being examined for its potential as a vaccine adjuvant, 
especially in patients who are immunosupressed, and it may also have 
value in the treatment of neoplastic disease.
The use of recombinant cytokines in veterinary medicine has more often 
been limited to the use of human or murine proteins because the native 
protein has not been available. There are essentially two problems with 
this approach. Firstly, the long term use of recombinant human or murine 
cytokines in other species, despite the high degree of conservation between 
species, leads to the development of antibodies to the recombinant protein
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by the host. While this may not be a problem in short term use of 
cytokines, say in the treatment of neoplasia, it would become a major 
factor in long term usage, for example, in the treatment of chronic 
haemopoietic disease. However, it is also note worthy that even native 
recombinant proteins can lead to the development of antibodies in the 
natural host. This may depend upon the type of system used to express the 
protein and may become important where there are differences in the 
glycosylation pattern such as that observed in the baculovirus system. The 
second problem associated with using a non-native recombinant protein is 
that the protein may not be cross reactive in that species. This is certainly 
true for interferon-y, which is highly species specific, with only ovine and 
bovine interferon-y species being cross reactive.
Recently, there has been an interest in cloning specific veterinary 
cytokines to examine their potential in veterinary diseases (reviewed by 
Campos et al 1991; Elmslie et al, 1991; MacEwen, 1990; MacEwen, 1993; 
Babuik, 1991; Tompkins and Tompkins, 1991; Lawman et al 1994). A 
number of veterinary cytokines have now been cloned from a variety of 
species. A limited number of clinical trials using veterinary cytokines are 
currently in progress, including the evaluation of canine rG-CSF in the 
management of chemotherapy induced myelosuppression; Feline rlFN- 
a(omega), in the treatment of feline acute respiratory infections; bovine 
interferon-a in the treatment of respiratory infections and bovine 
interferon-y in the treatment of acute mastitis and the treatment and 
prevention of bovine viral diseases.
This thesis has described the sequence of events in taking a gene from the 
cloning stage towards purification and eventual clinical application. The 
work forms part of a larger project continuing at Glasgow concerned with
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the expression of a panel of domestic animal cytokine genes in order to 
examine their therapeutic potential. The interest in the cloning and 
expression of feline cytokine genes stems from their potential in the 
treatment of neoplastic, haematological and infectious diseases. In 
addition, Interferon-y is a good candidate as a vaccine adjuvant.
There are essentially three main areas where it is felt that recombinant 
interferon may have a role in treatment of diseases in cats. These areas 
are, the treatment of chronic retroviral infections; the treatment of 
neoplastic disease and the use of interferon-y as a vaccine adjuvant. The 
use of cytokines in a clinical setting fall into two broad categories viz. the 
direct, parenteral administration of the recombinant protein, and the 
administration of the cytokines by gene transfer methods. In chapter 1, it 
was indicated that cytokines act in a paracrine or autocrine fashion. If the 
recombinant protein is given systemically then it must act in an endocrine 
fashion, but to do this the dose required often has to be high in order to 
obtain a clinical effect. This problem has precluded the use of many 
cytokines in the treatment of clinical cases because, in certain instances, 
the doses required for clinical benefit are toxic to the host. For example, 
while TNF-a has a direct anti-tumour effect, the systemic administration 
of the recombinant protein may lead to excessive morbidity. In contrast, 
gene transfer methods allow local production of cytokines in the area in 
which they are required and thus mimic the natural situation.
6.2 THE TREATMENT OF RETROVIRAL INFECTIONS
Exogenous interferon-y may have a role in the treatment o f retroviral 
infections in cats. The two major retroviral infections in cats are Feline 
leukaemia virus (FeLV) and Feline immunodeficiency virus (FIV). FeLV
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is an oncovirus and is characterised by the ability to produce haemopoeitic 
tumours in cats. FIV is a lentivirus and is characterised by a long 
asymptomatic period and a progressive immunodeficiency similar to that 
seen with HIV infection in man. There have been recent reports of the use 
of combined interferon-a, Zidovudine and adoptive cell transfer in the 
treatment of established FeLV infection (Zeidner et al, 1993). The 
interferon was a human recombinant product and the study was limited by 
the production of neutralising antibodies to the interferon. This group 
reported that 50% of the cats cleared their viraemia and developed virus 
neutralising antibody which indicated both viral clearance and immune 
reconstitution. As discussed in Chapter 1, interferon-a is a more potent 
antiviral cytokine than interferon-y and one could hypothesise that 
interferon-a would therefore be a better candidate for use as an antiviral 
agent than interferon-y. However, one may consider a more appropriate 
role for interferon-gamma as an enhancer of immune effector functions. 
The exact role that cell mediated immunity plays in FeLV infection is, as 
yet, undefined, but as the immunological mechanisms which accompany 
infection are unravelled a clearer role for exogenous interferon-y may 
appear.
Against this is a report by one group (Khan et al 1992) which suggests a 
deleterious role for interferon-y in FeLV-C infection. FeLV-C infection is 
associated with erythroid aplasia causing severe aplastic anaemia in 
affected cats and is also associated with raised serum levels o f interferon- 
gamma and TNF-a. These two cytokines may act synergistically to cause 
haemopoeitic suppression. Khan et al (1992) evaluated the effects of 
interferon-y (purified feline interferon-y from stimulated splenocytes) and 
TNF-a on feline bone marrow progenitors. They found that a combination 
o f TNF-a and IFN-y incubated with bone marrow cells caused marked
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suppression of feline colony forming units-erythroid (CFU-E), burst 
forming units-erythroid (BFU-E), and colony forming units-fibroblasts 
(CFU-F), whereas colony forming units-granulocyte/macrophage (CFU- 
GM) were minimally affected. The effects of incubating the cells with 
these cytokines independently had minimal effects. These results not only 
suggest that these two cytokines may have a role in the pathogenesis of 
FeLV-C infection, but also they may have a role in regulating 
haemopoeisis in the cat.
FIV is a lentivirus infection which causes progressive immunosupression 
characterised by a decline in CD4+ T cell counts. The disease mimics that 
seen in HIV infected humans. Shortly after infection there is a brief febrile 
period involving a high level of viral replication. There then follows an 
asymptomatic phase of variable length and finally a terminal stage where 
the cat is susceptible to opportunistic infections and tumour development. 
Initially, many workers involved in HIV research concentrated on the 
terminal stages of the disease, but it is becoming apparent that important 
immunological processes may be occurring in the early stages o f infection 
which may influence the subsequent disease course (Barcellini et al, 
1994). The cat provides an ideal model for the human equivalent and 
much attention has focused on the immunological changes which occur 
during the course of this disease which, in experimental animals, can be 
followed from the point of infection.
The factors responsible for initiating a switch from asymptomatic to 
symptomatic disease in HIV and FIV infection has yet to be resolved. It 
has been proposed that changes in THj and TH2 T helper cell responses 
may mediate disease progression during HIV infection. Patients with THj 
type responses, i.e. secretion of IL-2 and IFN-y remain asymptomatic
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whereas those that switch from THj to TH2, as indicated by a fall in IL-2 
production and a rise in IL-4 production, go on to develop AIDS 
(Mosmann, 1994; Clerici, 1994). The mechanism by which retroviruses, 
including FeLV, cause immunosuppression is the subject of much 
research. Haraguchi et al (1995) have recently reported that a synthetic 
retroviral peptide, designated CKS-17, was able to regulate THj and TH2 
cytokines in a negative and positive fashion, respectively. CKS-17 is a 
heptadecapeptide which represents the conserved domain of the 
transmembrane envelope protein, P15e, of feline and murine leukaemia 
virus. The regulation of T cell cytokines appears, from this study, to be 
due to regulation of IL-10 and IL-12.
A longitudinal study of cytokine production by cats infected with feline 
immunodeficiency virus has recently been reported (Lawrence et al, 1995). 
This group found that similar mechanisms of immune dysfunction, 
involving a switch from THj to TH2 T cell responses, may be occurring 
during FIV infection. Cats in the terminal stages of infection, produce low 
levels of IL-2 and high levels of IL-6, whereas those with high levels of 
IL-2 and low levels of IL-6 remain asymptomatic. As described in Chapter 
1, interferon-y plays an intimate role in the determination of whether a 
THi or a TH2 response occurs. Interferon down-regulates IL-10 
production and the development of TH2 responses. One might conclude 
that the long term administration of interferon-y during the asymptomatic 
phase of FIV may maintain the THj predominance and slow the 
progression of disease. However, further studies monitoring the changes 
in levels o f IL-4, IFN-y and antibody isotype during infection with FIV are 
required before a definitive role for T helper cell subsets in the 
immunopathology of FIV can be determined.
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This kind of approach has, in part, been addressed by Clerici et al (1993). 
This group have used IL-12 in an attempt to restore HIV-specific cell- 
mediated immune responses in-vitro. As described in Chapter 1, IL-12 is 
not only is a potent inducer of interferon-y but also promotes the 
establishment of THj responses. In this study it is not clear, at present, 
whether IL-12 was directly acting on existing T cells to create a THj 
predominance or whether it was acting through the generation of THi T 
cell populations.
While retrovirus induced immune dysfunction may offer the possibility of 
immunological intervention with cytokines it is impossible to predict the 
outcome of such therapy. We do not fully understand the intricate 
cytokine network and it may be that combination cytokine therapy, as 
opposed to single agent therapy, may be more beneficial. Also the dose of 
cytokine to cause a beneficial clinical response may be too toxic or not 
tolerated by the host. In addition, the timing of therapy may be critical as 
administration of different cytokines may be more or less beneficial 
depending on the stage of disease. As the knowledge of cytokine 
interactions and the mechanisms of immune disruption in retroviral 
infections becomes clearer then a more rational approach to cytokine 
therapy may be adopted.
While one can speculate on the potential roles that cytokines may play in 
the resolution or the slowing of progression of retroviral infections, one 
also must consider the practicalities of treatment, especially in the 
veterinary clinical setting. The long term use of interferon-y in cats with 
pre-clinical FIV may not be a practical one for several reasons. Firstly, the 
dose required to cause an immunomodulatory effect may be toxic to the 
host; secondly, the cost of treatment may be excessive despite recombinant
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DNA technology aiming to reduce the costs of such therapies and thirdly, 
for treatment to be effective one would need to screen cats prior to the 
development of clinical FIV. In reality, veterinarians often see FIV 
positive cats when they have progressed to being clinically ill and, even if 
cats are tested positive prior to becoming ill, it may be difficult to convince 
owners that their cat requires treatment. However, the use of interferon-y 
in FIV may be important in experimental FIV infection in order to help 
unravel the complexities of immunological dysfunction in this disease.
6.3 INTERFERON AS A VACCINE ADJUVANT
A clearer clinical role for recombinant interferon-y is in its use as a vaccine 
adjuvant. The adjuvant properties of interferon-y have been demonstrated 
in both human and murine systems and is discussed extensively in Chapter 
1. Non-specific stimulation of the immune response by adjuvant 
formulations is often beneficial in cases of prophylactic or therapeutic 
vaccination. However, in certain instances, a more defined stimulation of 
the immune response using specific cytokines as adjuvants or co-adjuvants 
might be more effective. This can take the form of direct administration of 
the recombinant cytokine or expression of cytokines within live or 
disabled virus vectors. In addition, a more recent approach has been to 
administer the cytokine, again in the form of DNA, in a non-viral 
expression vector capable of expression in mammalian cells, i.e. so called 
DNA vaccination. Cytokines associated with adjuvanticity include IL-1, 
IL-2 and IFN-y.
As discussed in Chapter 1, IFN-y up-regulates MHC class II expression, 
enhancing antigen presentation, and suppresses the TH2 lymphocyte 
response with resultant inhibition of humoral immunity. Thus, an
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interferon-y adjuvant might drive a vaccine induced immune response 
towards cell mediated mechanisms which correlate more effectively with 
protective immunity against viruses (Ramshaw et al 1992). Candidate live 
virus vectors for use in cats include feline herpesvirus, although the latent 
capacity of this virus may preclude its use. In latent virus infections there 
may be constitutive production of the inserted cytokine, the relevance of 
which is uncertain. However, if there was a scenario of superinfection 
after vaccination it may theoretically possible for the wild-type virus to 
recombine with the modified vector and have the cytokine gene transferred 
to the wild-type virus. Again the relevance of this is uncertain, but may 
allow the development of a new virus able to modify the host immune 
response.
Historically, the most effective vaccines against infectious agents have 
relied upon the use of attenuated or killed preparations of the wild-type 
infectious agent. Although these vaccines have been successful for a 
variety of diseases, some organisms are unable to be attenuated by 
traditional methods or are poorly immunogenic when administered as the 
killed preparation. In addition, attenuated vaccines have the added 
concern that the vaccine may be contaminated with virulent infectious 
agent or that attenuation is unsuitable for certain viruses which show 
latency or integrate in to the host genome. The use of recombinant DNA 
technology allows the production of vaccines using only those genes 
which are immunologically relevant so that there is only the minimal 
amount o f information necessary to generate a protective immune response 
without the addition of irrelevant antigens that contribute to unwanted 
side-effects. The added advantage of recombinant vaccines is the ability to 
co-express cytokine genes in order to enhance the immune response.
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Recombinant vaccines may be divided into several categories, but 
probably the two which have warranted the greatest attention are 
recombinant-vector vaccines and DNA vaccines. Recombinant vector 
vaccines use a viral vector to deliver relevant genes to generate an immune 
response. The most widely studied recombinant vaccine vehicle is 
Vaccinia Virus (VV). The gene encoding the protein to be expressed is 
inserted into the VV genome by the process of homologous recombination. 
Most genes are inserted into the Thymidine Kinase gene such that VV 
virulance is reduced. The advantage of these vector approaches are that 
multiple genes can be co-expressed so that fusion proteins can be 
produced. Cytokine genes can be conjugated to the relevant immunogen 
by this process. Vaccines have also been developed using other vectors. 
For example, an Avipox vaccine vector has been used to express gag and 
env genes of FeLV (Tartaglia et al, 1993). The disadvantage of using 
vectored vaccines is that, in addition to generating an immune response 
against the inserted gene, they also induce a response against the vector. 
This may in turn reduce the response against the insert or prevent the 
future use of the carrier for subsequent vaccinations (J.C Neil personal 
communication).
Nucleic acid or DNA vaccines have the advantage over vectored vaccines 
in that they can be administered repeatedly for booster inoculations 
without the generation of immunity to irrelevant antigens. In addition, the 
formulation of these vaccines are far easier in that they only require the 
simple purification of nucleic acid. In this approach, the genetic template 
is directly injected into the tissues resulting in the transfection o f the host's 
cells and endogenous production of the antigen encoded by the genetic 
template. The plasmid DNA injected in to the host can be engineered to 
express both the relevant gene(s) and a cytokine gene(s) either as single or
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fusion proteins. Alternatively, two plasmids can be injected, one 
expressing the required gene and one expressing single or multiple 
cytokine genes. This approach has been hindered by the method of 
injection of the vaccine. Direct injection into the muscle mass will lead to 
loss o f some DNA along the fascial planes of the muscle and thus large 
amounts of DNA would have to be injected to ensure at least some entered 
the muscle cell. Ideally, it would be an advantage to be able to inject at 
multiple levels of the muscle in order to maximise the intracellular 
delivery of the DNA. To overcome these difficulties of delivery, a new 
approach has now been taken by some workers. This approach involves 
the adsorption of DNA onto gold particles which are then injected via a 
gene gun that delivers the DNA into the epidermal cells without the 
disruption of cell membranes. The motive force to accelerate the DNA 
particles is generated by release of a high pressure burst of helium gas 
within the gun.
DNA vaccination may become relevant in the cat in an attempt to protect 
against the retrovirus infections of FeLV and FIV. There are available 
plasmid constructs containing either replication defective FIV or FeLV 
DNA under the control of their own LTR promoters. It is planned to carry 
out a vaccination study using these constructs co-injected with a plasmid 
vector containing the feline recombinant Interferon-y cDNA. The plasmid 
vector chosen to express interferon is a pRc/RSV plasmid (Invitrogen) 
which allows high levels of expression of the gene, in mammalian cells, 
under the control of an RSV LTR (Rous Sarcoma virus) promoter and 
enhancer.
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6.4 INTERFERON IN THE TREATMENT OF NEOPLASIA
The third main area where feline interferon-y may be considered for 
clinical use is in the treatment of neoplasia. Interferons have both 
immunomodulatory actions and affect cell growth and differentiation. 
Interferon-y, along with other immunomodulatory cytokines, may be 
important in the development or enhancement of the anti-tumour response. 
The area of tumour immunology is a controversial one and has been 
reviewed by Onions and Gorman (1989); Onions (1987), and Elmslie 
(1995).
The development of an anti-tumour immune response requires the 
existence of tumour specific antigens. The existence of tumour specific 
antigens in non-viral induced tumours in domestic animals has been poorly 
defined. A cancer cell represents altered self and tumour antigens can be 
considered under three broad categories: altered glycoproteins on the 
surface of the cancer cell as a result of transformation; viral epitopes, and 
the expression of differentiation antigens which are usually only present 
during development. The effector cells in the anti-tumour response 
include cytotoxic T cells (CTL’s), B lymphocytes, macrophages, natural 
killer (NK) cells and lymphokine activated killer cells (LAK). Research 
over the past few years has demonstrated that cell mediated responses are 
more important than humoral immunity in the development of the anti­
tumour immune response. Moreover, the relevance of each cell subset to 
the development of the response may vary with the stage of disease. In the 
early stages of neoplasia, NK cells may play a significant role, but as the 
disease progresses, CTL responses and macrophages may become more 
important. NK cells, LAK cells and macrophages lyse tumour cells in a 
non-MHC restricted fashion whereas the CTL response is MHC restricted.
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Tumours may escape immune mechanisms for several reasons. While 
some tumours are antigenic, they may not necessarily be immunogenic. 
In addition some tumours have low levels of MHC Class I expression (e.g. 
Transmissible Venereal Tumour, TVT, in dogs), or produce, as yet 
undefined, soluble factors which down regulate the anti-tumour response. 
Another, more recent mechanism of immune escape has recently been 
defined. Activation of the T cell to lyse the tumour cell requires, not only 
recognition of antigen in the context of MHC, but also co-stimulation by 
accessory molecules. Some tumour cells do not possess these co­
stimulatory molecules so that, after T cell binding, the T cell becomes 
anergic. The discovery of cytokines and their immunomodulatory 
properties lead to renewed interest in mechanisms of immune enhancement 
against tumours, the premise being that administration of exogenous 
cytokines will enhance immune effector cells.
Both IL-2 and IFN-y are pivotal immunomodulatory cytokines and early 
clinical trials focused around these molecules. Greatest clinical success 
has been achieved using recombinant IL-2 in the treatment o f renal cell 
carcinoma and malignant melanoma (reviewed by Foa 1992). IL-2 causes 
generalised immune enhancement by CTL activation, enhancement of NK 
activity, generation of LAK cells and in-vivo release of other cytokines 
such as IFN-y. In addition, the administration of exogenous IL-2 can 
reverse T cell anergy. The use of recombinant interferon-y has proved to 
be less beneficial with only moderate responses being observed.
The problem in using direct, systemic administration of cytokines is that 
the dose required to cause a clinical effect is often too high to be tolerated 
by the host. To minimise these side effects, studies have been carried out
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to evaluate localised, peritumoural or paracrine cytokine therapy, either by 
intratumoural injection of recombinant proteins or by a gene transfer 
approach (reviewed by Yang and Sun (1995); Fujiwara et al (1994); Fomi 
et al (1994); Pardoll (1992); Pardoll (1993); Rosenthal et al (1994); Sikora 
(1994) and Schmidt-Wolf and Schmidt-Wolf (1995).
The ultimate goal of cytokine gene therapy is to induce a sustained 
regional or even systemic antitumour response by transferring genes 
encoding specific cytokines into tumour bearing hosts, while avoiding 
systemic toxicity often associated with conventional cytokine 
immunotherapy. Gene delivery systems include both viral and non viral 
methods.
The cytokine gene therapy strategy may have applications for treatment of 
localised or regional tumours that are surgically unresectable or have 
disseminated. It has been suggested that local administration of ex-vivo 
cytokine transgene-modified tumour vaccine cells or transfection of 
tumour cells in-vivo to induce a tumour vaccine response at a tumour site 
or its draining lymphnode, may result in local as well as systemic anti­
tumour effects against non-modified tumours. There have now begun 
several studies looking at this cytokine based gene therapy approach.
Some studies have focused on the transduction of interferon-y genes into 
tumour cells. In mice, injection of IFN-y transduced tumour cells gives 
rise to an increased cytotoxic T-lymphocyte response against tumour 
associated antigens. Restifo et al (1992) studied a murine sarcoma that 
had very low MHC class I expression and gave rise to no detectable 
immune response. Following retroviral gene transduction with interferon- 
y, class I expression on the tumour was significantly increased and tumour
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infiltrating lymphocytes could be derived that successfully treated 
establish lung metastases from the parental unmodified tumour. More 
recently, Ogasawara and Rosenberg (1993) transduced a series of human 
tumours with retroviral vectors containing the interferon-y gene. This 
group demonstrated a significant up-regulation of surface MHC antigens 
and, in addition, demonstrated that melanoma cells that have been 
transduced with the interferon-y gene and express HLA.DR are able to 
stimulate cytokine release when co-cultured with autologous tumour 
infiltrating lymphocytes. At present a phase I clinical trial of human IFN-y 
transduced autologous tumour cells in patients with disseminated 
malignant melanoma is being conducted (Seigler, 1994).
The mechanisms underlying the rejection of tumours after targeted gene 
transfer with various cytokines has been addressed by Hock et al (1992). 
This group demonstrated that all the cytokines tested required CD8+ T cell 
for complete long-term eradication of tumours but different cytokines 
activated heterogeneous transient tumour suppressive mechanisms. For 
interferon-y this is mediated, in part by NK cells and macrophages.
While gene therapy in domestic animals would appear to be impracticable 
at the present time, there are important considerations. Domestic animals 
provide a population of naturally occurring tumours and are the closest 
model that we have to human equivalents. Thus the results of clinical 
trials in naturally occurring tumours in domestic animals can, in part be 
extrapolated to human medicine. It should, however, be borne in mind that 
cytokine gene therapy will probably never form the sole treatment for 
neoplasm but be an adjunctive treatment alongside more conventional 
therapies. Factors against the use of gene therapy, include the cost of 
treatment in domestic animals and the time delay involved in ex-vivo
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tumour transduction. Both of these factors may be reduced considerably 
by the use of non-viral in-vivo methods for gene transduction (reviewed by 
Yang and Sun (1995). The most promising method may be the use of gene 
guns as described for DNA vaccination above. Another problem 
concerning gene therapy is that we are uncertain about the effects o f long 
term constitutive expression of the transduced gene.
In summary, The cloning of domestic animal cytokine genes opens the 
door to explore their potential in therapy. While interferon-y may 
eventually find a role in the treatment of retrovirus infections, at present 
the main clinical application would appear to be in the form of vaccine 
adjuvanticity. The use of interferon-y in the treatment of neoplasia in 
humans has been, in part, disappointing but with the advent of gene 
therapy interferon-y may eventually find a role in the fight against cancer.
Above, I have discussed the potential applications of these cytokines but 
practical considerations must also be borne in mind. These include 
practicalities of treatments, cost of treatments and efficacy and toxicity 
compared to conventional treatments. All of these points, along with pre- 
clinical data obtained from experimental animals, must be taken into 
consideration in the design of clinical trials.
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